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Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a disease defined by necrotic 
jaw bone that has become exposed through the surrounding soft tissue, which affects 
patients with osteoporosis and bone metastases taking the anti-resorptive 
bisphosphonate (BP) drugs. Currently this disease is without a specific treatment, in part 
due to its complex, and not fully understood, pathophysiology. 
This research used tissue engineering principles to further investigate the effects 
of BPs on the soft tissue, both in two and three dimensions, and investigated a potential 
preventative treatment for the disease in vitro. The BPs investigated were pamidronic 
acid (PA) and zoledronic acid (ZA), two BPs most commonly associated with BRONJ. 
We explored the effects of PA and ZA on human oral fibroblasts and keratinocytes 
at clinically relevant concentrations in 2D. Both PA and ZA caused significant reductions 
to metabolic activity, and further study indicated an increase in apoptosis in fibroblasts, 
and apoptosis and necrosis in keratinocytes. PA and ZA led to a significant reduction in 
proliferation, and ZA reduced the adhesion of keratinocytes. However, BPs did not affect 
cellular migration. 
A 3D oral mucosa model was used to investigate PA and ZA. PA prevented the 
stratification of newly formed epithelia and reduced the thickness of healthy epithelia. ZA 
showed the same effects, but at higher concentrations was also toxic. We began the 
development of a 3D wound healing assay which could be used as an in vitro model of 
BRONJ, and indicated that BPs also inhibit oral mucosa wound healing. 
Finally, we examined the ability of hydroxyapatite (HA) to bind BPs. The abilities of 
a variety of spectroscopic methods to detect BP binding were tested. Biological assays 
were also performed to examine the ability of HA to prevent BP toxicity. We have 
successfully demonstrated that HA could be used to reduce PA and ZA toxicity in vitro. 
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Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a disease defined by necrotic 
jaw bone that has become exposed through the surrounding soft tissue [1]. As the name 
suggests, it is suffered by patients receiving bisphosphonate (BP) treatment. BPs are a 
group of anti-resorptive drugs and are therefore used to treat diseases that present with 
increased bone resorption. They are primarily used to treat osteoporosis and bone 
metastases, and are currently the most commonly prescribed anti-resorptive worldwide 
[1], [2]. BRONJ typically develops following wounding to the jaw, and in the majority of 
cases follows a tooth extraction [1]. It affects between 1 in 10 and 100 patients prescribed 
BPs for bone metastases, and 1 in 10,000 and 100,000 of those being treated for 
osteoporosis [3]–[5]. 
BPs affect both the bone and surrounding oral mucosa to contribute to the 
development of the disease. Four main pathways are thought to be involved: osteoclast 
inhibition, angiogenesis inhibition, soft tissue toxicity, and infection and inflammation. Soft 
tissue toxicity is the primary clinical feature of BRONJ, and closure of the BRONJ wound 
has been hypothesised as the key to the treatment of the disease [2]. This complex 
pathophysiology makes treatment of BRONJ difficult, and, as such, there is currently no 
definitive treatment for the disease, with treatment based around conservative 
management [1]. This work in this thesis aimed to use tissue engineering approaches to 
study the soft tissue component of BRONJ; investigating both the development of the 
disease and potential solutions. 
This thesis reports on a wide variety of BP effects on the oral mucosa in both two 
and three dimensions. Further understanding of how BPs affect the oral mucosa and lead 
to the exposure of necrotic bone is an important step in the treatment of the disease. The 
work in this thesis also examined whether calcium phosphate-containing bone filler 
materials can be used to locally reduce BP effects, as BPs have a well-documented 
binding affinity for calcium. These materials are already in use as post-extraction medical 
devices, and therefore present an attractive method by which to treat the disease. 
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2. Literature review 
 
This chapter reviews the current literature regarding BRONJ, including introductions to the 
bone diseases which require BP treatment, an explanation of BP effects and side-effects, 
and a summary of what is known about BRONJ pathophysiology, incidence and treatment. 
The field of research regarding BPs and their effects in the development of BRONJ is then 
summarised. Calcium containing bone filler materials and their BP binding properties are 
reviewed, before a final summary of methods to detect BPs, with the aim of justifying the 




Bone is a dynamic organ, constantly remodelling and repairing in response to mechanical 
stimuli and structural damage [6], [7]. Remodelling mainly involves two cell types – 
osteoblasts and osteoclasts - which are responsible for formation and resorption, 
respectively [7]. These processes are usually balanced, and this balance is important for 
the shape, size and integrity of the bone [8]. 
Osteoblasts are involved in the formation of bone matrix and contribute to the 
mineralization of bone. They differentiate from osteogenic progenitor cells, and their 
number increases in response to stress or fracture, making them key to wound healing [9]. 
Osteoclasts are polykaryonic macrophages formed through the fusion of stem cells 
[6], [9] and are the principal cells in bone resorption [10]. They are formed following the 
stimulation of precursor monocyte/macrophage cells by receptor activator of nuclear factor 
kappa-B ligand (RANKL) [10]. When stimulated, an osteoclast goes through internal 
changes in preparation for resorption, before lining up on the surface of its target bone [6]. 
Once on the bone surface, the osteoclast polarizes, forming a ruffled border, demonstrated 
in Figure 2.1 [10]. This ruffled border is the resorptive organelle [11]. In resorption, an 
osteoclast attaches to the target matrix, whereby it secretes hydrogen ions into the local 
environment, which are followed by chloride ions, creating a lacuna filled with hydrochloric 
acid (HCl). The lacuna has a pH of around 4.5 [10]. The acidic environment dissolves the 
bone mineral, before secreted proteases digest the organic component of bone. This 
leaves trenches within the bone, which are filled with new bone matrix by osteoblasts [12]. 
The balance between the osteoblast and osteoclast function allows for bone mineral 
density to be maintained at a constant level [13]. However, several diseases present with 









Figure 2.1. Diagram of an osteoclast resorbing bone. Reproduced with permission from 
Poroca et al. [14] under a Creative Commons license. 




Osteoporosis occurs when bone remodelling is imbalanced, so that resorption takes place 
at a greater rate than formation. It is a disease that affects both the quality and quantity of 
bone in patients, leading to a risk of osteoporotic fractures of vertebrae and long bones. 
The risk of hip fracture has been reported as high as 1 in 6 [15]. It affects approximately 
50 % of women and 20 % of men over the age of 50 in white populations, and treating 
osteoporotic fractures in the European Union amounts to approximately $30 billion 
expenditure per year [15]. Due to the aging population, the number of these fractures is 
constantly increasing [16]. In patients with osteoporosis, resorption rate is increased as 
osteoclasts are over-stimulated. This alters the micro- and macro-architecture of the 
remaining bone, causing it to be weaker, more brittle and to have a lower bone mineral 
density [15]. Once the mineral density lowers to a clinically significant level, a patient is 
diagnosed as having osteoporosis. 
 
2.2.2 Osteogenesis imperfecta 
 
Osteogenesis imperfecta (OI), or ‘brittle bone disease’ [17], is an inherited genetic disease 
where a mutation in the collagen encoding genes leads to poor collagen formation [18], 
[19]. It is the most common bone fragility disease, affecting approximately 
 Literature review  
5 
 
1 in 150,00 people in the United States of America (US), and as a genetic disorder, it 
affects people from birth [17]. As collagen makes up most of the organic component of 
bone, this disease primarily affects bone tissue [18]. The bone formed by OI patients is 
thinner, with less trabecular bone, and common symptoms of the disease are fractures, 
bowed long bones, stunted growth and scoliosis [18]. 
 
2.2.3 Paget’s disease of bone 
 
Osteitis deformans, more commonly known as Paget’s disease of bone (PDB) is a chronic 
bone disorder primarily found in older adults [20]. In this disease, osteoclasts become 
hypersensitive to RANKL and other factors, leading them to become higher in number and 
size and hypernucleated, which in turn increases the rate of bone resorption, often in one 
site alone [20]. In response, osteoblasts are recruited to the site which increases bone 
formation [21]. The abnormally high rate of both resorption and formation leads to a 
reduction in bone quality, which leads to fractures, fissures and enlarged bones [20]. 
Symptoms include pain, arthritis and bone deformity, though around 20 % of cases are 
asymptomatic [22]. In the United Kingdom, around 5 % of the population have the disease, 
hypothesised to be due to viral transmission in patients genetically predisposed to its 
development [21]. 
 
2.2.4 Bone metastases 
 
As well as diseases purely related to bone, resorption is also affected by bone metastases 
of cancer. Metastases occur when tumours from one tissue translocate to another [23]. 
Breast and prostate cancers are the most likely to metastasise [24], with approximately 
70 % of people with advanced forms of these cancers developing metastases [25]. 
Approximately 90 % of cancer related deaths are due to metastases [23]. 
The skeleton – and in particular the axial skeleton – is the most common site [24], 
[25]. The red marrow, high blood flow and immobilised growth factors within the bone 
cause the preference for skeletal tissue and provide a fertile ground for tumour growth 
[11]. Metastases are defined by their primary cellular action – those that affect osteoclasts 
and resorption are osteolytic, while those affecting osteoblasts and formation are 
osteosclerotic [24], [26]. These differing types of tumours have differing effects on bone. 
 Osteosclerotic metastases stimulate osteoblast activity to increase bone formation 
and can cause severe pain [11]. Osteolytic metastases, mostly associated with breast 
cancer [11],  are destructive lesions mediated by osteoclasts, and involve large resorption 
of bone. They cause severe bone pain, along with poor bone density and hypercalcemia 
[26], [27]. Osteolytic tumours create a feedback loop with osteoclasts, shown in Figure 2.2 
[11]. Once in bone, the tumours release factors that increase osteoclast activity [26], [27]. 




This increased activity leads to higher resorption rates, causing factors immobilised within 
bone to be released, which in turn stimulate the tumour growth. As the tumour grows it 
releases more factors, restarting the loop.  
 
Figure 2.2. The feedback loop osteolytic tumours and bone. Reproduced with permission 
from Roodman et al. [11] Copyright Massachusetts Medical Society. 
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2.3 Bisphosphonates  
 
A key treatment for diseases which present with high resorption are anti-resorptives. 
Bisphosphonates (BPs) are the most commonly used anti-resorptive treatments for 
skeletal disorders [28] and one of the most common in the treatment of cancer-related 
bone resorption [26], [29], [30]. They are taken either orally or intravenously (IV) and bind 
to the mineral content of bone. During resorption they are released, where they work on a 
biological and physicochemical level to lower the level of resorption taking place [31]. Due 
to osteoporosis being an irreversible disease, BP treatment length is long, with a usual 
initial course of 3 to 5 years, depending on disease severity, before a review. In many 
patients, BP treatment is a lifelong process [32], [33]. 
In the US, the market for BPs was reported at $11-12 billion in 2012 [34] and it is 
estimated that over 190 million prescriptions for oral BPs have been dispensed worldwide 
since their first clinical use in 1969 [35]. A study of women in the US noted over 
300,000 patients initiating BP treatment for osteoporosis in the first quarter of 2012 [36]. It 
has been reported that as many as 1 in 7 post-menopausal women in the US have 
received BP treatment. [37]. However, BP treatment numbers have been decreasing due 
to concerns regarding their side effects, which is leading to complications associated with 
osteoporosis to increase [38]–[41]. 
The properties of some of the more commonly prescribed BPs are summarised in 
Table 2.1. Throughout this thesis, BPs are referred to by their British Approved Names, 
i.e. those ending with the –onic acid suffix, rather than the –ate forms, as they match the 
international non-proprietary names designated by the World Health Organisation. 
 
  




Table 2.1. Commonly prescribed bisphosphonates and their primary treatment, delivery 
method (oral or intravenous (IV)), anti-resorptive potency (*relative to etidronic acid) and 
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2.3.1 Chemical structure and mechanism of action 
 
BPs are synthetic analogues of inorganic pyrophosphate (PPi) [16], [45], a naturally 
occurring regulator of bone mineralization. Both contain two phosphonate molecules 
bound to a central atom. BPs differ from PPi in that they contain a non-hydrolysable carbon 
as their central atom, rather than an oxygen molecule [29]. This prevents the enzymatic 
breakdown of the drug [46] and reduces the risk of negative effects occurring throughout 
the body. All BPs have the same generic structure shown in Figure 2.3, and this structure 
gives the BPs their specific mechanism of action. 
 
 
Figure 2.3. The generic bisphosphonate structure. 
The BP structure controls two key effects: calcium affinity and anti-resorptive 
action. The generic structure causes BPs to bind to bone [31], and in particular bones with 
high turnover rates [47].  BPs readily chelate Ca2+ ions [42], [48], and once in the body, 
they target the calcium in hydroxyapatite (HA) - Ca10(PO4)6(OH)2 [49] - the mineral 
component of bone. The two phosphonate molecules work as  “bone hooks” to give the 
BPs their high affinity for bone mineral [31]. The calcium affinity provided by the chemical 
structure allow for the bone specific effects of BPs.  
BPs also contain two functional groups. The first functional group (R1) is usually a 
hydroxyl group, which allows for chelation of calcium ions by tridentate bonding, as 
opposed to bidentate [31], [45], [48], [50]. This further increases the BP ability to bind 
calcium. The second functional group (R2) can also cause a slight effect on calcium binding 
affinity, though this is not its primary function [42], [45]. For example, the primary amine 
group in pamidronic acid and alendronic acid creates more hydrogen bonds with the 
surface of the HA, and thus further increases their affinity for the mineral [51]. When BPs 
bind to HA, they can prevent dissolution, which is thought to contribute slightly to their 
prevention of resorption [31], [49], [52]. 
The amount of BP bound by bone is controlled by two factors. Firstly, administration 
method, which affects bioavailability. This is lower than 1 % for oral administration, but 
100 % for IV [16]. Secondly, the affinity for calcium affects the amount of the bioavailable 
drug that binds to bone. Approximately 50 % of bioavailable BP locates to the bone, with 
the remaining 50 % quickly leaving via renal excretion [29], [53]. Zoledronic acid (ZA), a 




higher affinity BP, has a reported release rate of only 38% [54]. The effects of BP calcium 




Figure 2.4. BP interaction with bone. Reproduced with permission from Nancollas et al. 
[45]. 
Over time, the BP in bone accumulates. Though the blood serum concentration is 
relatively low (estimated to be 1.47 µM for IV ZA [55]), the high affinity for calcium and 
prolonged treatment length leads to much higher concentrations within the bone. The 
dormant bone concentration is thought to lie between 200 and 2000 µM, depending on BP 
used, treatment method and length [56], [57]. This is thought to be higher still in bones 
with high turnover rates, such as the jaws [56]. 
Once bound, the BP remains inactive until it is displaced by other ions, or in the 
case of resorption, when the structure it is bound to degrades and it is released into the 
surrounding area [31]. It is hypothesised that the low pH of a resorption lacuna facilitates 
the release of the BPs into the local environment further, by protonation of the 
phosphonate groups and reducing chelation [48]. The concentration of BPs in an 
osteoclast lacuna is estimated to be approximately 1000 µM [26], [31]. After BPs are 
released into an osteoclast lacuna, they are internalised by the endocytic osteoclasts [31], 
[58], [59]. Their proximity to osteoclasts, and the tendency of osteoclasts to internalise 
molecules are thought to be behind BPs specific effect on bone resorption. 
On a biological level, BPs reduce resorption by causing apoptosis of osteoclasts. 
The R2 group mainly controls the mechanism of action for this, as well as efficacy and 
potency [29], [45], [48]. The mechanism by which apoptosis is caused varies depending 
on the generation of the BP. There are currently three BP generations, with each new 
generation being more potent than the last [50]. First generation BPs are metabolised by 
the osteoclasts into a cytotoxic analogue of adenosine triphosphate, which accumulates 
within the cells [58]. Second and third generation BPs are collectively known as 
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nitrogen containing BPs (nBPs), as their R2 group contains a nitrogen molecule [48]. In 
third generation BPs this nitrogen molecule is found in a heterocyclic ring [31], [42]. nBPs 
have a much more specific mechanism, blocking the production of farnesyl pyrophosphate 
synthase in the mevalonate pathway [42], [60], [61]. The mevalonate pathway regulates 
several processes key to the osteoclast, including protein ruffling and cell migration, and 
is shown in Figure 2.5 [29], [31]. The inhibition of this pathway prevents the ruffled border 
from forming, removing the osteoclasts’ ability to resorb bone [62], and ultimately leads to 
apoptosis, as the mevalonate pathway effect prevents the formation of proteins key for 
cellular survival [63].  
 
Figure 2.5. The mevalonate pathway. Reproduced with permission from Paulo et al. [48] 
under a Creative Commons license. 
As Table 2.1 indicates, there is a wide range of BP potencies. These potencies are 
defined related to the first BP, etidronic acid, and are measured by the ability of BPs to 
increase bone density in rats in the ‘Schenk’ model [31], [64]. The more potent BPs are 
used to treat bone metastases, while the less potent are used to treat osteoporosis, or 
other similar bone related diseases [1], [48], [65]. The BP effect is not limited to preventing 
resorption through osteoclast apoptosis, however. 
Although the primary effect of BPs is on osteoclasts, BPs have also been shown 
to affect osteoblasts. An in vitro study showed that, when cultured in the presence of 
different BPs, osteoblast proliferation increased [66]. However, differentiation and 




mineralisation decreased. These effects could potentially cause an increase in osteoclast 
number while decreasing maturation. Further work from the same group indicated that 
transforming growth factor β (TGFβ) production increased while RANKL production 
decreased [67]. These effects were manly seen with low concentrations of BPs (<1 µM), 
while higher concentrations saw less of an effect [66]. These signalling effects may lead 
to the promotion of matrix production and the reduction of osteoclast formation, 
contributing to the clinically seen anti-resorptive effects. 
Mesenchymal stem cells are a key part of bone tissue regeneration, due to their 
ability to differentiate into bone cells, and as such, BP effects on these cells have been 
examined. A study from Park et al. investigated the effects of clinically relevant 
concentrations of ZA on stem cells from bone marrow of four different areas of the mouth, 
however, they saw no effects on viability, proliferation and morphology [68]. 
 
2.3.2 Effects of treatment 
 
BPs prevent osteoclast activity, which lowers bone resorption. During treatment, patient 
resorption rate lowers to a new steady state level, where it stays approximately constant 
and does not progress over time [31]. This takes 3 months for oral treatment, and less with 
IV administration [29]. The new resorption level is vital in the treatment of osteoporosis, 
allowing for an increase in bone density and a reduction in the risk of fracture [69]. BPs 
can lower the fracture rates of osteoporosis patients by between 20 and 50 % [70]–[72]. 
This new steady state resorption level is maintained until the BP has left the body. 
The length of time taken to leave the body following the cessation of treatment 
varies with binding affinity [45]. ZA can inhibit resorption for up to a year from a single 4 mg 
dose [73]. Several studies have compared patients receiving 10 years of alendronic acid 
treatment to patients receiving 5 years of alendronic acid followed by 5 years of placebo 
treatment [74]–[76]. In all cases, a BP effect on resorption was still seen 5 years after the 
cessation of treatment.  
The reduced resorption rate is also beneficial to patients with OI and PDB. In OI 
patients, bone mass and mineral density increase as resorption rate decreases. This leads 
to a lower fracture rate, though still higher than a healthy patient [18], [19], [77]. Osteoclast 
inhibition prevents the high resorption triggered by the hypersensitive osteoclasts in PDB 
patients, allowing for bone remodelling to return to a normal rate, decreasing fracture rate 
and reducing pain [20]. 
Due to the resorption effect seen in bone metastases, BPs are a common 
treatment. BPs are hypothesised to work both directly and indirectly against tumours, as 
shown in Figure 2.6 [26], [78]–[81]. The high resorption rate triggered by the tumours is 
reduced, which helps manage symptoms [31]. Tumour cell invasion is reduced, while 
apoptosis is increased, reducing tumour burden. BPs also reduce the adhesion of cancer 
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cells [82]. Lowered osteoclast activity and effects on the immune system indirectly affect 
tumours. BPs are anti-angiogenic, reducing the level of circulating Vascular Endothelial 
Growth Factor (VEGF), the most important factor in angiogenesis [83]. This 
anti-angiogenic effect is hypothesised to contribute to the reduction of tumour burden 
through the reduction of tumour vascularisation [81]. 
The reduced resorption rate closes the feedback loop caused by osteolytic 
metastases, preventing the release of immobilised growth factors and thereby reducing 
tumour burden [11], [26]. Although osteosclerotic tumours primarily affect osteoblast 
activity, BPs have been shown to be beneficial in their treatment; helping the management 
of pain and preventing fracture [11]. It has been demonstrated that osteoclast activation is 
involved in the formation of osteoblastic metastases [84], and therefore their regulation by 
BPs is advantageous. This wide range of effects make BPs useful in the treatment of bone 
metastases, however BPs also come with side effects. 
Several adverse effects can come from BP treatment. Oral BP administration 
causes toxicity to the mucosa of the gastrointestinal tract, which in severe cases can lead 
to ulceration, and this previously led to a lack of patient adherence [29], [85]–[87]. 
Advances in the field have reduced these effects. Increased potency BPs allow for reduced 
treatment frequency, and IV administration avoids contact with the gastrointestinal system 
entirely. BP treatment has more recently been associated with side effects in the jaw, 
especially in longer term courses of treatment [1]. Though the bone is affected, BPs also 
effect the oral mucosa. 
 
 





Figure 2.6. Proposed anti-tumour effects of bisphosphonates in bone. Reproduced with 
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2.4 Oral mucosa 
 
The oral mucosa is a mucous membrane found in the oral cavity. It provides protection; 
both from mechanical forces and as a barrier against microorganisms. It also has a role in 
taste and touch, and is involved in the secretion of saliva [88]. It is made up of a stratified 
squamous epithelium, a basement membrane, the lamina propria and a submucosal layer 
containing nerves and blood vessels [89], [90].  A diagram of the oral mucosa is shown in 
Figure 2.7, with a histological section shown in Figure 2.8. 
The epithelium is made up of keratinocytes with four distinct morphologies [91], 
[92]. The basal layer is a single layer of cells and lies above the basement membrane. The 
keratinocytes in this layer are cuboidal and the least mature of the epithelium. They are 
attached to the basement membrane through hemidesmosomes and focal adhesions. The 
basal keratinocytes are proliferative [89], [93]. Above this are differentiated, squamous 
cells, forming the prickle cell layer. These two layers make up approximately two thirds of 
the epithelium. Next is the granular layer, where cells appear longer and flatter. The final 
layer is the keratinised or cornified layer, where cells are dead and normally contain no 
organelles [89]. When the epithelium exists in this form it is orthokeratinised, though some 
oral mucosa is parakeratinised, that is, its keratinised layers still contain nuclei [92]. The 
epithelial thickness within the mouth varies from approximately 100 µm in the soft palate 
and floor of the mouth, and 500 µm in the buccal and labial mucosa [91]. At the junction 
between the epithelium and the connective tissue below, there are downward projections 
of epithelium – called rete ridges – which increase the surface area of the junction and 
allows for mechanical forces placed on the epithelium to be spread over a greater area of 
tissue [91]. 
Below the epithelium is the basement membrane, which contains laminin 5 and 
collagen IV [94]. The lamina propria is connective tissue, made of mainly collagen I and III, 
and contains fibroblasts. The fibroblasts synthesise the majority of molecules found in the 
extra cellular matrix (ECM). Below the lamina propria usually lies the submucosa. This 
layer is made up of fatty tissue, blood vessels and nerves, and contains the salivary glands. 
The blood supply is rich, particularly in regards to other epithelial tissue such as skin, and 
this is thought to contribute to the fast healing of the oral mucosa [91]. This layer, however, 











Figure 2.7. A simplified cross sectional diagram of the oral mucosa. Adapted with 
permission from Glim et al. [89] 
 
 
Figure 2.8. Haematoxylin and eosin stained section of healthy oral mucosa. Reproduced 
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The gingiva is the specific oral mucosa that sits over the jaws, and contains no 
submucosal layer, with the lamina propria instead attaching directly to the bone [89]. This 
arrangement is called mucoperiosteum [91]. It is a masticatory mucosa, and contains a 
relatively thick epithelial layer (approximately 250 µm), as it is subjected to shear forces 
and abrasion [91]. Its epithelium can be up to 75 % parakeratinised, however this varies 
from person to person [92]. The lamina propria contains more dense collagen, with less 
elastin and vascularisation [89], [91], [92]. A histological section of gingiva is shown in 




Figure 2.9. Haematoxylin and eosin stained section of healthy gingiva. Reproduced with 
permission from Buskermolen et al. [94] under a Creative Commons license. Annotations 
own. 
2.4.1 Oral wound healing 
 
The wound healing process in the mouth involves several different cell types from both the 
hard and soft tissue working in unison to close the wound and generate new tissue. Wound 
healing follows four phases: the haemostatic phase, the inflammatory phase, the 
proliferative phase and the remodelling phase [96]. In the first phase, a blood clot seals 
the wound before a provisional matrix made of fibrin mesh and adhesion proteins is 
formed, while inflammatory cells are recruited. Within 24 hours of the wound creation, 
inflammatory cells arrive, secreting proteases and removing bacteria from the wound [96]. 
In the proliferative phase, ‘granulation tissue’ – highly vascularised tissue made of ECM 
and fibroblasts – replaces the provisional matrix, while fibroblasts, keratinocytes and 
endothelial cells from the wound edges proliferate and migrate towards the centre of the 
wound [96]–[98]. Myofibroblasts – fibroblasts that express high levels of α-smooth muscle 
actin – contract to close the wound. In the remodelling phase, the newly formed tissue 








 Within the proliferative phase, the soft tissue wound closes. This process is mainly 
controlled by keratinocytes [99]. When the epithelium is wounded, cells in the basal 
epithelium loosen their adhesions to allow migration and begin to divide more rapidly [99], 
[100]. The cells directly at the wound edge migrate across the wound, until cells from both 
sides meet and contact inhibition prevents further migration [91], [101]. Cells behind the 
wound edge proliferate in place, and some cells from the layers above the basal layer roll 
across as the cells below them migrate. Once a single layer of epithelia covers the wound, 
the keratinocytes proliferate in place to stratify and form a complete, multi-layered 
epithelium [99]. The proliferation is controlled by growth factors. During this process, 
keratinocytes release growth factors which in turn stimulate fibroblasts to migrate and 
deposit new ECM [102]. This new ECM allows for more keratinocyte motility [103]. 
Throughout this process, both fibroblasts and keratinocytes release TGFβ, which 
stimulates granulation tissue and myofibroblast formation required to complete the 
proliferative phase [104]. Currently, most of what is known of epithelial wound healing 
comes from skin [96], however several key differences exist in oral mucosa healing [105], 
[106]. 
 With the oral mucosa, wounds heal more quickly. Oral mucosa wounds also heal 
with less scarring. Several theories exist as to why this is. Firstly, more interleukin 1 (IL-1) 
is found in oral wounds, which increases the immune response to injury [107]. Saliva is 
known to contain the antimicrobial peptide histatin, which has been demonstrated to speed 
up the wound healing process [108]. Oral cells are thought to proliferate more quickly in 
response to injury and close the wound faster [98]. Finally, oral mucosal fibroblasts have 
been demonstrated to be phenotypically different to those in skin [109]. 
 Several studies have demonstrated the differences between skin and oral mucosal 
fibroblasts, and how those differences allow for faster, non-scarring wounds in the oral 
mucosa. Oral fibroblasts are phenotypically closer to foetal cells, and foetal wounds also 
heal without scarring [110]. A variety of genes relating to this healing phenotype are 
expressed in greater number in oral fibroblasts, compared to those found in skin [111]. 
Oral fibroblasts express higher levels of matrix metalloproteinases (MMPs), a facilitator of 
remodelling, whilst skin fibroblasts express higher levels of tissue inhibitors of  MMPs 
[109]. Oral fibroblasts also have longer telomeres, and therefore a higher proliferative 
lifespan [112], an increased ability to reorganise and contract collagen [113], and 
demonstrate a resistance to the myofibroblast formation caused by TGFβ [114]. These 
phenotypic differences allow for a complete, scarless wound healing process. 
The wound healing process for a tooth extraction is shown in Figure 2.10. Bone 
resorption is induced and a blood clot forms [115]. Epithelial cells begin migration 12 hours 
after surgery. Granulation tissue forms over the first few days [97]. Between days 
7 and 10, bone production begins [116]. A provisional matrix is formed, and mineralisation 
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and the formation of immature bone occur. Re-epithelialisation occurs between days 
20 and 40. Within 1 year of extraction, the socket is completely healed, with most of the 
bone remodelling occurring within 3 months [117]. However, in BP patients, these 
processes are affected, which may lead to BRONJ, and tooth extraction is the most 














   
Figure 2.10. Diagram representing the healing of an extraction socket. Immediately after 
extraction, a blood clot forms. Granulation tissue begins replacing the clot after 2-3 days. 
At 4 days epithelisation begins. After 7 days, provisional matrix begins to replace 
granulation tissue, some mineralisation begins. Granulation tissue is replaced by 
connective tissue after 20 days. Epithelial fusion occurs between 20 and 40 days. Adapted 











2.5 Bisphosphonate-related osteonecrosis of the jaw (BRONJ) 
 
Osteonecrosis of the jaw (ONJ) as a symptom in BP patients was first reported in 2003 
[43], and was first recognised by oral and maxillofacial surgeons in 2004 [118]. A 
photograph of a BRONJ case is shown in Figure 2.11. It usually develops following 
damage to the jaw, where the BP mechanism has a chain reaction effect, affecting both 
the bone and surrounding soft tissues and causing the development of a disease that is 
extremely difficult to treat. 
The current BRONJ definition was created by the American Association of Oral 
and Maxillofacial Surgeons (AAOMS) in 2007 [119]. A patient is defined as having BRONJ 
when they have “exposed bone or bone that can be probed through a fistula(e) that has 
persisted for more than eight weeks”, provided they are being or have been treated with 
BPs, and have no history of radiation therapy to the jaws [1]. Within this definition of 
BRONJ, there are four stages of increasing severity, shown in Table 2.2. It has been 
hypothesised that up to 25 % of BRONJ patients may be Stage 0 and as yet undiagnosed 
[120], [121]. 
As BRONJ is a recently defined condition, the risk factors associated with its 
development are not yet fully clear. The specific BP taken, the method of administration 
and the length of treatment are all thought to influence the risk of BRONJ developing. The 
incidence of BRONJ has been difficult to determine due to a variety of factors [122] – with 
differing treatment lengths, doses, administration methods and the various potencies of 
the different BPs making collating the data difficult. Generally, the risk of developing 
BRONJ in patients receiving intravenous BPs is between 1 and 10 %, and in patients 
receiving oral BPs, between 0.01 and 0.001 % [3]–[5]. This risk increases with length of 
exposure, with a 4 year BP treatment course thought to double the risk of a patient 
developing BRONJ compared to a 2 year treatment [1], [123]. Due to the risk factors 
associated with longer term treatment, and the high number of new BP prescriptions, the 
number of BRONJ cases increases every year [121]. 
Another risk factor is operative treatment to the jaws. The majority of BRONJ cases 
are preceded by a ‘dental event’ [5].  Approximately 60 % of BRONJ cases follow a tooth 
extraction [5], [34], [57], and as such, a tooth extraction is known to increase the risk of 
BRONJ. Patients taking BPs orally are reported to have a 2 % chance of developing 
BRONJ following tooth extraction [124], while the risk following extraction in patients 
receiving IV BPs has been reported higher than 14 % [125]. BRONJ can also be preceded 
by other oral surgeries, and periodontitis and trauma from poor-fitting dentures have been 
reported as triggers [126]. Spontaneous cases of BRONJ have been reported, however 
these are rare and often in areas most susceptible to oral mucosa trauma, and as such it 
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is hypothesised that these cases are not in fact spontaneous, but the result of undetected 
trauma [47], [127]. 
BRONJ affects the two jawbones with differing frequency. The mandible alone is 
affected in 73 % of cases, while 22.5 % affect only the maxilla [5]. In 4.5 % of BRONJ 
cases both jaws are affected simultaneously. BPs accumulate in greater concentrations in 
bone with higher turnover rates. Due to mastication forces often leading to micro fractures 
and requiring remodelling, the jaws have one of the highest turnover rates in the body [2], 
[47]. This, in combination of the presence of dental pathology and the proximity of the bone 
to the oral environment, is thought to contribute the specificity of BRONJ to the jaw. 
Age and sex have been reported as risk factors for BRONJ [128], but there is the 
possibility that this is due to older females being more susceptible to conditions which 
require BP treatment, and therefore at a higher risk of contracting BRONJ. Both breast 
cancer and osteoporosis are more common in females, and in particular older females, 
and hence this group is prescribed BPs at a higher rate than males. 
Other medications have also caused ONJ, and these can be grouped with BRONJ 
under the umbrella term Medication Related Osteonecrosis of the Jaw (MRONJ) [123]. 
Denosumab prevents bone resorption by inhibiting RANKL, and patients have a 
comparable risk of ONJ as those prescribed ZA [123]. Anti-angiogenic medications 
prescribed as cancer treatments, such as sunitinib (a tyrosine kinase inhibitor) and 
bevacizumab (a VEGF inhibitor), have been shown to cause ONJ [129]. These 
medications are often prescribed alongside BPs, and can raise the risk of BRONJ by as 
much as 10% [123]. 
Some debate over the name of the condition still exists, with AAOMS preferring the 
term MRONJ, while the International Task Force on Osteonecrosis of the Jaw prefer 
anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) [130]. These definitions 
cover ONJ caused by denosumab and anti-angiogenic medications. While denosumab 
causes an anti-resorptive effect, it does not cause cytotoxicity [131]. As the work in this 
thesis investigated the cytotoxic effects of BPs, the term BRONJ is used throughout. 
Osteonecrosis can also be caused by radiotherapy, termed osteoradionecrosis 
(ORN), hence the need for the exclusion of radiotherapy patients from the BRONJ 
diagnostic criteria [98], [132]. ORN also presents with necrotic bone, the formation of 
fistulae and a dehiscent oral mucosa wound [133], [134]. However, as the source of this 
issue is radiation, this was not included in the focus of the work in this thesis. 
  





Figure 2.11. Exposed necrotic bone in a zoledronic acid patient. Reproduced with 
permission from Ruggiero et al. [118]. 
 
Table 2.2. Stage definitions of BRONJ. [1] 
Stage Symptoms 
Stage 0 No clinical evidence of necrotic bone, but non-specific 
symptoms or clinical and radiographic findings not attributable 
to other jaw diseases 
Stage 1 Exposed, necrotic bone or necrotic bone that can be probed 
through a fistula(e) in asymptomatic patients with no evidence 
of infection 
Stage 2 Exposed, necrotic bone or necrotic bone that can be probed 
through a fistula(e) with evidence of infection 
Stage 3 As stage 2, with one or more of: 
• Exposed, necrotic bone extending beyond alveolar 
bone 
• Pathologic fracture 
• Extra-oral fistula 
• Oral antral/oral nasal communication 
• Osteolysis extending to the inferior border of the 
mandible or sinus floor 
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2.6 Pathophysiology of BRONJ 
 
The mechanisms by which BRONJ develops are yet to be fully determined [135], however, 
it is hypothesised that several combine to cause the disease to develop following the 
wounding of the jaw, affecting both the bone and the surrounding mucosa. BP effects on 
bone remodelling, angiogenesis, inflammation, soft tissue and infection are all thought to 
contribute to the disease. A diagram showing one hypothesis for the sequence of BRONJ 
development is shown in Figure 2.12. 
 When bone is damaged, osteoclast resorption is a key part of the remodelling 
process during wound healing [136]. BP effects on osteoclasts prevent remodelling from 
occurring, which thereby prevents full wound healing [137]. This non-healing jaw wound is 
the beginning of BRONJ. This is similar in MRONJ cases where resorption is prevented, 
supporting the hypothesis that osteoclast inhibition is involved in the development of 
BRONJ [138]. 
Osteonecrosis is considered as the death of bone tissue due to lack of blood supply 
[1]. Mandibular bone is one of the densest bones in the body and at its thickest part 
contains few blood vessels, making it a prime target for necrosis [48]. Successful bone 
healing relies on angiogenesis [139]. BPs’ anti-angiogenic properties inhibit the formation 
of new blood vessels [140], which hinders wound healing and leads to the damaged bone 
becoming necrotic. Anti-angiogenic medications have led to ONJ, supporting the 
hypothesis that BP-inhibited angiogenesis is involved in the development of BRONJ [129]. 
Inflammation has also been linked to the development of BRONJ, with it 
hypothesised that early, low level inflammation may be a trigger for the condition [141] and 
BPs shown to be pro-inflammatory [137]. Inflammation is part of the normal healing 
response in an extraction socket [115], and therefore low level inflammation will exist prior 
to the development of BRONJ. The number of medullary inflammatory cells has been 
statistically linked to the onset of BRONJ in patients, suggesting that inflammation may 
progress to necrosis in some cases [141]. 
As the damaged bone is exposed to the surrounding environment, BPs are 
released, and at certain concentrations, become toxic to the surrounding tissues. The full 
mechanism by which BPs are released into the mouth, and the concentration to which the 
oral mucosa is exposed are not known, and is difficult to estimate given the variety of BPs, 
affinities and dosing regimen [56]. A study by Scheper et al. measured the ZA 
concentration in the saliva of BP patients 5 minutes after IV treatment at between 
0.4 and 5 µM [142]. In higher affinity BPs, such as ZA, more BP will be present and it will 
be located close to the surface of the bone [45]. Therefore the concentration of BPs with 
a lower calcium affinity may be lower. During wound healing and infection, the pH in the 




mouth can decrease, which is hypothesised to lead to further and more prolonged release 
of BPs due to the effect of pH on chelation described in section 2.3.1 [143]. 
BPs within the expected oral range have been shown to be toxic to both oral 
keratinocytes and fibroblasts, and negatively affect cell proliferation and migration [57], 
[140], [144]. Oral mucosa wound healing is known to be more difficult without healthy 
underlying bone [98]. These combine to prevent the damage soft tissue from healing and 
maintain bone exposure. This is Stage 1 BRONJ, and this soft tissue toxicity is 
hypothesised to be key to BRONJ development [2]. As the mucosa of the lower jaw is 
thinner, it contributes to the mandible being more susceptible to the development of 
BRONJ [53].  
With no oral mucosa surrounding it, the necrotic bone becomes exposed to the 
inside of the mouth, and therefore to several species of bacteria [47], [145]. Infections both 
prior to and post-extraction have been hypothesised as risk factors for BRONJ, with 
bacteria commonly present in biopsied necrotic tissue, and infection thought to occur in 
60 % of BRONJ patients [146], [147]. BPs can lead to an increased biofilm formation in 
the mouth, which increases infection risk  [58], [148]. These factors, and the lack of blood 
flow to the necrotic area, makes BRONJ patients particularly at risk of infection. This 
infection is Stage 2 BRONJ, with Stage 3 then developing if it goes untreated. 
If untreated, the symptoms worsen. The first fatal case of BRONJ was reported in 
2018, where a ZA patient developed BRONJ following a routine tooth extraction [149]. This 
was unable to be treated and progressed to Stage 3 BRONJ, whereby the patient began 
to bleed from the wound and later died following haemorrhagic shock. 
 
 
Figure 2.12. One hypothesis for the sequence of BRONJ development following tooth 
extraction. Reproduced with permission from Ikebe et al. [47]. 
 Literature review  
25 
 
2.7 BRONJ treatment 
 
There is no specific treatment for BRONJ currently available [150], and management 
strategies vary depending on the patients other co-morbidities, quality of life, and stage of 
the disease. The relatively low incidence and incomplete knowledge of its pathogenesis 
has made devising a definitive treatment challenging [151]. The main treatments are 
summarised in Table 2.3. These include pain medication, antibiotics and antibacterial 
rinses, and in more severe cases, the surgical debridement of necrotic tissue [44], [135], 
[152]. The guideline treatment for BRONJ is to treat conservatively without surgical 
intervention, however this has a success rate lower than 50 % [153]. Surgical intervention 
has been demonstrated to have success [154]–[158], however this is not always possible 
due to patient ineligibility, and can lead to relapse, often due to infection [159]. Surgery to 
remove the necrotic bone is difficult, as distinguishing between necrotic and healthy bone 
may be challenging and dependent on surgical skill [159], [160]. Surgery can expose vital 
bone which has also been subjected to systemic BP treatment and is therefore not ideal 
[118], [161]. As such, other treatments have been sought. 
One treatment suggested is a drug holiday - whereby a patient ceases BP 
treatment for several months prior to dental extractions. However, in a retrospective study 
of risk factors, this was shown to be ineffective in the prevention of BRONJ [162]. The 
calcium binding affinity for BPs, as described in section 2.3.2, gives them an incredibly 
high bone retention rate for BPs and an extended period of action, and as previously 
mentioned, studies showing 5 year placebo treatment after 5 years alendronic acid 
treatment did not completely remove BP effect [74]–[76]. As such, a short term drug 
holiday is inadvisable. Given the severity of conditions that BPs are used to treat, longer 
term drug holidays are also likely to be unsuitable for patients. 
 The need for a more specific BRONJ treatment is clear, and as such current 
research in the area focusses on two areas: further identification of the pathophysiology 
of BRONJ and potential novel treatments. 
 
Table 2.3. Current treatment methods for BRONJ. [1] 
Stage Treatment 
Stage 0 Systemic treatment, including antibiotics and pain medication 
Stage 1 Antibacterial rinse, quarterly clinical follow-up, & patient education 
and review of indications for continued bisphosphonate therapy 
Stage 2 Systemic treatment with oral antibiotics, oral antibacterial rinse, 
pain control, debridement, and infection control 
Stage 3 Antibacterial rinse, antibiotic therapy, pain control, surgical 
debridement or resection to reduce pain/infection 




2.8 Current position of BRONJ research 
 
Due to the severity of BRONJ and the increasing number of BRONJ patients diagnosed 
every year [121], there is an increasing amount of research focussed in the area, aiming 
to further understand the causes of BRONJ while also developing a more specific and 
successful treatment for the disease. In understanding the causes of BRONJ, a key focus 
is the effects of BPs on the oral mucosa, due to the hypothesis that this is key to the 
development of the disease [2]. Work in this area focusses on both 2D and 3D cell culture, 
and a wide variety of BP effects. In order to gain a further understanding of the condition, 
several in vivo models of the disease have been developed in small and large animals. 
Finally, a variety of novel treatments for the disease have been developed and examined, 
using 2D and 3D cell culture and in vivo BRONJ models to test their efficacy. The work 
presented in this section mainly covers BRONJ soft tissue research, due to the previously 
described hypothesis regarding its importance. 
 
2.8.1 2D effects of BPs 
 
Several studies have investigated the effects of BPs on cells of the oral mucosa in 2D, 
examining a broad variety of effects, including viability, migration, proliferation and 
adhesion. This section summarises the main findings of these studies. This section only 
reviews articles which have used either pamidronic acid (PA) or zoledronic acid (ZA), as 
these BPs are most commonly associated with BRONJ [153], [163]. A summary of the 
effects seen on fibroblasts is shown in Table 2.4, with the effects on keratinocytes shown 
in Table 2.5. 
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Table 2.4. A summary of the current literature investigating the 2D effects of pamidronic 
acid (PA) and zoledronic acid (ZA) on fibroblasts. 
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Table 2.5. A summary of the current literature investigating the 2D effects of pamidronic 
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 Cell viability 
 
The effects of BPs on oral mucosa cell viability have been extensively studied. 
Investigations have used fibroblasts and keratinocytes from a variety of sources to assess 
the effects of BPs over time. Both PA and ZA have been reported to be toxic to fibroblasts 
and keratinocytes at concentrations clinically relevant to BRONJ patients [35], [57], [170]–
[172], [175]–[177], [86], [144], [164]–[169]. 
 PA has been demonstrated to be toxic to human oral fibroblasts after 24 hours, 
72 hours, 96 hours and 1 week of administration. When studied for 24 hours, a 5 µM 
concentration was shown to be toxic by Walter et al. [170]. However in the longer term 
studies, this concentration was shown to have no effect. A half-maximal inhibitory 
concentration (IC50) of 42 µM was generated at 72 hours of treatment [165]. 
Concentrations above 10 µM were required to significantly reduce viability in the 96 hour 
study, and 30 µM and above in the 1 week study [144], [164]. In the 24 hour study, Walter 
et al. also tested ZA and found only a 50 µM concentration was toxic, indicating PA is more 
potent. ZA is known to be more a potent anti-resorptive and has consistently been 
demonstrated to be more toxic to oral mucosa cells, however, supporting the results of the 
longer term studies and negating the results seen by Walter et al. [86], [144], [170].  
 Similar studies have been conducted with ZA. A study by Ravosa et al. indicated 
ZA concentrations above 30 µM were toxic to a human gingival fibroblast (HGF) cell line 
after 48 hours of treatment [35]. Komatsu et al. saw toxicity from a 14.7 µM treatment at 
this time point [55]. Two studies examined HGFs in the presence of ZA over 72 hours, one 
found concentrations of 30 and 100 µM toxic [167], and the other indicated 50 µM (the only 
concentration tested) to significantly reduce viability [168]. Jung et al. found 5 µM and 
above ZA was toxic to periodontal ligament fibroblasts at the same time point. Zafar et al. 
demonstrated 10 µM concentrations were toxic to HGFs at 96 hours [171], and the 
previously referenced study by Cozin et al. found a dose dependent effect above 2 µM at 
1 week of dosing [144]. The effect of ZA on fibroblast viability has been tested as far as 
4 weeks of treatment, where concentrations ranging from 0.15625 to 2.5 µM were shown 
to have a dose dependent, significant effect on viability [166]. While it is evident that PA 
and ZA are toxic to fibroblasts, there is a lack of clarity regarding this effect. 
 Keratinocyte viability in the presence of both drugs has also been examined. Pabst 
et al. cultured human oral keratinocytes in the presence of either PA or ZA in two studies, 
one over 24 hours [175] and one over 72 hours [86]. It was demonstrated that ZA was 
twice as toxic as PA at 24 hours, with a 50 µM concentration causing a significant reduction 
of cell viability, compared to 100 µM for PA, using a calcein viability assay. By 72 hours, 
5 µM concentrations of both drugs caused a significant reduction in viability, with ZA 
leading to a more pronounced effect. Kim et al. also demonstrated 5 µM concentrations of 
PA reduced human oral keratinocyte viability after 72 hours [164]. Although this again was 




only a slight reduction, with their data indicating an IC50 of approximately 50 µM. Work by 
Ohnuki et al. indicated 3 and 10 µM ZA reduced primary oral keratinocyte viability by a 
small but significant amount after only 48 hours of treatment [177]. Murine oral 
keratinocytes appeared more resilient in a study by Landesberg et al., where 
concentrations from 3 to 30 µM had no effect on cell viability over 1 week, but 100 µM PA 
significantly reduced viability after 24 hours [57]. In the previously mentioned study by 
Ravosa et al. [35], human oral keratinocytes immortalised through transduction to prevent 
telomere shortening (OKF6/TERT-2) [179] were cultured for 48 hours in the presence of 
ZA, where 10 µM and above concentrations significantly reduced viability. 
However, Renò et al. indicated that sub-toxic concentrations had beneficial effects 
on HaCaT cells (a common immortalised skin keratinocyte line), with 10 nM to 10 µM ZA 
concentrations increasing cellular viability, measured through a resazurin reduction based 
assay [178]. It was suggested this was due to BPs inhibiting farnesyl pyrophosphate (FPP), 
an intermediate in the mevalonate pathway. This can inhibit wound healing as it acts as 
an agonist for glucocorticoid receptor. Therefore concentrations low enough to not cause 
toxicity but high enough to reduce FPP levels could have a positive effect on epithelial 
cells. This theory, however, is unsupported by the previously mentioned literature using 
BP concentrations below 1 µM which demonstrated no effect [165], [166], [169], [177]. 
Arai et al. also treated HaCaT cells with ZA at 10 nM and above concentrations, and 
showed no beneficial effect of nanomolar BP treatment [176]. They did, however, indicate 
that local calcium levels could drastically affect the potency of BPs. They theorised that 
due to the BP binding affinity for calcium, increasing cellular calcium levels would thereby 
increase the amount of BP acting upon the cell. While these papers are an indication of 
BP keratinocyte effects, as HaCaT cells are immortalised skin keratinocytes, this data is 
therefore not particularly relevant to BRONJ patients. Due to this, and the inconsistencies 




As well as confirming that BPs reduce viability to cells of the oral mucosa, the mechanism 
by which BPs cause cell death has been investigated. Apoptosis is the programmed death 
of a cell, and can occur in response to certain external triggers, and both PA and ZA have 
been shown to increase apoptosis in human oral fibroblasts and keratinocytes. Apoptosis 
is measured in vitro through several different techniques, generally through staining for 
specific apoptosis markers. Caspases are enzymes activated during apoptosis, and cells 
are often stained with antibodies targeted at specific caspases to identify apoptotic cells. 
Annexin V binds competitively to phosphatidylserine, a protein expressed during 
apoptosis. Fluorescently labelled annexin V staining is another commonly used method 
for measuring apoptotic cells. 
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Agis et al. demonstrated 30 and 50 µM ZA led to HGF apoptosis after 48 hours of 
treatment through annexin V staining [167]. They also confirmed their results by detecting 
the presence of cleaved poly (ADP-ribose) polymerase, another apoptosis marker. This 
work was supported by Zafar et al., who used the same cell type and ZA concentrations, 
and found increased caspase 3 staining over 96 hours [171]. Jung et al. used different oral 
fibroblasts, taken from the periodontal ligament, and saw a similar effect, as caspase 3 
staining indicated apoptosis increased fivefold with 72 hours of ZA treatment [172]. 
Soydan et al. indicated PA also led to HGF apoptosis over 72 hours in a dose dependent 
manner from 0.1 to 100 µM concentrations through measuring caspase 3 levels [165]. 
Contrarily, while Cozin et al. did observe apoptosis in HGFs with both PA and ZA, they 
indicated only PA led to increased caspase activity [144]. 
 While fibroblast apoptosis is a fairly consistent effect throughout the literature, there 
is less clarity regarding keratinocytes. Scheper et al. investigated the effects of ZA on both 
a HGF cell line and HaCaT cells [169]. They indicated apoptosis was triggered at a slightly 
lower concentration in keratinocytes (0.25 µM to 1 µM), and occurred at a considerably 
greater rate than in fibroblasts. This contradicts work from both Ravosa et al. and Kim et al, 
who compared apoptosis levels in fibroblasts and keratinocytes when treated with ZA and 
PA, respectively [35], [164]. In both studies, while apoptosis was high in fibroblasts, there 
was no significant increase in keratinocyte apoptosis. This is supported by the previously 
mentioned paper from Landesberg et al. who indicated PA did not lead to a significant 
increase in keratinocyte apoptosis [57]. Kim et al. suggested that BPs led to the cell death 
of keratinocytes by triggering early senescence, rather than apoptosis as in fibroblasts, 
and successfully stained for markers of senescence to confirm their theory [164]. 
 However, other literature again states keratinocyte apoptosis can be triggered 
through BP treatment. Both previously mentioned papers by Pabst et al. indicated a 
significant increase in human oral keratinocyte apoptosis in response to both PA and ZA 
concentrations of 5 and 50 µM, however in one paper indicated ZA led to more apoptosis, 
while the other saw higher apoptosis in PA treated cells [86], [175]. Kobayashi et al. found 
a slight increase of murine oral epithelial cell apoptosis in response to concentrations of 
100 nM to 10 µM, but only a significant increase at 100 µM [140]. Further work is needed 




Cell proliferation is a key part of wound healing. Regenerating tissue requires new cells, 
and proliferation is the process by which they are generated. It has been suggested that a 
potential mechanism by which BPs prevent oral mucosa wound healing is through 
decreasing proliferation. 




Several papers in this literature review purported to have reported on effects on 
proliferation, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or 
similar metabolic activity assays [35], [57], [144], [166], [178]. However, as these assays 
in fact measure metabolic activity, not proliferation, those results have been discussed in 
section 2.8.1.1. The review of literature in this section only relates to those papers that 
have directly measured proliferation. 
PA and ZA have both been shown to reduce proliferation of human oral fibroblasts. 
Soydan et al. examined HGF proliferation through staining for Ki67, a cellular proliferation 
marker [165]. They found PA reduced proliferation in a dose dependent manner with 
concentrations ranging from 0.1 to 100 µM, however only sampling 100 cells. A similar 
effect was found in HGFs when treated with ZA [167]. Cells were labelled with 
3[H]thymidine to track proliferation, and both 30 and 100 µM concentrations caused a 
significant reduction, in comparison to untreated cells. ZA concentrations as low as 1 and 
3 µM were found to reduce proliferation by Scheper et al., who observed proliferation 
through cell counts [169]. 
Keratinocyte proliferation has also been found to be affected by ZA. In the 
previously mentioned study by Scheper et al., HaCaT proliferation was also significantly 
decreased by 1 and 3 µM concentrations of ZA [169]. McLeod et al. found 1 µM ZA had 
no effect on OKF6 proliferation, but a 5 µM dose significantly reduced proliferation 
between 2 and 5 days culture [173]. This effect was also observed in foreskin fibroblasts 
in the same study. Work from Ohnuki et al. indicated ZA reduced primary oral keratinocyte 
proliferation, through fluorescent labelling of DNA [177]. Concentrations ranging from 
0.1 to 10 µM caused a dose dependent reduction in DNA over 48 hours. Further analysis 
indicated that this was due to the cell cycle being arrested in the S phase by damaging 
DNA and thereby reducing the expression of proteins involved in cell cycle regulation. This 
effect was also seen in work from Kim et al. [164]. Which analysed the cell cycle of both 
oral fibroblasts and keratinocytes treated with 10 and 50 µM PA. Their data again indicated 
the arrest of keratinocytes in the S phase of the cell cycle, where fibroblasts treated with 
50 µM PA were largely in the sub-G1 phase. This suggests that keratinocytes were 
prevented from completing their cell cycles while fibroblasts became apoptotic when 
treated with BPs. 
As of yet, no work has directly measured the effect of PA on keratinocyte 




In the development of BRONJ, sections of the oral mucosa fail to heal following a dental 
event. As migration is a key part of oral mucosa wound healing, the effects of BPs on 
cellular migration have been examined. Migration is often studied in vitro with a scratch 
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assay, whereby cells are cultured to confluence, before a sterile pipette tip is scratched 
across the cell monolayer to create a gap between the cells [180]. Migration across this 
‘wound’ is then assessed over time. 
 The effects of BPs on fibroblast migration have been investigated in several studies 
[35], [144], [170], [172], [173]. Data from these have shown 60 and 100 µM concentrations 
of PA significantly slowed migration over a 72 hour time period [144], [170]. As with viability 
and proliferation, the higher potency of ZA is again thought to transfer to migration effects. 
ZA concentrations of only 10, 30 and 50 µM were variably required to cause a similar effect 
to 60 and 100 µM PA [35], [144], [172]. As previously with viability, Walter et al. found ZA 
to cause less of an effect than PA, when migration was measured in the presence of both 
drugs, which is again contradictory to the other data seen with these cells [170]. 
 Keratinocyte migration has also been assessed, however several different effects 
have been reported. In two studies by Pabst et al. 50 µM concentrations of both PA and 
ZA slowed the rate of migration of human oral keratinocytes over 72 hours in scratch 
assays [86], [175]. Kobayashi et al. demonstrated a similar effect on murine oral 
keratinocytes, with ZA concentrations ranging from 100 nM to 10 µM slowing migration 
over 15 hours [140]. However, Landesberg et al. reported PA concentrations from 
3 to 100 µM had no effect on murine oral keratinocyte migration over 96 hours [57]. Only 
when cells were pre-treated with 100 µM for 72 hours prior to the experiment was any 
effect seen, and this concentration was reported to be toxic at this exposure time earlier 
the paper [57]. Several papers report cellular toxicity and migration effects from the same 
concentrations at the same time points [86], [144], [170], [172], [175], likely pointing to lack 
of wound closure through cell toxicity, rather than a separate migration effect. In all except 
the paper by Cozin et al., images of the cells are not included, and in that paper the cells 
of the unclosed wounds do not appear to be alive, with either side of the wound no longer 
well-formed [144], particularly when treated with ZA shown in Figure 2.13. 
 
 
Figure 2.13. Wound healing of primary human oral fibroblasts treated with 30 µM 
zoledronic acid. M shows fibroblasts immediately after the creation of a scratch. N shows 
the same cells 72 hours after. Reproduced with permission from Cozin et al. [144]. 
  




Alternatively, ZA has also been reported to promote migration of keratinocytes. 
Ravosa et al. also investigated migration effects on OKF6 cells, and demonstrated scratch 
wounds closed faster over 30 hours when treated with 10 µM ZA [35]. They did not explain 
this effect. Renò et al. again found ZA to promote migration in a human skin cell line 
(HaCaT) [178]. Concentrations ranging from 10 nM to 10 µM all decreased wound closure 
time in a scratch assay. 
 As previously described, proliferation is a key part of wound healing, and therefore, 
to truly assess migration effects, proliferation must be prevented. None of the previously 
mentioned papers appeared to control for proliferation in their assays. 
The migration of immortalised human foreskin fibroblasts and OKF6 cells was 
studied in the presence of sub-toxic levels of ZA by McLeod et al. [173]. Using sub-toxic 
levels of the drug ensures that toxicity will not prevent the wound from closing. Rather than 
the usual scratch assay, a transwell migration assay was performed, which assesses 
cellular ability to migrate towards a chemoattractant. This therefore gives a clearer picture 
of motility effects alone. No effect on the migration of either cell type was observed over a 
24 hour time period in this study. 
While a range of data exists for the effects of BPs on cellular migration, the methods 
by which this data has been obtained leave a lot to be desired. A study which controlled 
for proliferation alone while examining concentrations below the toxic levels of the drug 





Nitrogen-containing BPs (nBPs) have been shown to affect the adhesion of a wide variety 
of cell types including smooth muscle cells [181], endothelial cells [182], [183] and cancer 
cells [82]. This is hypothesised to be due to the nBP effect on the mevalonate pathway. 
The mevalonate pathway is responsible for the prenylation of proteins [31] – the 
BP effect prevents proteins from acting at the correct location in the cell. This leads to 
changes in proliferation, survival, cytoskeletal organisation and vesicular trafficking. The 
main effect is on Guanosine-5'-triphosphatases in the Rho family. These proteins are in a 
signalling pathway with Focal Adhesion Kinase (FAK) [184]. The phosphorylation of FAK 
is critical for the assembly and disassembly of focal adhesions [185]. Therefore the 
mevalonate pathway effect of BPs could theoretically lead to a reduction in adhesion. 
ZA has been demonstrated to decrease FAK phosphorylation in several cell types 
in vitro [82], [181], [182], [186], in conjunction with a reduction in adhesion, this further 
strengthens the theory of a link between BPs and reduced cellular adhesion. Cozin et al. 
demonstrated that 30 µM concentrations of ZA lowered fibroblast adhesion alongside its 
toxic effect [144]. Cells were stained to visualise focal adhesions and f-actin bundles in the 
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cytoskeleton, and these were seen to be reduced when cells were treated with the BP, 
shown in Figure 2.14. 
 
 
Figure 2.14 Effect of zoledronic acid on integrin-mediated cell-substratum adhesions of 
oral fibroblasts. Cells were plated on fibronectin-coated coverslips and exposed to 30 or 
60 µM zoledronic acid. The cells were fixed after 120 hours and then stained with vinculin 
and phalloidin to visualize the focal adhesions and actin cytoskeleton. Reproduced with 
permission from Cozin et al. [144]. 
ZA has also been shown to prevent some integrin-mediated adhesion, specifically 
αvβ3 [82] and αvβ6 [187]. However, these integrins are not present in the epithelium of 
healthy oral mucosa, with αvβ6 only expressed in response to wounding [188]. As BRONJ 
develops following wounding of the epithelium, this pathway would be a likely candidate 
for any effect that BPs have on oral epithelial adhesion. Alendronic acid has also been 
linked to a reduction in epithelial adhesion, with biopsies from long term oral BP patients 
stained for desmoglein-1, a protein involved in the adhesion of keratinocytes in the oral 
epithelium [189]. In the patients tested, the epithelium was still intact though the outer 
layers contained less desmoglein. This suggests that in even in BP patients which appear 
healthy, the epithelium is already weaker and more susceptible to lesions forming, which 
may play a role in the development of BRONJ. 
The effects of ZA on gingival fibroblast and HaCaT adhesion to titanium were 
tested by Basso et al. [174]. In their study 0.5 and 1 µM treatments of ZA led to fewer cell 
numbers and less actin and homing cell adhesion molecule staining over 48 hours. 
However, as this was investigating their effects on titanium it is less relevant to BRONJ 
patients. 




2.8.2 3D effects of BPs 
 
 3D cell culture 
 
While 2D cell culture is a useful tool, it is not fully representative of the true in vivo setting. 
As such, 3D culture systems have been developed to provide a greater understanding of 
the function of tissues. 3D systems allow for the inclusion of several cell types in an 
environment analogous to how they would be found in vivo, and thereby allow for cell-cell 
interactions and signalling similar to the native environment, making any studies performed 
with these tissues more physiologically relevant to the clinical scenario they are 
approximating. 
Originally, 3D culture was performed on ex vivo pieces of tissue, maintained in a 
culture system [190], however due to limited availability, ethical issues, and high variability 
between samples, tissue engineered models have been developed. 
The first full thickness, in vitro oral mucosa model was developed by Masuda et al. 
in 1996 [191] and involved contracted collagen gels containing fibroblasts, with 
keratinocytes seeded on top. A similar model was developed by Rouabhia and Deslauriers 
[192], involving collagen mixed with oral fibroblasts as an analogue to the lamina propria, 
with oral epithelial cells seeded four days later. The models were cultured at air-liquid 
interface (ALI), whereby the epithelial layer was in contact with air which caused 
stratification to occur. The tissue engineered mucosa was characterised and shown to 
express several cell markers and integrins involved in the interaction between the two cell 
types within the model, and cytokine analysis of the supernatants demonstrated the 
presence of interleukins. 
This model was developed further by Dongari-Bagtzoglou and Kashleva [190], who 
used immortalised keratinocytes to increase the reproducibility of the model and the 
precision of any results generated, as the donor variability found in primary culture can 
lead to differences in the behaviour of the epithelium when stratifying [193]. Along with 
collagen, other natural materials have been used as scaffolds for tissue engineered oral 
mucosa, including gelatin and fibrin. These models have some disadvantages, primarily in 
the poor mechanical properties of the scaffold material [194]. In response to this, several 
compounds have been added to these in an attempt to improve the mechanical properties 
while also improving biological activity. For example, chitosan, a naturally derived 
polysaccharide has been added to both collagen and gelatin based scaffolds with good 
results [195], [196]. 
As well as modification of the natural materials, scaffolds from other sources have 
been developed in order to overcome the issues. Scaffolds have been derived from skin, 
with acellular dermis common, whether from a commercial source (e.g. AlloDermTM) or 
prepared in the lab (e.g. de-epidermised dermis (DED)). DED is prepared by removing the 
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epithelium and dermal fibroblasts from split thickness skin [197]. As these models already 
contain the structural architecture desired in the 3D model, they have the benefit of 
creating models that more closely represent the native environment, however they rely on 
the regular sourcing of donor skin. Through the seeding of oral cells, these scaffolds have 
been used to develop reproducible organotypic oral mucosa models which appear similar 
to native tissue with histology (Figure 2.15) and immunohistochemistry [198]–[200]. 
 
 
Figure 2.15. An example of a 3D oral mucosa model. Primary oral fibroblasts and 
keratinocytes cultured on DED for 14 days. Scale bar = 200 µM. Reproduced with 
permission from Colley et al. [199]. 
The oral mucosa sits above bone, and as such, the inclusion of a bone component 
in a 3D organotypic oral mucosa model has also been tested. In a study by Almela et al. 
[201], HA/tricalcium phosphate (TCP) discs were placed in suspension with an 
osteosarcoma cell line for three months to allows cells to invade and mineralize, creating 
something similar to human alveolar bone. A collagen based mucosa model was then fixed 
to the top of the disc with fibrin glue, shown in Figure 2.16. Bae et al. [202] placed rat 
calvariae on an acellular collagen gel, then directly seeded oral fibroblasts in a collagen 
gel onto the bone component, with keratinocytes seeded on top three days later. While 
these scaffolds increase the physiological relevance of the model, they introduce another 
layer of complexity to the seeding process. Differing cell types require different cell culture 
media, and the bone layer is thought to prevent the delivery of the culture medium to the 
epithelium [201], [202]. The optimisation of these models is a significant step to overcome 
before they can be used for further analysis. 
 






Figure 2.16. H&E stained sections of a collagen based oral mucosa model with bone 
component. Reproduced with permission from Almela et al. [201] under a Creative 
Commons license.  
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 Use of organotypic 3D wound models 
 
The development of organotypic models allows for the study of tissue response to certain 
conditions, including wounding. Several different wounding methods have been 
developed. Both hot and cold burning, whereby a metal rod was heated with an element 
or cooled in liquid nitrogen, before applying to a model for a set amount of time have been 
shown to give repeatable healing wounds [94], [203], [204]. 
Sharps have also been used for the same purpose. Kim et al. [164] used a biopsy 
punch to create a circular wound in the epithelium of an oral mucosa model, and 
demonstrated the re-epithelialisation of the wound. Scalpels have been used similarly 
[198], [205]. These wounds, however, have issues with reproducibility and analysis [206], 
and therefore other methods have been studied. These include modifications to current 
methods – e.g. an ‘excision tool’ made from two scalpels fixed together [187] – or 
modifications to the seeding process. 
One prospective solution is through selective seeding of cells, creating a space in 
the epithelium of a known size, and examining how this gap closes over time, similar to a 
2D migration assay. This has been done by using a stainless steel ring to create an 
exclusion zone where cells cannot adhere using both skin, in a model devised by the 
MacNeil group, and a commercially sourced collagen scaffold [207], [208]. Another method 
involved placing sterile plastic strips over a collagen model prior to the seeding of 
keratinocytes, then removing the strip following the formation of an epithelium [209]. These 
models are not ideal, however. In the model devised by the MacNeil group, large amounts 
of DED and primary cells are required [207]. When using a collagen model, the dermal 
equivalent is less representative of the in vivo scenario [194]. As such, a more 
representative model using fewer cells would be ideal. 
The use of 3D in vitro models also allows for more in depth assessment of tissue 
response to wounding. Assaying allows for in situ analysis of cell response, and histology 
and immunohistochemistry give a representative sample of the tissue as a whole at 
specific time points. Several assays have been used in oral mucosa models to assess the 
cellular response to wounding. These include basic cell viability assays – such as the MTT 
assay [94] – more complex assays for specific proteins – including VEGF & hepatocyte 
growth factor [203] and lactate dehydrogenase [209] – and assays looking for specific 
cytokines thought to be present in the supernatant [94], [164], [203]. These models can 
also be fixed and processed for histology to allow further analysis. 
Histology allows for the staining of specific substances to gain a further 
understanding of how the wound healing occurs at certain time points. Haematoxylin and 
eosin (H&E) staining is often used [94], [187], [198], [202], [209] to give a general picture 
of the tissue by staining nuclei violet and cytoplasm pink, with the contrast provided by this 
stain showing tissue morphology. Further information can be gained through 




immunohistochemistry – the selective binding of a variety of proteins using specific 
antibodies [210]. This allows for the detection of specific proteins – e.g. different collagen 
varieties known to be found in various regions within tissues [203] – and also allows 
markers of specific processes – e.g. Ki67, a proliferation marker [198]. 
 
 3D in vitro effects of BPs 
 
To gain a greater understanding of how BPs effect oral tissues, a variety of 3D oral mucosa 
models have been used to examine BP effects. The effects of BPs on both healthy and 
healing tissue have been investigated, to examine both general BP effects on the oral 
mucosa and how BPs may contribute to the development of BRONJ following the 
introduction of a wound prior to the condition. 
 The effects of BPs on epithelial development have been investigated. 
McLeod et al. used a collagen/matrigel model with an OKF6 epithelium to study the effects 
of sub-toxic BP levels on epithelial development [173]. They treated models with 1 µM ZA 
for 7 days immediately after raising to ALI, and through histology saw no differences 
between the models. With or without BP treatment, the epithelium was able to stratify as 
normal. However, as ZA concentration in BRONJ patients is known to rise above 1 µM 
[142], more study is needed to fully examine the effects of BPs on epithelial development. 
 BP effects on healthy mucosa equivalents have also been examined. A study by 
Bae et al. [202] introduced a less potent but fluorescently labelled version of ZA on a 
collagen model with immortalised keratinocytes, including a rat calvariae bone layer, to 
examine the localisation of the drug. The model was allowed to stratify at ALI for 1 week 
before treating with the drug for a further week. When examined, BPs were found in both 
the bone and outer layers of the epithelium, even though the mucosal section of the model 
was never in direct contact with the drug containing media. The calcium content of the 
outer epithelial layers is higher than the basal layers [211], which therefore suggests that 
even within the epithelium, the calcium binding affinity of BPs plays a role in its effects. 
They also used standard ZA at a 4 µM concentration, and saw a reduction in epithelial 
thickness due to loss of the keratinised outer layers of the epithelium, where the 
fluorescent BP had localised. It was theorised that low levels of BPs may localise to the 
soft tissue prior to the BRONJ-precipitating event, and be released following the damage 
to the soft tissues, potentially explaining part of the pathway by which BRONJ develops.  
 A reduction in epithelial thickness was also seen by Ohnuki et al. when 
keratinocytes alone were seeded on AlloDerm® (a commercially available cadaveric 
dermis) [177]. The model was raised to ALI and allowed to stratify for a week before 
treating with 10 µM ZA for a further week. However, rather than a reduction in the 
keratinised outer layers, they saw effects on the basal cells. As mentioned in 
section 2.8.1.3, further testing showed basal cells proliferated less with BP treatment, due 
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to the drug arresting cells in the S phase of the cell cycle. The group then took this further, 
seeding AlloDerm® with both primary oral keratinocytes and fibroblasts, then treating with 
10 µM ZA at ALI from day 8 to 19 of culture [187]. Using the ‘excision tool’ described in 
section 2.8.2.2, they created a wound in the epithelium of the model, and found ZA slowed 
the healing significantly. Through further staining, they determined this to be due to a 
reduction in proliferation, and reduction in expression of the αvβ6 integrin, indicating BPs 
prevent the intracellular signalling mechanisms which promote wound healing. 
 Kim et al. also saw a reduction in epithelial thickness with BP treatment [164]. A 
collagen model with primary oral cells was treated with 10 µM PA from day 5 of culture to 
day 14. They saw a thinner basal layer and intact keratinised layers, and suggested that 
BP treatment may speed up keratinocyte differentiation. To examine wound healing, they 
created a biopsy punch wound on culture day 7. PA prevented these wounds from healing 
and further examination again pointed to a lack of proliferation. These studies represent a 
promising start in examining the effects of BPs on healthy mucosa, but more detail is 
required. 
 
2.8.3 Models of BRONJ 
 
While in vitro testing allows for the study of individual mechanisms within BRONJ 
pathology, in vivo studies give a broader view of the disease. Ethical issues limit the in 
vivo work able to do be done in humans, however. Inducing BRONJ in a patient is 
unethical, and including untreated control groups in studies goes against treatment 
guidelines [150]. For these reasons, animals have been used in the in vivo assessment of 
BRONJ. 
 Small animal models (mice, rats and rabbits) are the most common [212]. BRONJ 
can be induced in rodents with relative ease, with 80 – 100 % of animals developing the 
disease after short term BP treatment and a tooth extraction [213]. The animals exhibit a 
wide range of the expected symptoms, including limited mucosal wound healing, 
decreased vascularisation, and increased inflammation and microbial colony formation. 
Often these models are of ‘high-risk’ BRONJ, using high doses of ZA to mimic the more 
severe cases of the disease [151].  These models are already in use in examining potential 
BRONJ treatments, with some success [214], [215]. 
While small animal models have benefits in comparison to large animals, including 
a lower cost, higher level of reproducibility, ease of handling, and fewer ethical issues, they 
also come with drawbacks [151], [213], [214]. Mice and rats have faster metabolisms than 
humans, meaning dosing them in a way that can extrapolate meaningfully in relation to 
humans is difficult [216]. Their bones also remodel differently to humans, and have 
differences in the anatomy and structure of the jaws [217]. A potential solution for this is 
the use of larger animal models, and as such, there has been some development of these 




with beagle dogs and minipigs [216]–[218]. Both these animals are closer to humans 
anatomically and have similar microflora in the mouth. 
Allen et al. attempted to develop a BRONJ model using beagle dogs [218]. Dogs 
were treated with ZA for 3 months, using doses comparable to those of metastases 
patients, with a tooth extraction after 1 month. In all cases, post-surgical healing was 
impaired, however only in 1 of 6 of the dogs was BRONJ induced, hence this model is 
unsuitable for further BRONJ investigations. 
A more robust large animal BRONJ model has been developed in minipigs. This 
was first reported in a paper by Pautke et al. in 2012 [216] and developed further by the 
same group in 2017 [217]. In their model, the minipigs were treated with ZA infusions for 
20 weeks, with some receiving molar extractions taking place at week 12. This work 
successfully induced BRONJ in all animals treated with BPs and receiving a tooth 
extraction, and also in some animals without extractions in areas of infection, confirming 
the theory that infection plays a key role in BRONJ development. This repeatable model 
offers a potential mechanism by which to further study the pathophysiology, however was 
not without drawbacks. 
Though animal models are useful, there are ethical implications involved. The 3Rs 
(replacement, reduction, refinement) advocate for the use of methods which do not require 
animal studies, the reduction in number of animals per study and the minimisation of the 
suffering of the animals involved in the studies [219]. As current animal models aim to 
create a severe version of the disease, this can lead to issues in the welfare of the animals 
used. Animals in the minipig studies suffered weight loss as their BRONJ became too 
severe for them to eat sufficient food [217]. An in vitro model would hence be a useful tool 
in the study of BRONJ in its development, bridging the gap between 2D cell culture and in 
vitro models and thereby allowing for a reduced number of animal models. 
 
2.8.4 Novel BRONJ treatments 
 
Due to the lack of consistent success with current BRONJ treatment methods, there has 
been widespread investigation into potential novel methods to either treat the disease or 
prevent its development post-extraction. This section covers five areas of research: full 
reversal of BP effects, drug therapy to counter specific BP effects, reduction of BP 
concentration, improved surgical intervention, and cell based therapies. 
 
 Reversal of BP effects 
 
Nitrogen containing BPs (nBPs) are more likely to cause BRONJ than first generation BPs, 
and as such, research into the prevention and treatment of BRONJ has a nBP focus. As 
nBPs inhibit the mevalonate pathway, introducing metabolites from the pathway that have 
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been inhibited has been suggested as a possible therapeutic agent to reverse nBP effects. 
Geranyl-geraniol (GGOH) is one such molecule. It was first demonstrated in 1999 that 
GGOH could be introduced as a way of reversing nBPs [220], [221]. Since then GGOH 
has been used to reverse a wide range of nBP effects including apoptosis [222], 
proliferation [86], [168], adhesion [144], [183], [222], migration [86], [144], [223] and anti-
angiogenic effects [171]. These reports cover a wide variety of cell types, notably including 
oral fibroblasts and keratinocytes. 
Several of the papers reviewed in section 2.8.1 also investigated the potential of 
GGOH as a method of counteracting nBP effects [86], [144], [164], [168], [171]. Cozin et al. 
demonstrated the ability of GGOH to counteract the effect of both ZA and PA in an in vitro 
study with primary human oral fibroblasts, adding GGOH alongside the BPs [144]. Cell 
proliferation was restored partially for cells dosed with PA and entirely for those dosed with 
ZA. This ability to reverse the effects of the nBPs is universal across the literature. 
GGOH has also been investigated using in vivo models of BRONJ. Nagaoka et al. 
used GGOH in a murine model [215]. In brief, mice were treated with ZA for a total of 
6 weeks. After two weeks, a molar was extracted, and GGOH was administered with the 
BP for the remainder of the study. Micro-computed tomography analysis demonstrated 
higher mineral density and bone deposition in mice treated with GGOH, in comparison to 
those treated with ZA alone. Koneski et al. examined local GGOH administration in a 
Wistar rat BRONJ model [214]. Rats were dosed once weekly with ZA for 5 weeks, and a 
tooth extraction was performed on day 21. A local 5 mM dose of GGOH was administered 
daily for 14 days after extraction. The GGOH treatment reduced infection rate, 
inflammation and bone exposure. The formation of new tissue was also increased, 
however, due to the level of BP already existing in the bone, tissue formation was not 
complete. Nonetheless, this is a promising avenue for exploration. 
 
 Drug therapy 
 
Due to the wide range of BP cell effects, several therapies have been tested to reduce 
some of these in small studies. Dexrazoxane is an FDA approved, cytoprotective drug that 
can reduce cell apoptosis [34]. It has been investigated as a treatment for BRONJ, both in 
vitro and in vivo. Human osteoclasts and gingival fibroblasts were treated with ZA both 
alone and in conjunction with dexrazoxane. Cell viability improved compared to cells 
treated with ZA alone. Bio-Oss® (bovine derived HA granules) was loaded with ZA and 
dexrazoxane before implantation into the tibia of rabbits, and again, dexrazoxane was 
shown to be beneficial in counteracting ZA effects. 
As infection is a key component of BRONJ, antibacterial treatments have been used 
in trials with some success. Sitafloxacin is an antibiotic capable of killing 
quinolone-resistant bacteria. In a study by Ikeda et al. [150], 20 patients suffering from 




either Stage 2 or 3 BRONJ were administered with the drug, for periods of 2 to 10 weeks, 
both as a standalone treatment and in conjunction with debridement and sequestration, 
depending on the severity of the BRONJ. In 19 of the cases, the infection was successfully 
removed and the BRONJ was either healed or in remission. However, it was not possible 
to include a control group in this study, due to ethical regulations. These drugs may provide 
a method of treating BRONJ, either alone or as part of a combination of methods. 
 
 Reduction of oral BP concentration 
 
Prevention of BRONJ has been suggested as the best solution for the disease [159], and 
methods of reducing the oral concentration of BPs to allow full wound healing have been 
suggested [40], [131], [224]–[227]. These studies have focussed on the removal or 
replacement of the bound BP in bone. 
BPs bound to bone can be replaced. Ethylenediaminetetraacetic acid (EDTA) is a 
calcium chelating agent with a higher affinity for calcium than BPs. A study by Elsayed 
et al. investigated using EDTA to prevent BRONJ in a rodent model [40]. They successfully 
demonstrated that rinsing an extraction socket with EDTA following surgery prevented the 
development of BRONJ in rats treated with ZA. The previously bound ZA was rinsed away 
using a saline solution. 
Interestingly, less potent BPs have also been suggested as a BRONJ treatment 
method, replacing the previously bound BPs with a BP less likely to cause BRONJ [131]. 
In a study by Oizumi et al., etidronic acid was able to expel the previously bound nBPs 
from bone in mice [226]. It was hypothesised that replacing the bound nBPs with the less 
potent etidronic acid would reduce the risk of BRONJ development will still maintaining 
some BP effect. A small clinical trial had success, with etidronic acid promoting the 
recovery of soft tissues while maintaining some reduction in anti-resoprtion [227]. 
BPs can be modified to be fluorescently labelled, which reduces their potency 
[202]. Two studies have used these fluorescently labelled BPs in vivo in rodents, and 
demonstrated that these BPs lead to reduced BRONJ development, again indicating the 
success of localised BP concentration reduction [224], [225]. 
 
 Improved surgical intervention 
 
As explained in section 2.7, surgical intervention has demonstrated some success in 
BRONJ treatment but is not without complications. In order to improve the success rate of 
these treatments, different methods have been suggested, including antimicrobial and 
laser therapy [228], [229], improved coverage of the wound [151], [230], [231] and 
fluorescent markers to allow better detection of necrotic bone [160]. 
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Several papers have investigated the use of laser based therapies in BRONJ 
treatment [228], [229], [232], [233]. Antimicrobial photodynamic therapy (aPDT) is a 
process whereby a photosensitive dye is applied to an area, then a laser is used to excite 
the dye and introduce reactive oxygen species to the area, leading to the death of bacterial 
species [234]. Several case reports have shown the success of aPDT in treating BRONJ, 
however these are only small studies and further clinical trials are needed [228], [232], 
[233].  Low level laser therapy (LLLT), where a low energy laser is focussed on a wound, 
is theorised to be biostimulating, leading to less cell death and improved wound healing, 
although the mechanism is unclear, and is as yet unproven in wide clinical study [235]. In 
work by Momesso et al., LLLT was demonstrated as successful in treating BRONJ, 
however this was also combined with a high dose of antibiotic treatment and removal of 
the implant that had triggered the BRONJ development, and as such, the specific effect of 
the LLLT is unclear [229]. 
Different methods have been demonstrated effective in closing the BRONJ soft 
tissue wound. Human amniotic membrane (HAM) is a biological dressing with several 
desirable properties for BRONJ treatment [231]. It is anti-inflammatory, anti-microbial and 
has low immunogenicity. In two cases where BRONJ was diagnosed after the slow healing 
of oral wounds, HAM was used as a dressing following a two month drug holiday and the 
removal of the osteonecrotic tissue. In both cases, the wounds were completely 
asymptomatic 180 days later. Mucoperiosteal coverage of the damaged jaw has been 
demonstrated as a preventative measure in Wistar rat BRONJ models [151], [230]. This is 
thought to be due to an increased blood supply and prevention of bacterial contamination, 
however this was not successful as a treatment in all cases, and is less likely to be 
successful in later stages of BRONJ (and potentially not possible) due to the amount of 
coverage required.  
As detecting necrotic bone is difficult, surgical intervention to remove necrotic bone 
is a complicated procedure and can often effect healthy bone [160]. Tetracycline is a 
fluorescent compound which can be used as a marker for osteonecrosis [236]. A study by 
Otto et al. used this method during surgical intervention on 54 BRONJ patients and 
demonstrated an 86 % success rate in treating BRONJ legions [160]. However, 10 % of 
legions relapsed and 4 % of legions did not heal following this surgery. While this is a 
relatively high level of success for BRONJ treatment, further improvement is required. 
 
 Cell-based therapies 
 
Cell-based therapies are an exciting avenue within tissue engineering, and, as such, have 
also been noted for their potential to treat BRONJ. Stem cells have immunomodulatory 
properties and secrete growth factors to improve healing [151]. Several studies have 
indicated mesenchymal stem cells (MSCs) as successful BRONJ treatments in murine 




and porcine models, and there are case reports of their successful use in humans [237]–
[240]. Barba-Recreo et al. used the previously defined ‘high-risk’ BRONJ model to 
examine the suitability of adipose-derived mesenchymal stem cells (AdMSCs) as a 
BRONJ treatment method [151]. They placed AdMSCs into the sockets following molar 
extraction before covering with a mucoperiosteal flap and suturing. The cell therapy 
significantly reduced the incidence rate of osteonecrosis, and increased the number of 
osteoclasts found in the sockets and thereby also improving resorption rate. While this is 
positive, as discussed in section 2.8.3, the limitations of small animal models of BRONJ 
mean further study is required before this has widespread use in humans. 
 
2.9 Bone filler materials – a potential BRONJ treatment method? 
 
Preventative treatment has been identified as the best solution for BRONJ, due to the 
potential severity of the condition and the difficulties in treatment [1], [40], [159]. Reduction 
of the oral concentration of BPs has been demonstrated to reduce the development of 
BRONJ in vivo [40], [131], [224]–[227]. We hypothesise that due to the known BP affinity 
for calcium, calcium phosphate bone filler materials could reduce local BP concentration. 
 Calcium phosphate bone fillers would be advantageous in the treatment of BRONJ. 
Their ability to bind and retain BPs has been demonstrated [241]. They are already 
approved and in use following the surgeries that make up BRONJ preceding events [242]. 
This would allow for a combined effect for a BRONJ patient: both reducing the BP 
concentration to which the oral mucosa is exposed, while also promoting faster healing of 
the bone wound. Ideally, a solution would also allow vascularisation so as to prevent 
osteonecrosis, promote soft tissue healing, and prevent infection. However these may be 
less important if the condition can be prevented from developing, or stopped early. 
As tooth extraction is the precipitating event for BRONJ over half the known cases, 
a treatment that could be implanted following this surgery would have the most impact on 
the condition, and therefore this review explores the potential of bone filler materials which 
could be used for BRONJ prevention in tooth extraction sockets. 
 
2.9.1 Common bone filler materials 
 
Though bone has a high regenerative potency, graft materials are often used to enhance 
bone repair. Autologous bone grafts are currently the gold standard as they are 
osteoinductive, however they come with certain limitations, such as donor site morbidity 
and low quantity of available graft material [243]. In BP patients, grafting from another area 
could lead to more severe complications as the donor site may experience poor healing. 
Allografts have some use, however they are only osteoconductive, and their regenerative 
potency varies relating to the age of the donor [244]. There is also the risk of viral 
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transmission and an immune response [243]. Xenografts are currently the most widely 
used in dental applications [245], but have a risk of viral transmission, have a costly 
production process, and lead to religious and ethical objections [246]. Synthetic materials 
similar to the mineral phase of bone - such as HA and beta tricalcium 
phosphate (β-TCP) [247] – have thus been developed as alternatives, due to increased 
availability, lower risk of disease transmission, and easy control over structural properties. 
Further tailoring of the chemical structure of HA is possible, including the introduction of 
other ions, which allows for a more application specific material [248]. 
HA has the benefit of being osteoconductive, non-toxic, not triggering an 
inflammatory or immune response, and being highly resorbable [52], [249]. Once 
implanted, it is resorbed and transformed into autologous bone. However, HA implants are 
often sintered, which reduces their porosity [250]. This lack of porosity can interfere with 
osteogenesis and angiogenesis, and therefore differing methods of incorporating these 
materials in implantable forms have been studied, and various commercially available 
clinical forms exist. 
In order to prevent BRONJ, the BP concentration in the mouth should be removed. 
The calcium containing nature of these materials make them suitable candidates for the 
binding of BPs, and this has been tested in several studies [251]–[253]. BPs’ high affinity 
for calcium will theoretically lead to a slow release rate once bound [50]. While the ability 
of these materials to absorb BPs quickly [46] and be used as localised delivery methods 
for BPs has been confirmed [34], [49], [60], [251]–[253], their binding profile and release 
rate is largely unreported. A summary of different calcium phosphate bone filler materials 
is shown in Table 2.6. 
  




Table 2.6. Evaluation of a variety of approved calcium phosphate bone filler materials for 



















































































































































































































































































































































































































































































































































































































































































































































































Granules are one of the most common forms of bone filler materials, with demineralised 
bovine bone matrix being the market leader in dental applications [246]. Porcine variants 
are also commercially available [245]. Granules are well tolerated, have a low toxicity and 
inflammatory response, and have been shown to be successful in the treatment of tooth 
extraction sockets in vivo in both human and animal models [249], [254], [258]–[260]. Due 
to the success of the granules, and the previously mentioned issues with xenografting, 
synthetic granules are also used clinically. 
Various synthetic granules have been produced, including the commercially 
available ReproBone® (indicated for use in non-load bearing osseous defects), with the 
structure and composition of them easily tailored to suit the application. Differing sizes and 
porosities have been shown to have an effect on the substitution of new bone, with lower 
porosity increasing bone formation [249]. Altering the composition has also been tested  
[246], [255], with differing ratios of HA and β-TCP giving a control of bone regeneration 
rate. As β-TCP dissolves faster than HA, it provides areas for new growth while the HA 
provides structure [255]. Synthetic granules give similar positive in vivo bone regeneration 
results to their animal derived counterparts [245], [246]. However, one study indicated a 
higher inflammatory response from synthetic granules compared to bovine, although this 
was hypothesised to be due to the morphology of the granules, which were smooth with a 
low surface area [245]. 
Bio-Oss®, bovine derived HA granules, have recently been studied in vivo as a 
localised BP delivery system, confirming the ability to bind BPs [34], [60], [252], [253]. 
Synthetic granules have been demonstrated as BP loading devices [256]. The success of 
these studies suggests this binding is not permanent, with the amount released being 
sufficient to trigger necrosis in one study [252]. As the studies were focussed on 
determining the ability of the materials to function as localised delivery methods, the 
binding and release profiles were not reported. However, the binding and release profiles 
of granules of differing size and surface area were tested chemically in a study by 
Sörensen et al, which indicated that although ZA binding increased with surface area, so 
did the release of bound ZA [257]. This is an important consideration, as if BPs were 




HA can be used as powder, such as NanoBone®, a nanocrystalline form. 
Nanohydroxyapatite (nHA) has been shown to have a similar chemical structure to 
naturally occurring bone [261] - as 60% of HA in bone is needle like and less than 100 nm 
on all axes [272] - and has a higher resorption potential than sintered HA [262]. As it is 




synthetic it has advantages in both price and disease transmission, and has been 
demonstrated to perform similarly in bone healing compared to Bio-Oss® in humans [260]. 
Nanocrystalline apatites have been shown to improve the synthesis of pro-osteogenic 
factors, further improving bone healing [116]. These characteristics make nHA a promising 
material for use in regeneration of periodontal defects, and early studies have shown its 
potential in this field [260], [262], [263]. However, one drawback is the potential of the 
particles to mobilise and be transported to a different area of the body [264]. 
It is possible to tailor and improve the regenerative potential of nHA through 
modifying its chemical structure and delivery method. The introduction of magnesium has 
been shown to promote angiogenesis and osteogenesis [248], while nHA in a silica matrix 
(NanoBone®) is reported to be osteoconductive and biomimetic [250], have good 
angiogenic properties [139] and show no difference in regeneration to bovine granules 
[260]. 
nHA has also been used as a localised BP delivery method, with HA nanocrystals 
confirmed to have a high affinity for alendronic acid, with a slow release profile [52]. This 
binding takes place through a two-step reaction involving the substitution of a phosphate 
and the interaction of the BP with a Ca2+ molecule on the surface of the apatite [265]. 
Pascaud et al. [266] found that nanocrystalline apatites adsorbed more of the BPs than 
regular HA. The adsorption was proven to be irreversible under normal conditions, and it 
was demonstrated that the BP was only released in the presence of phosphate ions, 
reversing the ionic exchange process which originally bound the BPs. The affinity and 
adsorption of three different nanocrystalline apatites were also measured [49]. The 
apatites were analogues of freshly formed bone material and more mature bone. The study 
showed that the fresher material analogue had a higher affinity for, and bound more, 




Aqueous pastes composed of nHA in water are also used in periodontal regenerations. 
The commercially available Ostim® is common and similar in regenerative potency to 
Bio Oss® [116], [267]–[270]. Pastes are viscous, bone-mimetic [269] and resorb quickly 
and completely [270]. In an experimental study by Canuto et al. [116] their potential as an 
extraction socket healing device was shown. In comparison to an unfilled socket in the 
same patient, Ostim® was evidenced to improve socket healing and epithelialisation, 
increase VEGF levels and improve the synthesis of pro-osteogenic factors. The Ostim® 
paste did unfortunately increase pain on day 1 following extraction, however it was 
suggested this may have been due to an inflammatory response being triggered, and 
therefore was an indication of the improved healing potential of the material. Conversely, 
a dorsal skinfold chamber study [269] demonstrated Ostim®’s lack of inflammatory 
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response in vivo. In this study, Ostim® was able to induce angiogenesis, with its 
degradation forming a scaffold into which cells could invade. While the ability to allow for 
angiogenesis would be important in a patient taking BPs, the pro-inflammatory response 
of the material could lead to BRONJ development and therefore confirmation of this effect 
or lack of it is required to allow for indication as to the use of HA paste as a potential 
BRONJ treatment device. 
 
 Bone cement 
 
The use of calcium phosphates in setting bone cements also has a history in extraction 
socket healing, such as Bone SourceTM [259], however they come with certain 
disadvantages. Once set, the cements have poor mechanical properties in comparison to 
the native bone and have issues with porosity [271]. The lack of porosity of the set cement 
inhibits the regeneration of bone, as cells cannot grow into the scaffold. As such, this 
cement is unlikely to be beneficial in BRONJ treatment. 
 
2.10 Detection and quantification methods 
 
To assess the ability of bone filler materials to bind BPs, the detection of BP concentration 
in solution is required. Detecting BPs is known to be difficult process [273], [274]. The lack 
of a chromophore on several of the BPs has made determination difficult [275]. However, 
several methods have been developed for the quantitative detection of BPs. These 
methods are summarised in Table 2.7. 
 BP detection methods vary in complexity, with some methods available for direct 
detection, others using chemical agents to increase BP signal, and others using 
chromatographic processes to separate BPs before detection. 
Direct detection of BPs has been performed with ultraviolet-visible (UV-vis) 
spectroscopy. The R2 group of certain BPs works as a chromophore to allow detection 
[265], [276]. This method has successfully been used to determine BP concentration 
following binding with HA. In three papers from a group at the University of Toulouse, 
UV-vis spectroscopy was used to determine risedronic acid and tiludronic acid 
concentration after incubation with HA [49], [265], [266]. The use of this method to examine 
the BP binding properties of HA suggests a useful mechanism for work in this thesis. 
As BP detection is difficult, methods of conjugating the BP to another molecule to 
allow for greater detection have been tested. Several of these also use UV-vis 
spectroscopy. One such method uses ninhydrin for the determination of alendronic acid 
[51], [52], [277]. The primary amine group reacts with the ninhydrin, whereby its colour can 
be determined using a UV-vis spectrophotometer set at 568 nm for detection, measured 
against a reagent blank. Cerium (IV) sulphate and copper (II) sulphate have been used to 




determine the concentration of BPs with a hydroxyl group at the R1 position [277], [278]. A 
novel method devised by Li et al. uses quantum dots synthesised from tea, which fluoresce 
[274]. The quantum dots bind to BPs, whereby their fluorescence is turned off. This allows 
for a quantitative measure of concentration that was tested in the presence of a variety of 
metal ions, including calcium. Fluorescence also plays a part in a paper from Gao et al. 
who bound BPs to a guanidinium-modified calix(5)arene molecule that turned on 
fluorescence, and again was quantifiable [279]. These methods however are novel and 
not optimised. 
A much more well-defined method is chromatography, which separates molecules 
within a mixture to allow for detection of individual components. High-performance liquid 
chromatography (HPLC) is commonly used as a BP detection method [280], [281]. 
However, the polar nature and acidic characteristics of BPs make them difficult to separate 
and detect with standard measures [282]. Despite this, several ion pair chromatography 
methods have been defined for a wide range of BPs [273], [282]–[285]. These methods 
have also shown success in the determination of BP concentration following incubation 
with both HA and bone cement. 
As well as the determination of BPs in solution, some work has been performed 
detecting BPs bound onto other structures through spectroscopic techniques. Fourier 
transform infrared spectroscopy (FTIR) has been used to detect the change in structure of 
a material following soaking in different BP solutions [49]–[51], [265]. The BP itself and the 
binding material before and after soaking in a BP were tested, and the spectra were 
compared. The technique was shown to be successful at confirming a change in 
composition during binding. Raman spectroscopy is a similar method which has also been 
successful in this task [265], [286]. X-ray photoelectron spectroscopy (XPS) is a technique 
used to determine the chemical composition of the surface of a material, and has been 
demonstrated as a method of BP binding determination [46], [51]. The nitrogen found in 
nBPs provides a simple method for detecting binding. XPS depth profiling can also be 
used to measure if the BP has diffused through a material, up to 260 nm [46]. This wide 
range of different BP detection methods suggest the possibility of measuring the binding 
of BPs to HA. 
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Table 2.7. Bisphosphonate concentration detection methods. AA = alendronic acid, CA = 
clodronic acid, EA = etidronic acid, NA, neridronic acid, PA = pamidronic acid, RA = 
risedronic acid, TA = tiludronic acid, ZA = zoledronic acid. HPLC = high performance liquid 
chromatography, UV-vis = ultraviolet-visible spectroscopy. 







Ceric (IV) sulphate with UV-
vis 
AA, EA, RA No 2 µg/ml [277] 
Copper (II) sulphate with 
UV-vis 






AA, CA, EA, 




0.1 µM [279] 
HPLC with evaporative light 
scattering detection 
AA, EA, PA, 
ZA  
No 15 – 
18 µg/ml 
[281] 
Ion pair HPLC with UV 
detection 
AA, PA, ZA Yes; HA and 
bone cement 
0.1 µg/ml [273], [282]–
[285] 
HPLC with fluorescence 
detection 
PA Yes; blood and 
urine 
0.1 µg/ml [280]  
Ion chromatography with 
UV detection 
AA, CA, EA, 
PA, ZA 
No 2.5 – 
10 µg/ml 
[276], [287] 
Ion Chromatography with 
Cu2+ complexation and UV 
detection 
AA, CA, EE, 
NA, PA 
No 0.4 µg/ml 
(PA) 
[288] 
Iron (III) chloride + UV-vis AA, PA No 2 µg/ml [289] 
Liquid chromatography-
mass spectrometry 
ZA Yes; human 
bone 
1 ng/mg [290] 
Ninhydrin with UV-vis AA, PA Yes; HA 3.75 µg/ml 
 
[52], [277] 
Quantum dots with UV 
detection 
PA, ZA Yes; metal ions 0.1 µM [274] 
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3. Aims and objectives 
 
The aims of this project were to investigate the effects of two BPs, pamidronic acid (PA) 
and zoledronic acid (ZA), on the oral mucosa, using a range of in vitro cell culture 
techniques, and to examine whether hydroxyapatite (HA) could be used as a localised 
BRONJ treatment method. 
 
The main objectives of the work presented within this thesis were: 
 
1. To investigate the 2D effects of PA and ZA on the viability, apoptosis, proliferation, 
migration and adhesion of human oral fibroblasts and keratinocytes. 
2. To use a 3D oral mucosa model to examine BP effects at different stages of 
epithelial development. 
3. To develop a 3D in vitro model of the soft tissue component of BRONJ. 
4. To investigate whether HA can be used to bind BPs through different spectroscopic 
techniques. 
5. To examine the ability of HA to locally reduce BP concentration in 2D and 3D using 
biological assays. 
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4. Materials and methods 
 
4.1 Cell culture 
 
4.1.1 Cell sources and media 
 
All cell culture work took place in Class II laminar flow hoods (Esco), sterilised in 70 % 
industrial methylated spirit (IMS) (Thermo Fisher Scientific) prior to use. Incubation took 
place at 37 °C in 5 % CO2. 
Non-tumoral oral fibroblasts derived from the oral cavity (NHS REC ethics 
#09/H1308/66) were used from passage 2 to 10. They were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma-Aldrich) with the supplements described in 
Table 4.1. Human oral keratinocytes, immortalised through transduction to prevent 
telomere shortening  (OKF6/TERT-2) [179] were used from passage 4 to 25. The medium 
used for OKF6 cells in 2D was keratinocyte serum free medium (KSFM) (Gibco) 
supplemented as described in Table 4.2. 
Primary human oral keratinocytes (NHS REC ethics #09/H1308/66) were used 
from passage 1 to passage 3. They were cultured in Green’s medium, which is described 
in Table 4.3. When cultured in 2D, primary keratinocytes were cultured on a feeder layer 
of irradiated mural fibroblasts (i3T3). 
Prior to experimentation, cell seeding densities were optimised for fibroblasts and 
immortalised keratinocytes (see Chapter 10). Primary keratinocytes were seeded 
according to a standard density within the laboratory. 
 
Table 4.1. Dulbecco’s modified Eagle’s medium composition. All components from 
Sigma-Aldrich, except foetal calf serum, from Biosera. 
Solution Concentration 
Dulbecco’s modified Eagle’s medium 88 % 
Foetal calf serum 10 % 
L-glutamine 0.01 mg/ml 











Table 4.2. Keratinocyte serum free medium composition. All components from Gibco, 
except penicillin/streptomycin, from Sigma-Aldrich. 
Solution Concentration 
Keratinocyte serum free medium 98 % 
Bovine pituitary extract 0.05 mg/ml 
Penicillin / streptomycin 100 i.u./ml / 100 µg/ml 
Human recombinant epithelial growth factor 0.005 µg/ml 
 
Table 4.3. Green’s medium composition. All components from Sigma-Aldrich, except 
foetal calf serum, from Biosera. 
Solution Concentration 
Dulbecco’s modified Eagle’s medium 66 % 
Ham’s F12 nutrient mixture 21.6 % 
Foetal calf serum 10 % 
L-glutamine 0.01 mg/ml 
Penicillin/Streptomycin 100 i.u./ml / 100 µg/ml 
Insulin 5 µg/ml 
Hydrocortisone 4 µg/ml 
Amphotericin B 0.625 µg/ml 
Adenine 0.025 µg/ml 
Cholera toxin 8.47 ng/ml 
Epidermal growth factor 5 ng/ml 
3, 3, 5-Tri-iodothyronine (T3) / Apo-transferrin 1.36 ng/ml T3 / 5 µg/ml apo-transferrin 
 
4.1.2 Cell maintenance 
 
Cells were maintained in T75 flasks (VWR) in an incubator, with media changes occurring 
at least once weekly. Confluency and viability was monitored using a phase contrast 
microscope (Motic). Cells were passaged when they were over 75 % confluent. Firstly, the 
media was removed, and the flasks were washed with phosphate buffered 
saline (PBS) (Oxoid). Trypsin-EDTA (Sigma-Aldrich), at a concentration of 5 mg/ml trypsin 
and 2 mg/ml EDTA, was added and cells incubated until detachment, before 
serum-containing DMEM was added to deactivate the trypsin. The cell-containing media 
was centrifuged for 5 minutes at 1000 rpm to form a cell pellet. The supernatant was 
discarded and the cell pellet resuspended in media, counted using a haemocytometer 
(Hawksley), and divided into flasks as necessary. 
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 Prior to passaging NOKs, the i3T3 feeder layer was first removed with a 5 minute 
incubation with 0.2 mg/ml EDTA (Sigma-Aldrich). Following this, passaging took place as 
described above. 
 
4.1.3 Primary cell isolation 
 
Before the isolation of cells, DifcoTM trypsin and collagenase A solutions were prepared. 
Trypsin 1:250 powder (BD Biosciences) was dissolved in 500 ml PBS to create a 0.1 % 
solution, which was then pH adjusted to 7.4 using an NaOH solution (Sigma-Aldrich) and 
sterilised with a 0.2 µm filter. This was supplemented with 
penicillin/streptomycin (0.01 mg/ml) and amphotericin B (0.625 µg/ml) and separated into 
10 ml aliquots. Collagenase A (Roche) was prepared in DMEM, supplemented as 
described in Table 4.1, at a concentration of 0.5 mg/ml. Both solutions were stored 
at -20 °C and defrosted immediately prior to use. 
Primary oral keratinocytes and fibroblasts were isolated from willingly donated 
sections of human buccal tissue removed by a dentist (NHS REC ethics #09/H1308/66). 
Samples were placed in DifcoTM trypsin overnight to begin cell detachment. The sample 
was transferred to a petri dish, where forceps and a scalpel were used to gently remove 
the epithelium containing keratinocytes. The remaining biopsy was transferred to PBS 
containing penicillin/streptomycin and amphotericin B and refrigerated. The DifcoTM 
trypsin/keratinocyte mixture was transferred to a universal tube. Green’s medium was 
used to wash the petri dish and ensure all keratinocytes were collected, before adding 
them to the DifcoTM mixture. This was then centrifuged for 5 minutes at 1000 rpm. The 
remaining medium was gently poured away, and the cells resuspended and added to a 
T75 flask containing an i3T3 feeder layer. Before the end of the day, the remaining biopsy 
was minced with a sterile scalpel, then placed into the collagenase A solution and 
incubated overnight in order to isolate the fibroblasts from the extracellular matrix. 
 The following day, the keratinocyte medium was replaced. Cells were then checked 
daily, with media changes as necessary until confluent. DMEM, supplemented as 
described in Table 4.1, was added to the collagenase containing the biopsy to deactivate 
the enzyme. This mixture was then centrifuged for 10 minutes at 2000 rpm. The medium 
was gently discarded, then resuspended in DMEM and added to a T25 flask (Thermo 
Fisher Scientific). Fibroblast growth was then monitored, and media changes performed 
as required, until confluent. Fibroblasts were then maintained in T75 flasks. 
 
4.1.4 Preparation of de-cellularised dermis (DED) 
 
Split thickness skin samples (NHS Ethics #15/YH/0177) were placed into a sterile 
1 M NaCl solution (Sigma-Aldrich) and kept in an incubator at 37 °C for 24 hours, or until 




the epithelium separated. Samples were transferred to a petri dish and the epithelium 
peeled off with forceps. The de-epidermised tissue was washed thrice in PBS and placed 
in DMEM containing penicillin/streptomycin and amphotericin B and stored at 5 °C. 
 When patient skin was unavailable, glycerol treated cadaveric skin (Euro Skin 
Bank) was used. To prepare for use, this was placed in PBS and incubated at 37 °C for 
up to 1 week, with daily PBS changes, to remove the glycerol. It was then prepared as 
with donor skin, using NaCl treatment and forceps to remove the epithelium before 




Pamidronate disodium salt hydrate (Sigma-Aldrich) and zoledronic acid monohydrate 
(Sigma-Aldrich) stock solutions ranging from 1 to 25 mM were made by dissolving the 
powders individually in sterile distilled water. These solutions were aliquoted and frozen 




Prism 7 (GraphPad) was used to perform all statistical analysis, unless otherwise stated. 
Statistical significance was defined as P≤0.05. Standard deviation (SD) was used for all 
error bars. When experiments were performed in triplicate, the mean value of each 
technical were repeat were averaged and the three values used to give N = 3. ‘N’ is used 
to denote experimental repeats, while ‘n’ is used to denote technical repeats throughout. 
In most cases, both time and BP concentration were independent variables, and 
therefore repeated measures two-way analysis of variance (ANOVA) tests were performed 
to confirm significance between groups. Dunnett’s multiple comparison tests were then 
carried out as post-hoc analysis to investigate the significance between BPs and control 
medium (0 µM) at each time point. These tests were used except where otherwise noted. 
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5. The effects of bisphosphonates on human oral fibroblasts and 




To examine the effects of pamidronic acid (PA) and zoledronic acid (ZA), two BPs most 




While osteonecrosis is a major part of BRONJ, the soft tissue component of the disease 
is hypothesised to be key to its development [2]. BRONJ is partly defined as “exposed 
bone or bone that can be probed through an intraoral or extraoral fistula(e)” [1], [123]. It is 
clear that the oral mucosa becomes damaged and fails to heal following the dental events 
leading to most cases of BRONJ, and the exposure through the surrounding mucosa leads 
to infection and the spread of the disease across the jaw. In cases where BRONJ has 
been successfully treated, the procedures have involved the closure of the oral mucosa 
wound through surgery [157]. This is not always possible, however, due to the limited 
availability of tissue to cover the wound, and the BP effects on the soft tissue. While the 
BP effect on bone remodelling and wound healing is a clearly defined pathway, the effects 
on the oral mucosa are less well defined. 
 Several studies have looked at a variety of BP and their effects on oral mucosa 
cells, with studies looking at toxicity, apoptosis, migration, proliferation and other 
processes. However, several different conclusions have been reached. While most studies 
agree that clinically relevant concentrations of BPs are toxic to oral mucosa cells [57], 
[144], [168]–[170], [175], there is a lack of consensus on the concentration at which this 
toxicity occurs, and low levels of BPs have been demonstrated to have a positive effect on 
keratinocytes [178]. The mechanism by which BPs cause toxicity is also not clear, with 
keratinocytes reported to undergo apoptosis [142], [175] and senescence [164]. BPs have 
also been shown to both promote [86], [140] and prevent keratinocyte migration [35]. The 
large number of different BPs also contribute to the wide-ranging spread of existing data 
on BPs with a lack of central consensus. 
 This chapter presents a comprehensive study of the effects of two BPs on the 
toxicity, proliferation, migration and adhesion effects of BPs on oral mucosa cells. 
Fibroblasts and keratinocytes derived from human oral tissue were used so as to be 
physiologically relevant. PA and ZA were used as they are two of the most commonly 
associated BPs with BRONJ [153], [163]. PA is largely used to treat osteoporosis and is 
taken both orally and intravenously, while ZA, as the most potent BP, is prescribed for 




bone metastases patients and only administered intravenously. The concentrations used 
ranged from 0.1 to 200 µM, as these are within the expected range found in BRONJ patient 
mucosa, based on patient saliva and estimated bone concentrations [57], [142], and have 
previously been shown to effect cells of the oral mucosa. 
 
5.3 Materials and methods 
 
Cell culture was performed as described in section 4.1. BPs were prepared as described 
in section 4.2. Throughout this chapter, medium containing no BPs (0 µM) was used as a 
control. 
  
5.3.1 MTT assay 
 
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) powder 
(Sigma-Aldrich) was dissolved in PBS at a concentration of 0.5 mg/ml. This took place in 
a fume cupboard, due to the mutagenic nature of MTT. This was then sterilised with a 
0.2 µm filter. The MTT solution was stored at 4 °C for up to two weeks, protected from 
light. 100 ml isopropanol (Thermo Fisher Scientific) was acidified with 125 µl of 10 M 
hydrochloric acid (HCl) (AnalaR). 
 Cells were seeded at the densities described in Table 5.1. All seeding took place 
in triplicate, with three wells per drug concentration. One plate was seeded per time point 
as MTT is an endpoint assay. BP stock solutions were diluted in media into concentrations 
from 0 to 100 µM. At 24 hours after seeding, the media was removed from the cells, and 
replaced with BP containing media in triplicate, before incubating further. 
At 24, 48 and 72 hours after treating, one of the plates was removed from the 
incubator. Media was removed and replaced with 500 µl of MTT solution (24 well plate) or 
100 µl (96 well plate), and incubated depending on cell type in accordance with Table 5.1. 
Following incubation, the remaining MTT solution was removed, and 125 µl acidified 
isopropanol was added to elute the stain. 100 µl from each well was transferred to a 96 well 
plate, and absorbance measured in a plate reader (BioTek ELx800™). Readings were 
taken at 540 nm, with a reference at 630 nm. 
 
Table 5.1. Seeding densities and incubation times for the MTT assay 
Cell Type Well 
plate 
Seeding density 
(cells per cm2) 
Incubation 
time 
Fibroblasts 24 1.0 x 104 90 minutes 
Immortalised keratinocytes 96 1.67 x 104 40 minutes 
Primary keratinocytes/i3T3 fibroblasts 24 1.0 x 104/5.0 x 103 60 minutes 
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5.3.2 Apoptosis and necrosis assay 
 
Fibroblasts were seeded at 5.55 x 103 cells per cm2 and immortalised keratinocytes at 
1.67 x 104 cells per cm2 in a 6 well plate and left to attach overnight. The media was 
removed from each well and replaced with BP containing media of a range from 10 to 
100 µM PA and 0.5 to 50 µM ZA. PBS containing 1 % saponin (Sigma) was used as a 
positive control for necrosis and added for 2 hours prior to the staining. As an apoptosis 
control, 30 % hydrogen peroxide (Sigma) was added and incubated for 5 minutes prior to 
staining. 
 At 72 hours, cells were stained using an Annexin V-fluorescein 
isothiocyanate (FITC) kit (Trevigen). Cell medium was collected from each sample and 
centrifuged at 6000 rpm for 5 minutes to collect any dead cells. Wells were then trypsinised 
and centrifuged. All centrifuged samples were resuspended in cold PBS. The pellets from 
both the medium and trypsinised cells for each sample were combined, and then these 
suspensions were centrifuged again. Staining took place as per the kit, in 100 µl solution 
containing 10 µl binding buffer, 10 µl propidium iodide (PI), 1 µl Annexin V-FITC and 79 µl 
distilled water. Samples were incubated at room temperature, protected from light for 
15 minutes, then 400 µl of binding buffer was added. As controls, both unstained and 
single stained cells were also prepared by the same method. 
 Cells were analysed using a flow cytometer (BD Biosciences FACSCaliburTM), 
using a 488 nm laser. Annexin V-FITC fluorescence was determined with a 530/30 nm 
filter, and PI fluorescence using a 650 nm long pass filter. A preliminary gate was set to 
remove debris and samples were processed so that 10,000 gated cells were analysed per 
sample. If 10,000 cells were not present due to toxicity, cytometry was performed for 5 
minutes at the highest speed setting. Analysis was performed using CellQuest ProTM (BD 
Biosciences), where a gate was applied to remove cell debris, and fluorescence gates, set 
using the single stained cells and positive controls, were applied to separate viable, 
necrotic and apoptotic cells. Cells were determined to be early apoptotic if they were 
stained with Annexin V alone, necrotic if they stained with PI alone, and late apoptotic if 
they were positive for both stains. Unstained cells were determined to be viable.  
 
5.3.3 Mitomycin C optimisation 
 
Mitomycin C (Sigma-Aldrich) was dissolved in distilled water in a fume cupboard at a 
concentration of 500 µg/ml and sterilised with a 0.2 µm filter, then aliquoted and snap 
frozen in liquid nitrogen. It was stored at -80 °C, protected from light and thawed prior to 
each experiment. 
Cells were seeded in 6-well plates at densities of 4 x 103 (fibroblasts) or 5 x 103 
(immortalised keratinocytes) cells per cm2. 24 hours after seeding, the media was removed 




and replaced with media containing Mitomycin C at concentrations ranging from 0 µg/ml 
to 10 µg/ml. After 4 hours, the media was removed, the wells were washed with PBS, and 
the media replaced. 
At time points between 24 to 96 hours, media was removed and wells were washed 
with PBS. To detach cells, 400 µl of trypsin-EDTA was added to each well and the plate 
was incubated for 5 minutes (or until cells detached). 400 µl of media was added to the 
wells to deactivate the trypsin. Three samples were taken from each well, and cell counts 
were performed using a haemocytometer. 
 
5.3.4 Proliferation assay 
 
CellTraceTM CFSE dye (Thermo Fisher Scientific) was dissolved in dimethyl 
sulfoxide (DMSO) (Thermo Fisher Scientific) at a concentration of 5 mM and stored 
at -20 °C. Prior to the assay, this stock was diluted into a 0.1 % bovine serum albumin 
(BSA) (Sigma-Aldrich) solution in PBS, to a working concentration of 2 µM. Fibroblasts 
and immortalised keratinocytes were independently trypsinised, counted, and 
resuspended in the CFSE solution, at a density of 1 x 106 cells per ml, before incubating 
at 37 °C for 10 minutes. Following this, 10 ml of cold DMEM was added to quench before 
incubating on ice for 5 minutes. Cells were then centrifuged at 1000 rpm for 5 minutes, the 
supernatant removed and cells resuspended in the 0.1 % BSA solution twice, before a 
final centrifugation. Following this, fibroblasts were seeded at 5.55 x 103 cells per cm2 and 
keratinocytes at 1.67 x 104 cells per cm2 in a 6 well plate. Unstained cells were also seeded 
as a control 
 The following day, the medium of one well was replaced with mitomycin C 
containing medium at a concentration of 2 µg/ml for fibroblasts and 0.5 µg/ml for 
keratinocytes. Plates were incubated for a further 4 hours, before media from all wells was 
removed, and replaced with BP containing media of a range from 10 to 100 µM PA and 
0.1 to 50 µM ZA. 
 At 24 and 72 hours, cells were trypsinised and resuspended in a 10 % formalin 
(37 % formaldehyde (Sigma-Aldrich) in PBS) solution and left for 30 minutes to fix. Cells 
were then centrifuged at 6000 rpm for 5 minutes and resuspended in a 1 % BSA solution 
in PBS. 
 Fluorescence intensity was analysed using a flow cytometer, with a 488 nm laser 
with a 530/30 filter. As before, a preliminary gate was set to remove debris and samples 
were processed so that 10,000 gated cells were analysed per sample. Analysis was 
performed using CellQuest ProTM where a gate was applied to remove cell debris. The 
mitomycin C treated, non-proliferating cells were used to calculate a proliferation 
index (Iplf), as shown in Equation 5.1. 
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Equation 5.1. An equation to convert median fluorescence intensity to proliferation index. 
 
5.3.5 Migration assay 
 
OrisTM stoppers (Platypus Technologies), shown in Figure 5.1, were placed into 96 well 
plates in assumed sterile conditions, using the provided stopper tool. Fibroblasts were 
seeded in sextuplicate at a density of 5.4 x 104 cells per cm2, and immortalised 
keratinocytes at 1.33 x 105 cells per cm2. 24 hours after seeding, media containing 
mitomycin C was added to the wells to make an overall concentration of 2 µg/ml for 
fibroblasts and 0.5 µg/ml for keratinocytes. They were then incubated for 4 hours. 
Following this, the stoppers were removed and the media replaced with BP containing 
media at a range of 1 to 30 µM for PA, and 0.1 to 10 µM for ZA. Fibroblasts were also 
treated with 30 µM PA for 72 hours in a tissue culture flask before seeding by the same 
process and treating with 30 µM PA. 
The stopper created a 2 mm circular exclusion zone in the centre of the wells. A 
phase contrast microscope (Motic AE2000) was used to image the wells at 0, 24, 48 and 
72 hours for fibroblasts and 0, 8, 16 and 24 hours for keratinocytes. If the exclusion zone 
between cells was too large for one image, two images were taken and combined in 
Photoshop CS2 (Adobe). A diagrammatical representation of the seeding process is 
shown in Figure 5.2. 
 
 
Figure 5.1. OrisTM migration stoppers, and being placed into a 96 well plate. 
  













Figure 5.2. Cross sectional diagram of the migration assay setup. (A) Stopper placed into 
96 well plate. (B) Cells seeded at high confluence. Mitomycin C is added after cells have 
adhered. (C) Stopper removed and media replaced. (D) Cell migration tracked. 
At each time point the area of the exclusion zone was measured using ImageJ 
(National Institute of Health). A circle was drawn, as demonstrated in Figure 5.3, and the 
area of this circle was then calculated by the software. Care was taken to create a circle 
that best approximated the exclusion zone. Migration rate was calculated by expressing 
each measurement as a percentage of the area of the original zone. A graphics tablet 
(Wacom) was used to trace around the edges of the exclusion zone and measure 
migration more accurately. However, no differences were visible in results, and therefore 
migration was measured with an approximate circle in the data presented in this thesis. 
The results of the traced measurements are shown in Figure 10.3 (see Chapter 10). 












Figure 5.3. Human oral fibroblasts seeded in control medium using the OrisTM migration 
stoppers, imaged over 72 hours. Using ImageJ, the largest complete circle possible was 
drawn and the area calculated to estimate migration. 
 




5.3.6 Adhesion assay 
 
The work described in this section was performed in part by an undergraduate MEng 
student in the Hearnden research group, Jerome Tan Zu Yao. This work formed part of 
his dissertation research project, of which I was involved in the training and supervision. 
To assess the effects of BPs on the adhesion of oral epithelial cells, an adhesion 
assay was performed. A crystal violet assay was used to measure cell number. A 0.2 % 
crystal violet (Sigma-Aldrich) solution was made up in 10 % ethanol (Thermo Fisher 
Scientific) in distilled water. A 10 % acetic acid (Thermo Fisher Scientific) solution in 
distilled water was also prepared. Cells were fixed by adding a 10 % formalin solution and 
incubated at room temperature for 30 minutes, before the formalin was removed and the 
wells washed thrice with PBS. Crystal violet was then added to the fixed cells for 
10 minutes at room temperature. This was then removed, and wells were washed with 
water until all excess crystal violet was removed. The well plates were then left in a fume 
cupboard to dry out. When the wells were dry, 400 µl of the acetic acid solution was added 
to elute the stain. Triplicate samples from each well were transferred to a 96 well plate, 
which was then read in an absorbance plate reader at 532 nm.  
 Before performing the assay, the adhesion time for OKF6 cells was examined. 
Cells were seeded in triplicate in 24 well plates, at a density of 1.5 x 104 cells per cm2. At 
time points ranging from 1 to 24 hours, media was removed, wells were washed thrice with 
PBS, cells were fixed and the crystal violet assay was performed. 
For the adhesion assay, cells were treated with ZA in a well plate for 24 hours, then 
detached with trypsin and moved to a new well plate. To account for any toxicity effects, a 
well plate was seeded where the cells were not detached as a control. A diagrammatical 
representation of the assay is shown in Figure 5.4. 
OKF6 cells were again seeded at a density of 1.5 x 104 cells per cm2, in two well 
plates, and left to adhere overnight. The medium was then changed to ZA containing 
medium from 1 to 30 µM, or replaced with control medium. Cells were treated in triplicate. 
Both plates were treated identically up this point. 
 After 24 hours of treating, the media was removed from both plates. The control 
plate was washed with PBS thrice and cells fixed as above. For the experimental plate, 
wells were washed with PBS and trypsin-EDTA was used to detach the cells. After 
detachment, DMEM was added to deactivate the trypsin, and cells were centrifuged for 
5 minutes at 5000 rpm. Cells were then resuspended and seeded into a new well plate in 
control medium. After 2 hours, the medium was removed, wells were washed with PBS 
and fixed as described above. A crystal violet assay was then performed on both plates.  
  




Figure 5.4. A flow diagram of the method for the crystal violet adhesion assay. 
 
5.3.7 120 hour cell viability 
 
To assess adhesion over longer time points, ZA concentration was first tested to ensure 
enough cells remained viable to assess. Keratinocytes were seeded in a 24 well plate at 
a density of 1.5 x 104 cells per cm2 and left to attach overnight. The following day, they 
were treated with 0.1 to 30 µM ZA and incubated for 120 hours. A crystal violet assay was 
then performed as described previously in section 5.3.6. 
 
5.3.8 Cytoskeleton staining 
 
To further investigate the effects of BPs on epithelial cell adhesion, immunolabeling of 
cellular adhesion proteins was performed. Glass coverslips (Thermo Fisher Scientific) 
were sterilised in 70 % IMS, and placed into a 24 well plate. They were then washed thrice 
with PBS and left to dry. Once dry, OKF6 cells were seeded at a density of 
1.5 x 104 per cm2 onto the coverslips, left to adhere overnight, then treated with ZA 




concentrations from 1 to 30 µM. Cells were then incubated for 24, 48 or 120 hours, then 
fixed as described previously in section 5.3.6. The 24 and 48 hour experiments were 
performed by Jerome Tan Zu Yao. 
 To perform the staining, an Actin Cytoskeleton and Focal Adhesion 
Staining Kit (Merck-Millipore) was used. This contained three components, 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated phalloidin, anti-vinculin and 
4′,6-diamidino-2-phenylindole (DAPI). Phalloidin staining was performed in a 1:300 dilution 
in PBS. Vinculin staining was performed in a 1:300 dilution in a blocking solution. DAPI 
was diluted 1:1000 in PBS. Also used for this staining was a FITC-conjugated anti-mouse 
secondary antibody (Merck-Millipore, #AP124F), diluted 1:100 in PBS. A 1 % BSA 
blocking solution was prepared in PBS. To permeabilise the cells, a 0.1 % Triton X-100 
(Thermo Fisher Scientific) solution in PBS was used. For washing cells, a buffer containing 
0.05 % Tween-20 (Sigma-Aldrich) in PBS was used. All staining took place protected from 
light on a rocking plate (Bibby Scientific), set to 45 rpm to ensure liquid coverage of the 
whole coverslip. 
 Firstly, each well was washed twice with the wash buffer, before cells were 
permeabilised for 5 minutes using the Triton X-100 solution. Wells were then washed twice 
again. The blocking solution was applied for 30 minutes and removed. Anti-vinculin diluted 
in blocking solution was then applied for 1 hour. Wells were then washed thrice with the 
wash buffer, with the buffer left on for 10 minutes each time. The secondary antibody and 
phalloidin were applied simultaneously for 1 hour. Wells were washed thrice for 10 minutes 
as before. DAPI was then applied for 5 minutes, before three 10 minute washes. 
Coverslips were then fixed to glass slides using p-Xylene-bis(N-pyridinium bromide) (DPX) 
mountant (Merck). 
 A confocal microscope (Zeiss LSM510 META) with a 543 nm and a 488 nm laser 
was used to image the samples. Samples were also imaged using a 2-photon 780 nm 
laser (Chameleon Ultra III, Coherent Inc). Samples were imaged with a Zeiss EC 
Plan-Neofluar 40x magnification lens and a Zeiss Plan-Apochromat 63x magnification oil 
immersion lens. For FITC fluorescence excitation and emission wavelengths of 
λex=488 nm/λem=525 nm were used. For TRITC, wavelengths of λex=543 nm/λem=576 nm 
were used. DAPI stained cell nuclei were visualized at λex=780 nm/λem=480 nm. Images 




Statistics were performed using Prism as described in section 4.3. ‘N’ is used to denote 
experimental repeats, while ‘n’ is used to denote technical repeats throughout. For the 
MTT results, values were normalised. The mean of the triplicate values for each condition 
at each time point were calculated. These new values were then calculated as a 
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percentage of the mean of the control values at 24 hours. One outlying value was removed 
from the MTT data. This value was identified as a significant outlier (P≤0.001) using 
Grubb’s test for outliers through Excel (Microsoft). For the full calculation see Figure 10.4 
(Chapter 10). 
The half maximal inhibitory concentrations (IC50) were calculated as follows. First, 
values were normalised to the control well at 72 hours. Next, 0 µM was set as 1 x 10-10 µM 
and concentrations transformed to log10(concentration). A non-linear fit for the data was 
calculated using an inhibitor vs. normalised response variable slope curve, using each 
value as an individual point. The software then generated a curve of best fit and an IC50 
value. 
Certain experiments did not involve time as an independent variable, and therefore 
other tests were used to determine significance than those described in section 4.3. These 
were the adhesion assay, 120 hour crystal violet assay, and the apoptosis assay. 
Adhesion assay significance was calculated based on Kendall’s rank correlation 
coefficients. These were calculated using SPSS (IBM). Concentration and cell number 
were set as scale variables. Data was sorted and split based on plate and Kendall’s rank 
correlation coefficient calculated for each plate, using two-tailed significance. 
To calculate significance in the 120 hour adhesion assay, a one way ANOVA was 
performed, again using Dunnett’s multiple comparison test to measure significance of each 
concentration against the control. For the apoptosis assay, these tests were performed 










5.4.1 Pamidronic acid and zoledronic acid were toxic to human oral fibroblasts and 
keratinocytes over 72 hours 
 
MTT assays give a colorimetric response to metabolic activity, which can be used as an 
approximation of viability. Figure 5.5 shows the response of oral fibroblasts when cultured 
in different concentrations of PA over 72 hours, normalised to the control value at 24 hours. 
At 24 hours there were no significant differences in metabolic activity between cells treated 
with different doses of PA. Metabolic activity of the control group increased by 
approximately 50 % between 24 and 72 hours, indicating cell proliferation. 
At 48 and 72 hours, a dose dependent response to PA was seen. At 48 hours, 
100 µM PA significantly reduced metabolic activity to approximately 40 % of the control 
cell activity at the same time point, respectively. Both 50 and 100 µM PA significantly 
lowered fibroblast metabolic activity after 72 hours in culture. No significant difference was 
seen between the control media and 10 µM PA at any time point. 
 
Figure 5.5. Human oral fibroblast metabolic activity over 72 hours in the presence of 
pamidronic acid. Values normalised to control cells at 24 hours. One outlying value 
removed. N=3, n=3. Error bars = SD. Significance against 0 µM at each time point 
indicated by *P≤0.05. 
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When immortalised keratinocytes (OKF6) were cultured in PA, there was no 
significant difference between metabolic activity for any of the doses tested at 24 hours, 
as shown in Figure 5.6. Metabolic activity of the control increased between time points at 
a much higher rate than with fibroblasts, increasing from 100 % to approximately 400 %, 
although there was high variation, indicated by the error bars. After 48 hours, a dose 
response was seen, with increasing concentrations of PA causing decreased cell 
metabolic activity, with 100 µM reducing metabolic activity by a significant amount in 
comparison to the control. PA concentrations of 30 µM and above significantly lowered 
keratinocyte metabolic activity after 72 hours in culture, in comparison to the control, with 
a dose dependent response again seen. 
 
 
Figure 5.6. Immortalised human oral keratinocyte (OKF6) metabolic activity over 72 hours 
in the presence of pamidronic acid. Values normalised to control cells at 24 hours. N=3, 
n=3. Error bars = SD. Significance against 0 µM at each time point indicated by *P≤0.05. 
  




Figure 5.7 shows the metabolic activity of primary oral keratinocytes treated with 
PA. The metabolic activity of the untreated control cells increased by approximately 25 % 
between 24 and 48 hours. This was much less than in the immortalised keratinocytes. PA 
treatment showed a small reduction metabolic activity at 24 and 48 hours, but not 
significantly, though variation was high. A dose dependent response was seen at 72 hours. 
However, while the 10, 30 and 50 µM PA treated cells had lower overall values than the 
control, the values were higher than those at 48 hours. 100 µM PA significantly reduced 
cell metabolic activity, to approximately 20 %. 
 
 
Figure 5.7. Primary human oral keratinocyte metabolic activity over 72 hours in the 
presence of pamidronic acid. Values normalised to control cells at 24 hours. N=3, n=3. 
Error bars = SD. Significance against 0 µM at each time point indicated by *P≤0.05. 
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ZA is a more potent anti-resorptive compared to PA, and also proved more toxic to 
oral mucosa cells. A dose dependent response was seen with fibroblasts in Figure 5.8, 
with 10 µM significantly reducing metabolic activity following 72 hours culture by around 
85 %, in comparison to the control. Metabolic activity of the control remained 




Figure 5.8. Human oral fibroblast metabolic activity over 72 hours in the presence of 
zoledronic acid. Values normalised to control cells at 24 hours. N=3, n=3. Error bars = SD. 
Significance against 0 µM at each time point indicated by *P≤0.05. 
  




Figure 5.9 shows the response of immortalised keratinocytes to ZA. Again, no 
significance was found between doses at 24 hours, and a dose response was seen at 
48 hours, however this was not significant. At 72 hours, concentrations of 20 and 50 µM 
significantly reduced cell metabolic activity in comparison to the control. 
 
 
Figure 5.9. Immortalised human oral keratinocyte (OKF6) metabolic activity over 72 hours 
in the presence of zoledronic acid. Values normalised to control cells at 24 hours. N=3, 
n=3. Error bars = SD. Significance against 0 µM at each time point indicated by *P≤0.05. 
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ZA caused no significant difference to primary keratinocyte metabolic activity at 
24 hours, as shown in Figure 5.10. At 48 hours, a dose dependent response was seen, 
with a 100 µM concentration reducing metabolic activity significantly. At 72 hours, the 
metabolic activity of the control cells had increased by approximately 40 % from 24 hours. 
ZA caused a dose dependent response, with concentrations of 10 µM and above 
significantly reducing cell metabolic activity. 
 
 
Figure 5.10. Primary human oral keratinocyte metabolic activity over 72 hours in the 
presence of zoledronic acid. Values normalised to control cells at 24 hours. N=3, n=3. 
Error bars = SD. Significance against 0 µM at each time point indicated by *P≤0.05. 
  




Using the data collected at 72 hours, approximate IC50 values were generated for 
each drug and cell type, shown in Figure 5.11. ZA was more potent in all cell types, the 
IC50 approximately 7 times that of PA in fibroblasts and primary keratinocytes, and twice 
the concentration in immortalised keratinocytes. Immortalised keratinocytes were more 
resistant to ZA than their primary counterparts, yet less resistant to PA.  
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Figure 5.11. IC50 graphs for fibroblasts, immortalised and primary keratinocytes when 
treated with either pamidronic acid or zoledronic acid for 72 hours. N=3, n=3. Cell 
metabolic activity normalised to control. 0 µM set as 10-10, data point not shown.  
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5.4.2 Pamidronic acid and zoledronic acid led to apoptosis in oral mucosa cells 
 
Fibroblasts and keratinocytes were treated with PA and ZA for 72 hours, before staining 
with Annexin V-FITC and propidium iodide (PI), to assess whether the previously defined 
BP toxicity was due to apoptosis or necrosis. Annexin V binds to phosphatidylserine, an 
apoptosis marker. PI is a fluorescent stain that cannot cross a cell membrane, therefore is 
an indicator of lysed cells. Cells were determined to be early apoptotic if they stained with 
Annexin V alone, and late apoptotic if they stained with Annexin V and PI. Cells which 
stained with PI alone were considered necrotic. Cells which did not stain were considered 
viable. 
 Figure 5.12 shows the proportion of fibroblasts in each category following 72 hours 
of treatment with PA and ZA. Approximately 90 % of the untreated control cells were viable 
after 72 hours, with approximately 7 % cells apoptotic and less than 3 % necrotic. When 
treated with 10 µM PA, 0.5 µM ZA and 10 µM ZA, no significant differences were seen 
compared to the untreated cells. When treated with 50 µM PA the proportion of viable cells 
was significantly reduced, with only approximately 25 % of cells staining with neither 
Annexin V nor PI. Of the stained cells, approximately 10 % were early apoptotic and 60 % 
late apoptotic, both significant increases in comparison to the control. 
 Approximately 90 % of immortalised keratinocytes were viable after 72 hours, as 
shown in Figure 5.13, with the remaining 10 % evenly split between apoptotic and necrotic. 
Following treatment with sub-toxic concentrations of either PA or ZA, no differences were 
seen compared to the untreated cells. Concentrations above the IC50 reduced the number 
of viable cells. When treated with 100 µM PA, approximately 10 % of cells became 
apoptotic, and 10 % became necrotic. When treated with 50 µM ZA, the amount of viable 
cells was reduced to approximately 70 %, with approximately 20 % cells apoptotic and 
10 % necrotic. The increase in late apoptosis was significant.  





Figure 5.12. Proportion of human oral fibroblasts viable, early apoptotic, late apoptotic or 
necrotic after 72 hours treatment with pamidronic acid or zoledronic acid. N=3. Error bars 
= SD. Significance against control indicated by *P≤0.05. 
 
Figure 5.13. Proportion of human oral immortalised keratinocytes viable, early apoptotic, 
late apoptotic or necrotic after 72 hours treatment with pamidronic acid or zoledronic acid. 
N=3. Error bars = SD. Significance against control indicated by *P≤0.05. 
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5.4.3 Mitomycin C prevented proliferation of fibroblasts and immortalised 
keratinocytes 
 
When performing a migration assay, it is necessary to stop proliferation and ensure that 
any wound closure seen is due to cell migration alone. Preventing proliferation also is used 
as a control during a proliferation assay. Mitomycin C is a DNA crosslinker that can be 
used to arrest the cell cycle, preventing proliferation. It significantly affected the 
proliferation of fibroblasts at concentrations of 0.625 µg/ml and above, as shown in Figure 
5.14. Cells treated with control media tripled in number over 96 hours in culture. 
Concentrations from 0.625 to 2.5 µg/ml had a near constant cell number over 96 hours. A 
5 µg/ml concentration caused a reduction in cell number, highlighting the toxic nature of 
higher concentrations of mitomycin C. Hence 2 µg/ml concentrations were used going 
forwards with fibroblasts. 
Mitomycin C concentrations from 0.1 to 0.5 µg/ml significantly reduced cell 
proliferation of keratinocytes over 72 hours in culture, as shown in Figure 5.15. 
Concentrations of 0.3 µg/ml and 0.5 µg/ml maintained a constant cell number over culture 
time. Below that concentration cell number increased due to proliferation. Hence we used 
0.5 µg/ml concentrations of mitomycin C to arrest cell proliferation in migration studies and 
to act as a control in proliferation assays with immortalised keratinocytes. 
  





Figure 5.14. Human oral fibroblast cell number over 96 hours in the presence of 




Figure 5.15. Immortalised human oral keratinocyte (OKF6) cell number over 72 hours in 
the presence of Mitomycin C. N=1, n=3. Error bars = SD. Significance against 0 µg/ml 
indicated by *P≤0.05. 
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5.4.4 Pamidronic acid and zoledronic acid prevented fibroblast and immortalised 
keratinocyte proliferation 
 
Fibroblasts and immortalised keratinocytes were stained with CellTraceTM CFSE before 
treating with PA and ZA for 72 hours to measure cell proliferation. Flow cytometry was 
used to measure the median fluorescence intensity of cells at 24 and 72 hours. 
CellTraceTM CFSE staining allows cell proliferation to be measured, as each time a cell 
divides, the fluorescence intensity of the two cells formed by that process will be reduced 
compared to cells which have not divided [291]. By comparing cells treated with 
mitomycin C that cannot undergo proliferation, it was possible to determine a proliferative 
index (Iplf) as per Equation 2.1. A higher Iplf indicated the cells proliferated more and a Iplf 
of 1 indicated no proliferation took place. 
Figure 5.16 shows fibroblast proliferation following treatment with PA and ZA. At 
24 hours, no significant differences were seen between any treatments. At 72 hours, low 
concentrations of each drug caused no differences in Iplf in comparison to the control. 
However, 50 µM PA and 10 µM ZA caused a significant reduction in proliferation. PA led 
to a Iplf close to that of the mitomycin C treated cells, indicating proliferation was halted 
entirely. 
Figure 5.17 demonstrates that keratinocyte proliferation was low over 24 hours, 
with values close to 1 for all treatments and no significant differences seen between the 
control cells and any of the drug treated cells. At 72 hours, the keratinocyte Iplf had 
increased to approximately 3. When treated with 10 µM and 100 µM PA, proliferation was 
significantly reduced. ZA also led to a significant reduction in keratinocyte proliferation at 
both 1 and 50 µM ZA concentrations, compared to untreated control cells. The higher 
concentrations of both drugs prevented keratinocyte proliferation almost entirely, with the 
Iplf close to 1 in both cases.  





Figure 5.16. Human oral fibroblast proliferation over 72 hours in the presence of 
pamidronic acid or zoledronic acid. Mitomycin C used as a non-proliferating control. N=3. 
Error bars = SD. Significance against control indicated by *P≤0.05. 
 
Figure 5.17. Immortalised human oral keratinocyte (OKF6) proliferation over 72 hours in 
the presence of pamidronic acid or zoledronic acid. Mitomycin C used as a 
non-proliferating control. N=3. Error bars = SD. Significance against control indicated by 
*P≤0.05. 
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5.4.5 Sub-toxic concentrations of pamidronic acid and zoledronic acid did not 
affect the migration rate of oral mucosa cells 
 
As a key part of BRONJ development is the prevention of oral mucosa wound healing, we 
next studied cell migration in the presence of BPs. Migration is a key part of wound healing, 
with both fibroblasts and keratinocytes migrating in the early stages. Sub-toxic 
concentrations were chosen, to confirm that any effects seen were not due to toxicity, but 
were BPs affecting the cells by another mechanism. 
Figure 5.18 shows representative images of fibroblast migration into an exclusion 
zone in a well plate over 72 hours when treated with PA. At 0 hours, uniform regions with 
no cells were seen in all conditions. At 24 and 48 hours, cells had migrated into these 
regions, and appeared viable at all time points. At 72 hours (not shown), all wells looked 
uniform and entirely covered by cells. Figure 5.19 shows the migration rate of fibroblasts 
over the time period. Neither 10 nor 30 µM concentrations showed an effect, with cells 
migrating into the exclusion zone at a similar rate and no significant difference between 
any values. By 72 hours, all zones had closed by approximately 95 %. 
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Figure 5.18. Human oral fibroblast migration over 48 hours in the presence of pamidronic 
acid. Dotted lines indicate approximate exclusion zones. Columns denote each time point, 
rows denote the concentration of pamidronic acid in µM. One representative well used for 
each condition. Wells at 72 hours not shown as all exclusion zones were completely 
closed. Scale bars = 1mm. 




Figure 5.19. Human oral fibroblast migration over 72 hours in the presence of pamidronic 
acid. N=3, n=6. Error bars = SD. Statistical tests showed significance (P≤0.05) between 
0 µM and any other concentration. 
  




Fibroblast migration was also unaffected by sub-toxic concentrations of ZA, as 
shown in Figure 5.20. Again, seeding was uniform at 0 hours, with migration occurring 
normally over 48 hours and all cells appearing viable at all time points.  When treated for 
72 hours with ZA concentrations of 0.5, 1 and 5 µM, there were no significant differences 
between migration at any time points, and all wells closed by approximately 98 % after 
72 hours, as shown in Figure 5.21. 
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Figure 5.20. Human oral fibroblast migration over 48 hours in the presence of zoledronic 
acid. Dotted lines indicate approximate exclusion zones. Columns denote each time point, 
rows denote the concentration of zoledronic acid in µM. One representative well used for 
each condition. Wells at 72 hours not shown as all exclusion zones were completely 
closed. Scale bars = 1mm. 
  





Figure 5.21. Human oral fibroblast migration over 72 hours in the presence of zoledronic 
acid. N=3, n=6. Error bars = SD. Statistical tests showed significance (P≤0.05) between 
0 µM and any other concentration. 
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Immortalised keratinocyte migration occurred at a faster rate, with exclusion zones 
closing after 24 hours. Concentrations ranging from 0 to 10 µM were used for both PA and 
ZA, and neither showed any effect on the migration of keratinocytes.  
Figure 5.22 shows representative images from each condition at 0, 8 and 16 hours 
and demonstrates that cells were viable at all time points. The exclusion zones, while 
similar, were not completely uniform, with a less defined circle than with fibroblasts, as in 
the 5 µM concentration of PA in Figure 5.22. Figure 5.23 shows that whilst PA treated cells 
did migrate more quickly, the differences were not statistically significant. All exclusion 
zones were approximately 95 % closed after 24 hours. The standard deviation, 
demonstrated as error bars, shows there was high variation between experiments, which 
was likely due to the variation in exclusion zone size and shape. 
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Figure 5.22. Immortalised human oral keratinocyte (OKF6) migration over 16 hours in the 
presence of pamidronic acid. Dotted lines indicate approximate exclusion zones. Columns 
denote each time point, rows denote the concentration of pamidronic acid in µM. One 
representative well used for each condition. Wells at 24 hours not shown as all exclusion 
zones were completely closed. Scale bars = 1mm. 
  




Figure 5.23. Immortalised human oral keratinocyte (OKF6) migration over 24 hours in the 
presence of pamidronic acid. N=3, n=6. Error bars = SD. Statistical tests showed 
significance (P≤0.05) between 0 µM and any other concentration. 
 




ZA also had no significant effect on the rate of keratinocyte migration, with all wells 
closing at a similar rate regardless of drug concentration. Figure 5.24 again shows 
relatively uniform exclusion zones at 0 hours, with migration of viable keratinocytes over 8 
and 16 hours in the ZA migration assay. Figure 5.25 highlights that exclusion zones closed 
at a faster rate, with around 90 % closure at 16 hours and approximately 98 % at 24 hours. 
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Figure 5.24. Immortalised human oral keratinocyte (OKF6) migration over 16 hours in the 
presence of zoledronic acid. Dotted lines indicate approximate exclusion zones. Columns 
denote each time point, rows denote the concentration of zoledronic acid in µM. One 
representative well used for each condition. Wells at 24 hours not shown as all exclusion 
zones were completely closed. Scale bars = 1mm. 





Figure 5.25. Immortalised human oral keratinocyte (OKF6) migration over 24 hours in the 
presence of zoledronic acid. N=3, n=6. Error bars = SD. Statistical tests showed 
significance (P≤0.05) between 0 µM and any other concentration. 
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5.4.6 Pre-treating fibroblasts with pamidronic acid prevented exclusion zone 
closure through toxicity 
 
As the oral mucosa of BRONJ patients is potentially exposed to BPs for longer time 
periods, including before the mucosa is wounded, migration was also examined when cells 
were treated with PA for 72 hours before seeding until the end of the experiment. 
Figure 5.26 shows representative wells during the study, with cells treated with 
media alone migrating normally. When pre-treated with 30 µM PA, fewer fibroblasts had 
migrated into the exclusion zone at 48 hours. By 72 hours, the cells were no longer viable, 
as shown in Figure 5.27. Treating fibroblasts for a total of 144 hours with 30 µM PA led to 
a large number of cells no longer attached to the well plate and caused the remaining cells 
to no longer retain their distinct morphology, indicating toxicity. 
Figure 5.28 shows the migration rate of the pre-treated fibroblasts in comparison 
to the control. Between 24 and 48 hours, PA led to a reduction in migration rate compared 
to untreated control cells, however this was not significant. The exclusion zone then 
re-opened between 48 and 72 hours. The exclusion zone closure in pre-treated fibroblasts 
at 72 hours was significantly lower compared to the untreated control. However, this effect 
was due to toxicity following 144 hours total treatment with 30 µM PA, rather than migration 
effects. 
  




  Time (hours) 



























   
30 
   
Figure 5.26.  Human oral fibroblast migration over 48 hours in the presence of pamidronic 
acid, following 72 hours pre-treatment. Dotted lines indicate approximate exclusion zones. 
Columns denote each time point, rows denote the concentration of pamidronic acid in µM. 
One representative well used for each condition. Scale bars = 1mm. 
  




Figure 5.27. Human oral fibroblasts after 72 hours in the presence of 30 µM pamidronic 
acid, following 72 hours pre-treatment. Dotted line indicates approximate exclusion zone. 
One representative image used. Scale bar = 1mm. 
 
Figure 5.28. Human oral fibroblast migration over 72 hours in the presence of pamidronic 
acid, following 72 hours pre-treatment. N=3, n=6. Error bars = SD. Significance against 
0 µM indicated by *P≤0.05. 
  




5.4.7 Zoledronic acid caused a small reduction in immortalised keratinocyte 
adhesion 
 
BPs have been demonstrated to affect the adhesion of several cell types, including oral 
fibroblasts, affecting both integrins and the cytoskeleton [82], [144], [181]–[183]. This has 
never been demonstrated in oral keratinocytes, and presents another potential mechanism 
through which the oral mucosa could be weakened from BP treatment. If epithelial cells 
became less adherent this could reduce the thickness and structural strength of the oral 
mucosa, increasing the risk of damage and thereby increasing the rate of bone exposure. 
A 2D adhesion assay was performed using immortalised keratinocytes to assess any in 
vitro BP effects on adhesion. To optimise this assay, the adhesion of immortalised 
keratinocytes was first studied over time through a crystal violet assay. 
 Figure 5.29 shows the percentage of cells that had adhered to a well plate over 
1 to 24 hours, normalised to the 24 hour value, as it can be assumed all cells will have 
adhered at this time point. Initially, the increase in cell attachment over time was quite 
steep. Approximately 50 % of cells had adhered 1 hour after seeding. By 2 hours, the 
adhesion level was approximately 70 %. After this time point, the rate of adhesion began 
to level off, with around 75 % being adhered at both 4 and 6 hours. Due to the adhesion 
amount being similar at 2, 4 and 6 hours, 2 hours was chosen as the time point for the 
adhesion assay, to maximise the ability to see an effect caused by BP treatment. 
 The results of the adhesion assay are shown in Figure 5.30. The cells of the control 
plate were not detached, and the crystal violet results show the cell number is largely 
unaffected by ZA treatment over 72 hours. Although a significant dose dependent 
reduction is observed, all values remain close to 100 % of the number of the untreated 
cells. When the cells were detached and allowed to re-attach for 2 hours, approximately 
63 % of the untreated cells attached. Again, a dose dependent response is seen when 
treated with increasing concentrations of ZA, however in this case, the response is more 
pronounced. Both the control plate and detached plate showed a significant correlation 
between cell number and ZA concentration. The correlation was stronger for the detached 
plate, suggesting ZA caused a small reduction on the ability of the immortalised 
keratinocytes to adhere, over and above toxic effects caused by the ZA. 
  




Figure 5.29. Adhesion of immortalised keratinocytes (OKF6) over time measured by 
crystal violet assay. Values normalised to 24 hours. N=1, n=3. Error bars = SD. 
 
Figure 5.30. Adhesion assay results for immortalised keratinocytes (OKF6) treated with 
zoledronic acid for 24 hours then fixed (control) or detached, re-seeded and allowed to 
adhere for 2 hours (detached), measured by crystal violet assay. Values normalised to 
0 µM of control plate. N=4, n=3. Error bars = SD. Kendall rank correlation coefficient for 
each plate indicated by τ. Significance against 0 µg/ml indicated by *P≤0.05. 
  




5.4.8 Zoledronic acid did not affect expression of keratinocyte cytoskeleton 
proteins 
 
Figure 5.31 shows images of immortalised keratinocyte cells stained for cytoskeleton 
proteins after 24 hours of zoledronic acid treatment. F-actin bundles were stained red, and 
vinculin was stained green. F-actin bundles appeared present in all images, with no 
obvious BP effect visible. There was a slight reduction of staining with 10 µM treatment, 
however this effect is not apparent with 30 µM zoledronic acid. Vinculin staining appears 
consistent across all concentrations, however is much less specific than would be 
expected, staining throughout the cell rather than obviously staining focal adhesions. 
 After 48 hours treatment, staining is again largely consistent across all samples for 
both vinculin and F-actin, shown in Figure 5.32. The control, 1 µM and 10 µM treated 
keratinocytes in particular have no noticeable differences. When treated for 48 hours with 
30 µM zoledronic acid, there is a slight difference in the F-actin appearance. Fewer 
obvious bundles appear, with staining appearing more in the cell cortex. Overall vinculin 
staining was non-specific but had a more diffuse staining pattern in cells treated with 30µM 
ZA compared to the other conditions.  
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Figure 5.31. Immortalised human oral keratinocytes (OKF6) after treatment with zoledronic 
acid for 24 hours, stained for F-actin (red) and vinculin (green). Panels show: vinculin 
staining alone (upper left), F-actin staining alone (upper right) and a combined image 
(lower left). 
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Figure 5.32. Immortalised human oral keratinocytes (OKF6) after treatment with zoledronic 
acid for 48 hours, stained for F-actin (red) and vinculin (green). Panels show: vinculin 
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Due to there being no clear differences in cytoskeleton staining with ZA treatment 
over 48 hours, treatment time was increased to 120 hours. Before this, BP toxicity over 
this time period was measured using a crystal violet assay. Figure 5.33 shows the 
percentage of cells remaining following treatment with zoledronic acid for 120 hours. A 
clear dose dependent reduction is apparent. Cells treated with 30 µM zoledronic acid all 
showed a dramatic reduction in cell number after 120 hours (approximately 80%) meaning 
this was unsuitable for staining studies. While concentrations from 1 to 10µM did show a 
reduction in cell number following 120 hours of treatment, it was anticipated enough cells 
would remain to allow staining to be performed.  There was no difference between cells 
treated with 0.1 µM and the control cells and this concentration was not used for the 
120 hour immunostaining experiment. 
 Figure 5.33 shows keratinocytes treated for 120 hours with 0, 1, 5 and 10 µM 
zoledronic acid. F-actin and vinculin were shown in red and green, respectively, and nuclei 
were stained blue. As expected from the crystal violet results, a reduction in cell number 
occurred with increasing BP concentration. However, again no obvious differences in 
staining were apparent. Changes in cell morphology were observed, with cells appearing 
smaller as ZA concentration is increased, though this was likely due to cytotoxicity, rather 
than a specific adhesion effect. 
 
Figure 5.33. Immortalised human oral keratinocyte (OKF6) cell number after treating with 
zoledronic acid for 120 hours. Cell number measured by crystal violet assay, normalised 
to 0 µM. N=1, n=3. Error bars = SD. Significance against 0 µM indicated by *P≤0.05. 
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Figure 5.34. Immortalised human oral keratinocytes (OKF6) after treatment with zoledronic 
acid for 120 hours, stained for F-actin (red), vinculin (green) and nuclei (blue). Panels 
show: vinculin staining alone (upper left), F-actin staining alone (upper right), DAPI stained 
nuclei (lower left) and a combined image (lower right). 
 
  





Toxicity to the oral mucosa is hypothesised to be key to BRONJ development [2]. Following 
tooth extraction, or other BRONJ precipitating events, the mucosa becomes damaged and 
does not heal, which exposes the necrotic bone to the surrounding area. This increases 
the risk of infection and allows BPs bound to the bone to be released into the mouth. 
However, the mechanisms by which BPs affect the oral mucosa have not been fully 
elucidated. Investigating the effects of PA and ZA – two BPs which most commonly cause 
BRONJ – on cells of the oral mucosa is therefore an important step in understanding the 
condition, as it will allow assessment of how BPs prevent wound healing. 
The BP concentration to which the oral mucosa is exposed is not known and 
difficult to estimate, given the differences in administration method, dosages and length of 
treatment. The concentration in bone has been estimated to be 2000 µM, assuming a 
90 mg monthly infusion of PA for 4 years [56], [57]. The maximum blood serum 
concentration of ZA following a 4 mg infusion is estimated to be 1.47 µM [55]. The ZA 
concentration of the saliva of patients with osteonecrosis was measured 5 minutes after 
an IV 4 mg infusion, and estimated to be between 0.4 and 5 µM [142]. It can hence be 
assumed that the oral mucosa of BRONJ patients will be subjected to BPs in the 
concentration range of 0.4 to 2000 µM, and therefore values within this range were used 
during our work. 
We have demonstrated that clinically relevant concentrations of both PA and ZA 
reduce the metabolic activity of cells from the human oral mucosa in a dose dependent 
manner over 72 hours of treatment. Our data supports the hypothesis that BP toxicity to 
the oral mucosa is likely to lead to the development of BRONJ, following dental surgery, 
with both the epithelium and connective tissue affected. 
It is hypothesised that the BPs chelated to the osteonecrotic jaw bone are 
consistently released into the surrounding environment [48], [175]. We have shown that 
exposure to concentrations towards the lower limits of those expected will lead to soft 
tissue cytotoxicity over a relatively short period of time. Our data indicates a clear 
mechanism by which BPs could prevent soft tissue wound healing and contribute to the 
prolonged exposure of necrotic bone. 
To measure the toxicity of oral mucosa cells, we performed MTT assays. Rather 
than directly measuring cell viability, these assays measure cell metabolic activity. When 
cells are subject to adverse conditions, they can occasionally increase their metabolic rate 
as a stress response and cause a false result, and, as highlighted through our apoptosis 
assay, metabolic activity can be reduced without a direct effect on viability. However, the 
assay is currently seen as the gold standard of cytotoxicity assays and we have therefore 
used it to measure PA and ZA toxicity in this thesis [292]. 




PA and ZA have previously been demonstrated to be toxic to fibroblasts and 
keratinocytes [34], [35], [168], [170]–[172], [175]–[177], [57], [86], [142], [144], [164]–[167]. 
However, these studies used cells from a variety of sources, examined different 
concentration ranges and treatment lengths, and used different assays to measure 
viability. Here, we have performed a comprehensive study of the toxicity of two BPs most 
commonly associated with BRONJ using cells from relevant sources and a broad range of 
BP concentrations allowing for a more direct comparison between two drugs and three 
different cell types. 
We have also generated IC50s for each cell and drug combination at 72 hours. This 
is a more precise measure than often used during BP studies and gives a more accurate 
picture of the toxicity of PA and ZA. Previous literature often features wide ranges and 
gaps between the highest non-toxic and lowest toxic concentrations (e.g. 30 µM and 
100 µM [57]) which makes the determination of the exact toxic level difficult. Our data 
presents a more accurate measurement which is used worldwide as a standard measure 
of drug toxicity. 
In our study, PA gave a 72 hour IC50 value of 43 µM for fibroblasts. Cozin et al. had 
previously shown toxicity to oral fibroblasts to fall between 30 µM and 60 µM at 72 hours 
[144]. Our data supports their study and allows for the direct determination of the point at 
which the BP is toxic. In both our work and theirs, concentrations higher than the IC50 value 
led to toxicity at 48 hours, and concentrations lower than the IC50 led to toxicity at further 
time points. While we did not directly measure toxicity past 72 hours, we did treat 
fibroblasts with 30 µM PA for a total of 144 hours in our migration assay, where there was 
obvious cell toxicity. This highlights the dangers of prolonged exposure to the drug and 
suggests that if BP exposure could be limited to short time periods and low doses, the 
toxicity associated with BRONJ development could be avoided. 
 ZA has a higher anti-resorptive potency than PA, and has previously been 
demonstrated to also be more toxic to cells of the oral mucosa [144], [175]. This was also 
the case in our study, where the 72 hour IC50 for fibroblasts was determined to be 6 µM. 
Concentrations ranging from 8 to 50 µM ZA have been reported as toxic concentrations 
for fibroblasts treated with ZA for 72 hours [144], [167], [168], [171], which hold true as 
they are over the IC50. Our data shows that ZA toxicity occurs at an even lower 
concentration, and one that is very close to the expected BRONJ patient saliva 
concentration. This demonstrates one reason why patients taking ZA are more likely to 
develop BRONJ compared to those taking PA. 
 We also examined the toxicity of both drugs on two different types of keratinocytes: 
immortalised OKF6 cells and primary cells derived from human oral mucosa. OKF6 cells 
were originally sourced from human oral mucosa and modified to achieve immortality 
[179]. They provide a good model of oral keratinocytes, whilst removing the difficulties that 
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come with the sourcing and culture of primary human cells. Commonly, in literature, 
HaCaT cells are used for BP testing [169], [174], [176], [178]. These are highly proliferative 
immortalised skin cells. While simple to culture, these do not provide an accurate 
representation of human oral tissue. Murine cells have also been used [57], [140], which 
have a similar drawback. Our data therefore presents a more representative model of how 
BPs affect BRONJ patients. 
Our work shows that both immortalised and primary keratinocytes are susceptible 
to BP toxicity. Immortalised cells proved more resistant to ZA toxicity than primaries, but 
less resistant to PA toxicity. However the toxicity values were all still well within the lower 
limits of the estimated clinical doses. 
 Our 72 hour IC50 values for keratinocytes treated with PA were 35 µM and 59 µM 
for immortalised and primary cells, respectively. Landesberg et al. previously showed PA 
led to keratinocyte toxicity between 30 and 100 µM [57]. Pabst et al. indicated toxicity 
between 50 and 100 µM [175]. Our data supports these values and gives a more accurate 
suggestion of where the point of toxicity lies. While not mathematically deduced, data from 
Kim et al. suggested a primary keratinocyte IC50 of approximately 50 µM at 96 hours [164], 
which fits with what is known about BP potency over time. This value, however, is higher 
than our immortalised keratinocyte IC50 at 72 hours, which suggests that primary 
keratinocytes may be generally more resistant to PA than the OKF6s. 
As with fibroblasts, both types of keratinocytes were more susceptible to ZA toxicity 
than PA. We generated a 72 hour IC50 value of 19 µM for OKF6 cells and 8 µM for primary 
cells. Ravosa et al. have previously demonstrated that 10 µM concentrations of ZA and 
above were enough to significantly reduce metabolic activity of OKF6 cells after 48 hours, 
with 10 µM leading to approximately 20 % toxicity in comparison to untreated cells [35]. In 
our work, though not significant, 10 µM ZA similarly caused around 15 % toxicity at 
48 hours.  
Pabst et al. demonstrated a dose dependent ZA toxicity to primary human oral 
keratinocytes after 72 hours treatment in two studies, with a significant viability reduction 
at 50 µM in the first study, and a small but significant reduction in viability at 5 µM in the 
second [86], [175]. Whilst 50 µM ZA did cause toxicity to both types of keratinocytes in our 
work, 5 µM concentrations were not significantly toxic at any time point, and our 72 hour 
IC50 values are above that value. Due to primary cells coming from different sources with 
inherent variability, it is to be expected that these differences between toxicity values exist. 
Due to these inherent differences between primary keratinocytes, as well as the difficulties 
that come with sourcing and culturing them when compared to immortalised keratinocytes, 
the rest of the work in this chapter used immortalised keratinocytes. 
Immortalised keratinocyte growth took place at a faster rate than with fibroblasts or 
primary keratinocytes, particularly in Figure 5.6, where the metabolic activity of the control 




had increased by around 300 % between 24 and 72 hours. Fibroblasts are metabolically 
slower than keratinocytes, and primary keratinocytes require an i3T3 feeder layer, so cells 
were closer to confluence in the well plate to ensure a good reading in the assay, which 
limited growth. Our proliferation data also indicates that fibroblasts proliferate at a slower 
rate than OKF6 cells, with the Iplf of control keratinocytes higher at 72 hours. Therefore 
more OKF6 growth between 24 and 72 hours was expected. 
In terms of anti-resorptive potency, ZA is approximately 100 times more potent than 
PA [29]. This potency, however, refers to the ability of the drug to increase bone density 
in rats in the ‘Schenk’ model [31], [64]. While ZA was also more toxic than PA in our work, 
the differences in toxicity were smaller by an order of magnitude compared to anti-
resorptive potency.  
Based on the IC50s generated, ZA was approximately seven times more toxic to 
fibroblasts and primary keratinocytes, and two times for immortalised keratinocytes. While 
the reduced difference in cytotoxic potency is a consistent result within the literature, the 
reasons for this are yet to be known. It is possible this is due to the mechanisms by which 
BPs cause their effects. 
Nitrogen-containing bisphosphonates (nBPs) prevent resorption by disrupting the 
mevalonate pathway [31]. This prevents the formation of the osteoclast ruffled border, 
leading to non-functioning osteoclasts. The BP inhibition of the mevalonate pathway is 
known to occur at lower concentrations than toxicity [178], [293]. It has been indicated that 
ZA causes this effect at concentrations orders of magnitude lower than PA [294]. Thereby 
it follows that ZA would prevent resorption at concentrations at orders of magnitude lower 
than PA. Toxicity, however occurs through a different mechanism. 
To determine the mechanism by which PA and ZA caused toxicity, we used flow 
cytometry to analyse the number of fibroblasts and immortalised keratinocytes undergoing 
apoptosis and necrosis, when treated with concentrations both above and below the IC50s 
for PA and ZA. We found that fibroblast toxicity took place mostly by an apoptotic pathway, 
while some keratinocyte necrosis also occurred, though not at a significant level. 
When treated with 10 µM PA for 72 hours, there were no differences in the number 
of viable, apoptotic and necrotic fibroblasts in comparison to the control. This was expected 
due to our MTT data, where no differences were seen between these groups. Soydan 
et al. previously found approximately 34 % of cells apoptotic after 72 hours treatment with 
10 µM PA, however this work only examined 100 cells. Our assay, which analysed 
10,000 cells, therefore, gives a more accurate and statistically robust measure of the 
proportion of cells undergoing apoptosis. In our work, a 50 µM PA treatment caused a 
significant amount of apoptosis, with only around 25 % of cells viable, and approximately 
70 % apoptotic. Again, this fits with our MTT data, where at 72 hours the metabolic activity 
was approximately 30 % of the untreated control. Concentrations of 30 µM and 50 µM 
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have been shown to cause fibroblast apoptosis after 96 hours treatment, with a study by 
Kim et al. indicating 10 µM PA had no effect at this time point [144], [164]. Our data 
supports this work and indicates that PA leads to apoptosis at an even earlier time point. 
 ZA did not cause a significant effect on fibroblast apoptosis when compared to the 
untreated control. Whilst 0.5 µM was not expected to cause a difference, as it led to no 
effect on metabolic activity in the MTT assay, a 10 µM ZA treatment reduced metabolic 
activity to approximately 30 % after 72 hours treatment and therefore more apoptosis was 
expected. Previously, Cozin et al. demonstrated ZA concentrations of 10 µM and above 
led to less fibroblast apoptosis at 7 days than with PA treatment [144], and Zafar et al. 
indicated 30 µM ZA only caused a slight increase in apoptosis at 96 hours [171]. This 
indicates that although 10 µM ZA is enough to cause an effect on fibroblast metabolism, 
higher concentrations of the drug are required to induce significant amounts of cell death. 
These higher concentrations are likely in BRONJ patients, given the estimated range to 
which the oral mucosa is exposed to. 
Keratinocytes were more resistant to BPs when tested by MTT, and this was also 
the case in the apoptosis assay. Both 10 and 100 µM PA led to less apoptosis than 
expected based on the MTT data, where metabolic activity was reduced to 65 % and 32 %, 
respectively, compared to a reduction in viable cells of approximately 10 % and 20 %. Cell 
death was split evenly between apoptosis and necrosis. PA concentrations ranging from 
3 to 100 µM have been shown to not induce apoptosis in keratinocytes before [57], [164]. 
This suggests the mechanism by which PA has its effect on keratinocytes is through 
another mechanism than apoptosis or necrosis. 
More cell death was seen with ZA treatment, though this was still below the 
expected level based around the MTT data. When treated with 1 µM ZA, both the MTT 
and apoptosis assay indicated no differences to the control. However, though 50 µM ZA 
caused a 66 % metabolic activity reduction, only 30 % of cells had undergone apoptosis 
or necrosis. When Ravosa et al. performed the same assay with OKF6 cells at 48 hours, 
they found concentrations from 30 to 100 µM ZA to cause less than 10 % apoptosis [35]. 
We saw a significant level of apoptosis, with approximately 20 % of cells early or late 
apoptotic, after 72 hours treatment with 50 µM ZA. A longer treatment period would be 
expected to cause a higher amount of cell death, and therefore our result is expected. 
Although ZA caused a significant amount of apoptosis, the general low level of cell death 
indicates another mechanism by which keratinocytes are affected by BPs. 
The mechanism by which BPs cause keratinocyte cell death has been examined 
previously, with different conclusions drawn. After discovering few apoptotic or necrotic 
cells after PA treatment, when compared to fibroblasts, Kim et al. also stained cells for 
senescence markers [164]. They found that keratinocyte senescence was increased by 
almost four times, with only a 10 µM PA treatment, while fibroblast senescence was 




unaffected. However, Pabst et al. have previously indicated over 50 % of human oral 
keratinocytes underwent apoptosis following 72 hours treatment with 50 µM PA and ZA 
[86]. Though we saw significant apoptosis with ZA, it was not at the same level as Pabst 
et al.’s work, and twice the concentration of PA caused no effect in our work. This adds to 
the hypothesis that a different mechanism of cell death may be induced in keratinocytes. 
The determination of this mechanism presents a route for future examination though was 
outside the scope of this project.  
Oral mucosa wound healing involves two key cellular processes: proliferation and 
migration. It has been hypothesised that BPs prevent the closure of the soft tissue wound 
following dental surgery by preventing both of these processes from occurring [2]. We 
therefore investigated both of these processes to determine the validity of the hypotheses. 
 We examined concentrations of PA and ZA both above and below the respective 
IC50s for both fibroblasts and immortalised keratinocytes. High concentrations of PA and 
ZA caused a reduction in the proliferation rate of both cell types over a 72 hour time period, 
with low PA and ZA also preventing keratinocyte proliferation. Again, this indicates a 
mechanism by which BPs lead to the exposure of necrotic bone tissue in a BRONJ patient. 
Proliferation is normally increased following the creation of an oral mucosa wound so as 
to provide cells by which to close the wound [89], [115]. If this process is prevented, it 
follows that the wound would not heal. 
 PA had a dose dependent effect on fibroblast proliferation, with a 10 µM 
concentration causing no effect at 24 or 72 hours but 50 µM leading to no proliferation to 
take place at 72 hours. Soydan et al. have previously indicated a dose dependent effect 
on fibroblast proliferation of concentrations ranging from 0.1 to 1000 µM [165]. This effect 
was evident at time points from 6 to 72 hours, though only significant above 10 µM.  
However, they measured this by staining cells for Ki67, a proliferative marker found within 
cell nuclei. This method is known to be a more sensitive assay by which to measure cellular 
proliferation, as it can detect changes within more phases of the cell cycle, whereas CFSE 
staining only detects a reduction in the M phase, where cells divide [295]. This sensitivity 
would explain the differences seen at earlier time points by Soydan et al., as cells would 
likely not have completed one cell cycle over 6 hours. As with apoptosis, however, Soydan 
et al. only sampled 100 cells, whereas we sampled up to 10,000, giving a more statistically 
robust measure of proliferation. 
 ZA also caused a dose dependent reduction in fibroblast proliferation over 
72 hours. A 0.5 µM concentration caused no effect, while 10 µM significantly reduced 
proliferation in comparison to the control. These values are consistent with literature. Agis 
et al. indicated concentrations of 30 µM and 100 µM reduced proliferation of human 
gingival fibroblasts (HGFs) [167]. Concentrations between 0.25 and 5 µM have been 
indicated to reduce the cellular growth rate of human oral fibroblasts over 5 days through 
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cell counting [169], [173]. However this method is less robust measure of proliferation that 
does not take into account the amount of cells undergoing cell division [296]. While their 
data indicates that BPs prevent cell growth, this may be an effect of toxicity. Our data 
examined viable cells, and therefore indicates that BPs do prevent proliferation, which is 
therefore an important explanation as to why the mucosa wounds of BRONJ patients fail 
to heal. 
 Immortalised human oral keratinocyte proliferation was also reduced following 
10 µM and 100 µM PA treatment. This study is the first time this has been demonstrated 
through a proliferation assay. Landesberg et al. previously indicated an effect on 
keratinocyte proliferation, however their study used murine cells and used a 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) based metabolic activity assay to determine proliferation [57]. While their work 
suggested a reduction in proliferation, here we can state the cell cycle of keratinocytes is 
affected and cells do not proliferate when treated with PA for 72 hours. 
 Keratinocyte proliferation was also reduced by ZA, where 1 and 50 µM significantly 
reduced proliferation, with 50 µM leading to a Iplf similar to that of the mitomycin C treated 
non-proliferating cells. Both 5 µM and 10 µM have previously been shown to effect OKF6 
proliferation [35], [173]. However both studies used less accurate measurements of 
proliferation (cell counting or MTS), and the 5 µM study took place over 5 days, where it 
would therefore be expected that lower concentrations would have more of an effect. 
Overall, it is clear that clinically relevant concentrations of the drug reduce OKF6 
proliferation and we have demonstrated it takes place at earlier time points and lower 
concentrations than previously known. 
 Our results demonstrate that cytotoxicity is not the only mechanism by which BPs 
lead to the soft tissue effects seen in BRONJ patients. At concentrations above the 
previously determined IC50s, both PA and ZA caused a significant reduction in proliferation. 
This combination of effects strongly support the hypothesis that BP effects on soft tissue 
are key to the development of BRONJ and in particular contribute to the lack of soft tissue 
regeneration observed in BRONJ patients. 
To further assess BP effects on wound healing, we also investigated how PA and 
ZA affect cell migration. Migration assays provide an in vitro approximation of in vivo 
wound healing [180]. Scratch assays are commonly used, where cells are cultured to 
confluence before a scratch is formed, but have issues with reproducibility and issues 
relating to cell damage in the creation of the scratch [297]. Using the OrisTM assay removed 
these issues, by creating uniform exclusion zones in a way which does not damage cells. 
Although cells are damaged in the development of BRONJ, this test was purely to assess 
any general effects of BPs on cell migration. 




Sub-toxic concentrations of PA and ZA showed no effect on fibroblast or 
keratinocyte migration. This suggests that the lack of closure of BRONJ wounds is due to 
toxicity and proliferation effects alone. This counters a commonly reported effect in 
literature, where BPs have been shown to prevent wound closure in migration assays 
several times [86], [140], [144], [170], [172], [175]. However, many of the previous studies 
in this area have limitations. In several cases, literature reports on toxic concentrations of 
a BP over a certain time period, before then performing a migration assay using the same 
variables [86], [144], [170], [172], [175]. Often, images are not included. Cozin et al., 
however, did feature images of their cells following the assay, and they did not appear 
viable, suggesting a cytotoxic effect is preventing their scratch assays from healing [144]. 
When performing a migration assay, it is important to ensure only migration is being 
studied. Concentrations below the IC50 values were chosen so as to ensure any effect 
seen was a pure migration effect, as it would be expected that over the time periods 
chosen, concentrations above those levels would lead to cell death and prevent closure of 
exclusion zones. It has previously been demonstrated that nanomolar concentrations of 
BPs can affect oral keratinocytes [178], [293], [294], suggesting the concentrations chosen 
here were high enough that any potential effect could be recorded. 
Wound closure is not due to migration alone, as proliferation also plays a part. For 
this reason, we used mitomycin C to prevent cellular proliferation, and therefore we could 
be certain any closure of the exclusion zone was due to cells migrating into the exclusion 
zones, rather than cells proliferating. While this was less representative of the clinical 
scenario, it allowed the two cell functions to be studied in isolation to further determine 
specific BP effects. Commonly, these assays are performed with no proliferation control 
[35], [57], [86], [140], [144], [170], [175], [178]. As we have shown, PA and ZA prevent 
cellular proliferation, and therefore the often observed literature effect on wound healing is 
likely due to proliferation differences, rather than the migration which is often reported. 
 When pre-treated with 30 µM PA for 72 hours, we found exclusion zones did not 
fully close. However, the cells in that case appeared to be subject to toxicity after 120 hours 
of BP treatment. This is similar to work from Landesberg et al., who used murine 
keratinocytes to demonstrate that only pre-treatment with toxic concentrations of PA had 
any effect on the closure of their scratch assay [57]. This highlights the danger of prolonged 
exposure of BRONJ wounds to BPs and suggests toxicity plays a greater role than 
migration in BRONJ wounds. McLeod et al. controlled for proliferation in their assay with 
both OKF6 cells and immortalised human foreskin fibroblasts, and also used sub-toxic BP 
concentrations and they reported no effect on migration [46]. It therefore appears that, 
when examined using a more appropriate assay, BP effects on migration are not apparent. 
The OrisTM assay did come with some limitations. While fibroblasts routinely formed 
well defined circles when cultured with the stoppers, keratinocytes were less precise. Cell 
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exclusion zones were less uniform, with spillage over the line following the removal of the 
stopper, and due to this more variation was found in the results. This is especially apparent 
in the data generated when keratinocytes were cultured in the presence of PA. Some cells 
lose contact inhibition when they are immortalised and begin to form multilayers when 
cultured to confluence, which could lead to a multi-layered formation of cells near the 
stopper which would theoretically spill into the exclusion zone when the stopper is 
removed. However, it has been reported that hTERT immortalised cell lines, such as the 
OKF6s, maintain contact inhibition which rules this out as a possible reason [298]. Even 
with this variation within the assay, the data still provided a clear picture of BP effects on 
migration. 
We conclude from our data that PA and ZA do not affect the migration rate of either 
fibroblasts or keratinocytes. Our data suggests that in previous studies of this nature, both 
BP reductions in viability and proliferation rate will have contributed directly to the reduced 
wound closure in the assays performed. 
BPs have also been shown to prevent cellular adhesion in different cell types, 
including oral fibroblasts, cancer cells and endothelial cells [82], [144], [181]–[183]. We 
have demonstrated for the first time that ZA causes an effect on oral keratinocyte adhesion 
in vitro. Treatment with the drug for 24 hours reduced the ability of cells to adhere to tissue 
culture plastic in a dose dependent manner. Though a fewer number of cells were 
expected to be found due to toxicity, the negative correlation between the groups was 
stronger in the detached and re-seeded cells, which indicates an effect further than just 
toxicity. 
Various methods exist for the determination of cell adhesion effects. Commonly, 
cells are seeded onto different substrates – collagen, fibronectin, gelatin and vitronectin – 
as it is known that specific integrins mediate the binding to these substrates [82], [181]–
[183]. Through this work it has been demonstrated that BPs effect binding in relation to the 
α1, αv and αvβ3 integrins. BPs have also been shown to reduce the levels of αvβ6 and 
thereby inhibit the re-epithelialisation of oral mucosa wounds [187]. Our work attempted to 
examine a wider picture, examining keratinocyte adhesion to a tissue culture plastic 
substrate rather than looking at one specific integrin, however this would be an interesting 
area for future work and investigation. 
We allowed attachment for 2 hours during our adhesion assay. In literature, cells 
are commonly seeded for 1 hour before the assay [82], [181]–[183]. When we measured 
keratinocyte adhesion over time, this did not seem suitable, as only approximately 50 % 
of cells adhered at 24 hours and there was more variation at this time point. Hence, we 
chose to adhere cells for longer to remove any potential noise from the data. A shorter 
period was desirable, as the longer the cells were on the substrate, the more time they 




had to attach, and thereby overcome any BP effects. A 2 hour adhesion time point allowed 
for more cell adhesion and less variation. 
Adhesion to tissue culture plastic takes place in three phases [299], [300]. Initially, 
electrostatic attraction draws the cell to the surface. Over the first few hours, integrin 
binding occurs to attach the cell more strongly, and then focal adhesions form and adhere 
the cell to the surface, which allows for cell spreading. As our assay is within the expected 
time frame for the second phase of cellular adhesion, we therefore hypothesise that ZA is 
affecting the integrin binding ability of oral keratinocytes. However, it is difficult to 
determine the mechanism by which ZA causes this effect. The integrins which have 
previously been shown to be affected by BPs in other cell types are mostly not expressed 
in keratinocytes [188]. Keratinocytes do express αvβ6, but only in response to wounding. 
In future, an integrin array would be a useful tool to determine exactly how BPs affect 
keratinocyte adhesion. 
BP effects on cell adhesion have been reported for several different cell types, 
including fibroblasts, breast cancer cells, muscle cells and endothelial cells [82], [144], 
[181]–[183]. Basso et al. showed 5 µM ZA reduced the adhesion of HaCaT cells to titanium 
over 24 hours [174]. They also demonstrated some cellular toxicity with the same 
concentration but did not draw a link between the two effects. Their keratinocytes were 
stained for homing cell adhesion molecule, where a reduction of the molecules was seen 
with increasing BP concentration, confirming an adhesion effect on a titanium substrate. 
As potential BRONJ sufferers may have titanium implants in their jaws, this information is 
useful, though not representative of all patients. We have shown here that a more general 
effect on cell adhesion happens due to ZA treatment. 
We saw no clear effect of ZA on the F-actin or focal adhesions of immortalised 
human keratinocytes. We also saw a much less specific focal adhesion staining than 
previously observed in similar studies using different cell types. The main effect notable in 
our staining was the toxicity, with fewer cells appearing at each time point. Cozin et al. 
noted a similar effect in fibroblasts when treated with pamidronic acid, however, they 
noticed marked differences in their staining following PA treatment [144]. In their work, 
fewer F-actin bundles were visible and the focal adhesion staining was much less specific. 
Previous vinculin staining of keratinocytes has appeared similar to our work, with fewer 
obvious focal adhesions and more general staining [301], [302]. Further, more detailed 
examinations of binding mechanisms and the effect of BPs on these are needed to draw 
any firm conclusions, however these were beyond the scope of this study. 
BPs have previously been demonstrated to have effects on processes regulating 
the cytoskeleton [82], [181], [182], [186]. The BP effect on the mevalonate pathway causes 
the inhibition of rho kinase [144], [183], a protein involved in the assembly and organisation 
of the cytoskeleton [303]. It also leads to the reduced phosphorylation of focal adhesion 
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kinase (FAK), which regulates the formation, maintenance and turnover of focal adhesions 
[184], [304]. This has been reported in several cell types, though not keratinocytes. FAK 
inhibition is known in keratinocytes to reduce migratory ability, not adhesion, as focal 
adhesions can still form without phosphorylated FAK, but they cannot disassemble and 
reassemble [185]. As we have previously shown that BPs do not affect keratinocyte 
migration, this suggests that phosphorylation of FAK is not affected by zoledronic acid in 




In summary, our data demonstrates that both PA and ZA affect a variety of cellular 
processes in human oral fibroblasts and keratinocytes, at concentrations toward the lower 
range of expected clinical dose. Both drugs reduced cellular metabolic activity of three 
different cell types over 72 hours. This toxicity took place through an apoptotic pathway, 
with higher levels of apoptosis seen in fibroblasts. Concentrations above IC50 values also 
led to a reduction in proliferation over the same time period. Cell migration, however, was 
not affected by sub-toxic concentrations of PA and ZA. A 24 hour treatment of immortalised 
keratinocytes with ZA led to a reduction in cellular adhesion to TCP over 2 hours. No clear 
effects on the keratinocyte cytoskeleton were observed through immunohistochemical 
staining following 120 hours of treatment. 
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6. The development of an in vitro model of the soft tissue 




To investigate the effects of pamidronic acid (PA) and zoledronic acid (ZA) on the oral 
mucosa at different stages of development using a 3D in vitro model, examining newly 




In chapter 5 we demonstrated that PA and ZA are toxic to oral mucosa cells in 2D, and 
prevent cell proliferation and adhesion, but have no effects on the rate of migration at 
sub-toxic concentrations. However, 2D cell culture comes with limitations. It is not truly 
representative of the in vivo setting, and, as such, 3D culture systems have long been 
used in vitro as a way of more closely approximating the in vivo scenario. 
 During BRONJ development, it is clear that BPs prevent the oral mucosa from 
healing, maintaining exposure of the necrotic bone. It has also been demonstrated that the 
adhesion and differentiation of the oral mucosa is affected in BP patients with no signs of 
BRONJ, which increases the risk of BRONJ development [189]. However, this is derived 
from patient data, and has not been quantified. This chapter studies the effects of BPs on 
the oral mucosa, modelling three key stages of development. First, models with a single 
cell epithelial layer, representing the thin oral mucosa formed during re-epithelialisation 
before stratification occurs. Second, stratified epithelial layers, representing the 
established, healthy epithelium that exists prior to surgery and surrounding the initial 
wound. And finally, in a 3D epithelial wound healing model representing the entire soft 
tissue component of BRONJ. The wound model was one developed for this work, through 
testing of a variety of different techniques. 
 Several in vitro models of oral mucosal tissue exist [194]. Mostly, these include a 
scaffold to mimic the lamina propria containing fibroblasts, with a stratified epithelium 
above. Scaffolds can be made from a wide variety of sources including natural polymers, 
such as collagen, polymeric blends, or acellular skin [200]. Our work used acellular skin, 
commonly known as de-epidermised dermis (DED), as it provides a scaffold close to that 
of the natural environment, and is more mechanically strong than other options, making it 
easier to wound without compromising the whole model. 
 Due to the similarities between BP effects on primary and immortalised 
keratinocytes and ease of culture of immortalised keratinocytes, this work was mostly 




performed with immortalised cells. Clinically relevant BP concentrations based on the IC50 
values generated from our 2D work were used. 
 
6.3 Materials and methods 
 
Cell culture was performed as described in section 4.1. Bisphosphonates were prepared 
as described in section 4.2. Throughout this chapter, medium containing no BPs (0 µM) 
was used as a control. 
 
6.3.1 Seeding of 3D oral mucosa model 
 
DED was cut into squares of approximately 20 x 20 mm using a sterile scalpel and placed 
into a 6 well plate. Chamfered stainless steel rings with a 10 mm internal diameter were 
placed onto the DED, and pressed lightly to create a seal. 250,000 fibroblasts in 0.25 ml 
medium, and 1 million keratinocytes in 0.25 ml medium were seeded into the middle of the 
ring. DMEM was added outside the ring to prevent the cell solution leaking. The models 
were placed into an incubator. 
After 24 hours, 0.25 ml of media was carefully removed from the middle of the ring, 
so as not to disturb any unattached cells, and replaced with either KSFM or Green’s, 
depending on the keratinocyte type used. At 48 hours after seeding, the media in the 
middle of the ring was replaced entirely by 0.5 ml of 1:1 KSFM and Green’s for OKF6 
models, or Green’s alone for primary cell models. 
At 72 hours after seeding, the models were lifted to ALI by placing onto a stainless 
steel grid in Green’s medium. The underside of the model was in contact with the liquid 
medium, while the top was in contact with air, to promote stratification of the epithelium. 
The seeding process is shown in Figure 6.1. 
 
 
Figure 6.1. The general seeding process for oral mucosa models 
6.3.2 DED model epithelium stratification test 
 
To examine the epithelial stratification of the immortalised keratinocyte models, two 
models were seeded as described in section 6.3.1. Before placing at ALI, they were 
quartered with a sterile scalpel, forming 8 samples. After 4, 7, 10 and 14 days, two of the 
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samples were fixed in a 10 % formalin solution in PBS and processed for histological 
staining. 
 
6.3.3 Resazurin assay 
 
A resazurin assay measures metabolic activity [305]. Resazurin sodium salt 
(Sigma-Aldrich) was dissolved in distilled water at a concentration of 251 µg/ml and 
sterilised with a 0.2 µm filter. This was stored at 4 °C, protected from light, for up to two 
weeks. Before each experiment, the stock solution was diluted 1 in 10 in media. At each 
time point, samples were moved from ALI to a well plate and incubated in resazurin 
containing medium for 4 hours. 100 µl samples from each well were taken in triplicate and 
placed in a 96 well plate. This plate was then read using an absorbance reader. Readings 
were taken at 562 nm, with a reference at 630 nm. Samples were removed from the 
resazurin solution, washed with PBS, and either placed back at ALI or fixed overnight in 
10 % formalin. 
 Every resazurin assay included a blank well, which contained only medium and the 
resazurin salt. This well was ran according to experimental conditions, and the value 
subtracted from the other results to give a no cell value of 0 %. As model to model variation 
exists in the 3D mucosa models, especially when these models were halved or quartered, 
the resazurin values were normalised to the earliest time point measured. These time 
points were set as 100 % to allow comparison between models, and are not displayed in 
figures. 
  
6.3.4 Oral mucosa models with bisphosphonates 
 
Models were seeded as previously described in section 6.3.1, then quartered, before 
treating with BPs in one of two different methods. A flow chart of the different regimens for 
treating the models is shown in Figure 6.2. 
 
 
Figure 6.2. A flow diagram to show the different treating regimens for oral mucosa models 
treated with bisphosphonates. 
 




To examine BP effects on epithelium formation, the models were then put to ALI in 
triplicate, in media at concentrations of 1 to 30 µM ZA and 50 to 100 µM PA, and control 
medium. After 4, 7 and 10 days, models were individually transferred to a well plate, where 
resazurin solution was added. Well plates were protected from light and incubated for 
4 hours, when 100 µl was removed from each well in triplicate and read in an absorbance 
reader, as described previously. Samples were then washed with PBS. At day 4 and 7, 
models were placed back to ALI and the media replaced. At day 10, samples were fixed. 
Images were taken of each model directly following each resazurin assay, and resazurin 
values were individually normalised to day 4 values. 
 To examine BP effects on established epithelia, models were placed at ALI for 
7 days in control medium. Resazurin assays were performed as above and models were 
placed in BP containing medium. At day 10 and 14, resazurin assays were repeated, 
before models were either placed back at ALI in fresh medium or fixed, respectively. 
Values were normalised to those gathered at day 7. 
 
6.3.5 Wounding of oral mucosa models 
 
Models were seeded as before and left whole. Media changes occurred at 4, 7 and 
10 days, and following a resazurin assay. Models were cultured at ALI for either 7 or 
10 days before wounding. One day prior to wounding, a resazurin assay was performed 
to establish a value by which to normalise further readings. A soldering iron (Antex) was 
allowed to reach full temperature, before being pressed to the centre of the model for 
1 second. A cauteriser wire (Fine Science) was heated and pressed against the model for 
1 second. A biopsy punch (Miltex) was used to manually create a circular wound with a 
3.5 mm diameter. Resazurin assays were performed as before. Models were then either 
fixed, or placed back at ALI for up to 10 days, with resazurin assays performed on days 3, 
7 and 10. Following the assay on day 10, models were fixed in 10 % formalin. 
 
6.3.6 3D printed ring design and manufacture 
 
Models were also selectively seeded with keratinocytes to create an in vitro wound 
equivalent. For this, a bespoke cell culture ring was designed using SketchUp (Trimble 
Inc.). The design of the ring is shown in Figure 6.3. The model was printed using a 
stereolithography printer (Form 2, FormLabs) from a photopolymer resin (Grey Resin, 
FormLabs). After printing, the rings were washed in isopropanol and cured in a UV curer 
(3D Systems). Rings were then sterilised in 70 % ethanol and rinsed thrice in PBS to 
remove any ethanol. They were then placed in DMEM in an incubator for 5 days to ensure 
any uncured polymer was released. After use, rings were rinsed in distilled water and 
detergent. 






Figure 6.3. The computer-aided design model of a bespoke cell culture ring from (A) top 
down, (B) isometric and (C) side on view. 
6.3.7 3D wound healing assay 
 
Seeding and treating models using the 3D rings took place according to three different 
regimens. Firstly, models were seeded using the rings then treated immediately when 
raised to ALI. The rings were sterilised and rinsed as previously described and placed in 
a petri dish. Sections of DED of approximately 20 x 20 mm were cut as before. The rings 
were placed, chamfered edge down, onto the DED. To ensure a tight seal was created, a 
stainless steel ring was placed into the lip of the 3D printed ring to add weight. Cells were 
then seeded, with 250,000 fibroblasts and 1 million keratinocytes in a total of 0.4 ml media, 
with media changes taking place over 3 days as in section 6.3.1. 
 At day 4, models were raised to ALI. Beforehand, the rings were removed and the 
models transferred to a well plate, where a resazurin assay was performed to visually 
assess seeding efficacy. This time point was set as day 0. Models were cultured for up to 
7 days, with resazurin assays performed at days 1, 4 and 7, at which point samples were 
fixed. 
 Models seeded by this method were also cultured in BP containing medium when 
placed at ALI, in 10 µM ZA and 50 and 100 µM PA. Resazurin assays were performed 
on days 0, 1, 4 and 7, with values normalised against day 0. At day 7, models were fixed 
and processed for histology. 
 The second and third seeding regimens were designed to ensure the epithelium of 
the two sections was stratified. These are represented diagrammatically in Figure 6.4. In 
both methods, the DED, ring placement and cell seeding was performed as described 
above. In the first method, the DED was placed onto a stainless steel grid before the rings 
were applied and pressed into the DED to create a seal. DMEM was then added to the 




well, above the level of the DED, and cells seeded. On day 4, media was removed from 
inside the rings and the liquid level outside the rings lowered to the level of the underside 
of the DED to create an ALI for the epithelial cells in both sections of the ring. Models were 
cultured until day 11, with a media change taking place on day 8. 
In the second method, DED was placed on the bottom of a well plate and seeded 
with the 3D printed ring as before. At day 4, media was removed from the inside of the 
ring, and the liquid level outside of the ring lowered to create an in situ ALI. Every 48 hours, 
media outside of the ring was replaced, and any media inside the ring was removed, until 
day 11. 
After this stage, the procedure for both methods was the same. The rings were 
removed, ensuring not to remove the epithelial sections. A sterile needle point was used 
to dislodge the epithelium from the ring for some models. Resazurin assays were 
performed, as before, with the first resazurin assay being referred to as day 0. Models 
were then cultured for up to 7 days before fixing and processing for histology. Models 
seeded by these methods were also treated with BPs. 
 
 
Figure 6.4. Cross sectional diagram of the process for seeding models at air-liquid 
interface (ALI) or with an in situ ALI. 
6.3.8 Histology 
 
Models were kept in overnight in a 10 % formalin solution in PBS. Samples were bisected 
with a scalpel to place the area of interest on the outside edge, demonstrated in Figure 
6.5. They were then placed in cassettes and ran through a tissue processor (Leica TP 
1020), which gradually dehydrated the samples in IMS, cleared them in xylene (Thermo 
Fisher Scientific) and infiltrated them with paraffin wax (VWR), according to the schedule 
in Table 6.1. 





Figure 6.5. A diagrammatical representation of sample preparation for histology, red 
arrows indicate side used for histological sections. 
Table 6.1. The tissue processing schedule 
Solution Time (hours) Purpose 
70 % IMS 1 
Gradual dehydration of sample 
70 % IMS 1 
80 % IMS 1.5 
85 % IMS 1.5 
90 % IMS 1.5 
95 % IMS 1.5 
100 % IMS 1.5 
100 % IMS 1.5 
Xylene 1.5 To clear the sample and allow for 
wax infiltration Xylene 1.5 
Molten paraffin wax 2 
Infiltration of wax 
Molten paraffin wax 2 
 
Following processing, samples were embedded in molten paraffin wax using an 
embedding centre (Leica EG1160). Samples were embedded with the surface of interest 
placed perpendicular to the bottom of the mould to ensure the right orientation when 
cutting. Moulds were placed on ice to cool for 1 hour minimum. Samples were then 
removed from the moulds and transferred to a microtome (Leica RM2145). Samples were 
initially trimmed in 30 µm slices to expose the full sample, which was then sliced at a 
thickness of 4 µm. Slices were placed in a 37 °C water bath (Barnstead Electrothermal) to 
allow them to flatten, then attached to a SuperFrost slide (Thermo Fisher Scientific). Slides 
were transferred to a 40 °C hot plate to ensure sample attachment to the slide. Slides were 




then stained with haematoxylin (Sigma-Aldrich) and eosin (Sigma-Aldrich) in accordance 
to the protocol in Table 6.2. 
 
Table 6.2. The process for histological staining with haematoxylin and eosin. 
Solution Time Purpose 
Xylene (twice) 3 minutes To de-wax the sample 
100 % alcohol 1 minute 
To gradually rehydrate the sample 70 % alcohol 30 seconds 
Distilled water 1 minute 
Haematoxylin 1.5 minutes 




4 minutes To ‘blue’ the stain by neutralizing the acid 
Eosin 5 minutes To stain acidophilic substances 
Tap water 1 second 
To gradually dehydrate the sample 
Tap water 1 second 
70 % alcohol 1 second 
100 % alcohol 30 seconds 
Xylene (twice) 1 second 
To clear the sample by removing excess 
alcohol 
 
After staining, glass coverslips were attached to the slides using DPX mountant 
and left to dry. Images of the samples were taken using a light microscope (Motic). Images 
were processed with Photoshop CS2, with images stitched together and backgrounds 




Statistics were performed using Prism as described in section 4.3. ‘N’ is used to denote 
experimental repeats, while ‘n’ is used to denote technical repeats throughout.  





6.4.1 DED models with immortalised keratinocytes were cultured to approximate 
native tissue 
 
3D models of the oral mucosa were cultured using DED as a scaffold, seeded with 
established human oral fibroblasts and immortalised human oral keratinocytes. 
Immortalised cells were used for optimisation of the model as they are easier to culture, in 
greater supply, and responded to BPs in a similar way to their primary equivalents in our 
2D work. 
 To use these models as close representations of native oral mucosa, it was 
necessary to determine the length of time the models needed to be at ALI before they 
contained a stratified epithelium across the whole model. Figure 6.6 shows the 
stratification of the epithelium over time. As the samples were fixed at each time point, 
each image is of a different sample. Two samples are included to demonstrate the 
epithelial consistency. Figure 6.6A & B show that after 4 days culture the epithelium was 
largely one or two cells thick. By 7 days, the epithelium had become multi-layered in most 
places with some differentiation between keratinocyte layers shown in Figure 6.6C. 
However, Figure 6.6D demonstrates there were thinner areas of epithelium at 7 days. After 
10 days of culture, the epithelium was multi-layered over the whole sample. Figure 
6.6E & F show the morphologies of the keratinocytes change from the basal to top layer 
of the epithelium, and rete ridges are visible on both samples. 
 The epithelium after 14 days, shown in Figure 6.6G & H, also has a stratified 
epithelium across the whole model, however with a thinner epithelium in Figure 6.6H. More 
haematoxylin staining was evident in the connective tissue in these models. 
  




















































Figure 6.6. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and immortalised human oral keratinocytes cultured at ALI then fixed after (A,B) 
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6.4.2 Bisphosphonates prevented a stratified epithelium from forming 
 
Oral mucosa models were cultured in BP-containing medium immediately when placed at 
ALI to assess how BPs affected the stratification of the epithelium. Figure 6.7 shows 
resazurin assay readings as a measure of metabolic activity for the models. When cultured 
in control medium, the metabolic activity of the models increased at each time point and 
Figure 6.8A shows a multi-layered, healthy epithelium after 10 days culture. Models 
cultured in PA showed approximately consistent values over the experiment. However the 
metabolic activity was significantly reduced in comparison to the control at 10 days. This 
suggests the BP was preventing growth whilst not toxic. This was confirmed through 
histology with Figure 6.8B & C showing a thin epithelium largely one or two cells thick 
following 10 days of treatment with 50 and 75 µM PA, respectively. When treated with 
100 µM, a single layer of keratinocytes was present, shown in Figure 6.8D. 
 ZA showed a more pronounced effect, with a dose dependent reduction of 
metabolic activity over 10 days. When treated with 1 µM ZA, similar to PA, metabolic 
activity maintained approximately the same throughout the experiment. However, 10 and 
30 µM ZA led to a significant reduction in metabolic activity at days 7 and 10. The 30 µM 
treated models had metabolic activities of approximately 20 and 10 % of their day 4 reading 
at days 7 and 10, respectively. The histology again supported the data, with Figure 6.8E 
demonstrating a thin, disrupted epithelium with a 1 µM ZA treatment, and Figure 6.8F & G 
demonstrating a lack of epithelium following ZA treatments of 10 and 30 µM.  






Figure 6.7. Metabolic activity of immortalised keratinocyte oral mucosa models when 
treated with 50, 75 and 100 µM pamidronic acid and 1, 10 and 30 µM zoledronic acid 
immediately after placing at ALI, measured with a resazurin assay. Blank well reading 
subtracted from values before normalising to day 4 values for each model. Day 4 not 
shown as all values 100 %. N=3, n=3. Error bars = SD. Statistical significance against 
control at each time point indicated by *P≤0.05.  




Figure 6.8. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and immortalised human oral keratinocytes cultured at ALI in (A) control 
medium, (B) 50 µM, (C) 75 µM and (D) 100 µM pamidronic acid, (E) 1 µM, (F) 10 µM and 


















































































6.4.3 Bisphosphonates reduced the thickness of healthy, established epithelia 
 
In order to study how BPs affected healthy mucosa, models were cultured for 7 days to 
allow the epithelium to stratify before treatment. This culture time was chosen as the 
models had previously been shown to be mostly stratified, while allowing for a shorter total 
culture time and thereby preventing any models from losing their metabolic activity due to 
length of culture. 
 Firstly, models were cultured with immortalised keratinocytes. Figure 6.9 shows 
that PA had no significant effect on the metabolic activity of the models in comparison to 
the control. Values for all samples, including the control, decreased from day 7 to day 14. 
Figure 6.10A shows the epithelium of a model cultured for 14 days in control medium, 
where the epithelium has stratified. Figure 6.10B, C and D demonstrate that while PA had 
no effect on metabolic activity, it caused a reduction in epithelial thickness. A dose 
dependent response was seen, with increasing concentration leading to reduced 
thickness. While these epithelia were thinner, differentiated keratinocytes were still present 
on the top layer. 
 ZA again had a more pronounced effect. While 1 and 10 µM concentrations led to 
no significant reduction, a 30 µM concentration significantly lowered the metabolic activity 
to approximately 10 % after 7 days of treatment (14 days total culture). Figure 6.10E & F 
demonstrate 1 and 10 µM concentrations of ZA reduced epithelial thickness in a dose 
dependent manner. No epithelium was visible on the samples treated with a 30 µM 
concentration, shown in Figure 6.10G.  
  





Figure 6.9. Metabolic activity of immortalised keratinocyte oral mucosa models when 
cultured at ALI for 7 days in control medium, then treated with 50, 75 and 100 µM 
pamidronic acid and 1, 10 and 30 µM zoledronic acid for 7 days, measured with a resazurin 
assay. Blank well reading subtracted from values before normalising to day 7 values for 
each model. Day 7 not shown as all values 100 %. N=3, n=3. Error bars = SD. Statistical 
significance against control at each time point indicated by *P≤0.05. 
 
 

















































































Figure 6.10. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and immortalised human oral keratinocytes cultured at ALI for 7 days in control 
medium, then treated with (A) control medium, (B) 50 µM, (C) 75 µM and (D) 50 µM 
pamidronic acid, (E) 1 µM, (F) 10 µM and (G) 30 µM zoledronic acid, respectively, for 
7 days. Representative images used. 
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 Models containing primary keratinocytes were also subjected to the same 
treatment regimen. Figure 6.11 shows the metabolic activity data. PA again showed no 
significant differences to control medium after 14 days culture. ZA caused no effect at a 
1 µM concentration, but was toxic at 10 and 30 µM at day 14, after 7 days treatment, with 
a dose dependent response seen.  In the primary models, the lowest concentration of both 
BPs caused an increase in metabolic activity at day 10, though this was not significant and 
variation was high. 
 Figure 6.12 shows histological sections of primary keratinocytes at day 14, 
following 7 days BP treatment. After culturing for 14 days in control medium, a complete, 
stratified epithelium was present on the model, as shown in Figure 6.12A. When treated 
with PA, though a complete epithelium was present on the models, treatment reduced the 
thickness of the epithelium in a dose dependent manner. Figure 6.12B shows that 50 µM 
PA led to an epithelium of a similar thickness to the control model, while 75 and 100 µM 
treatments led to an epithelium that appeared 1 or 2 cells thick and flattened, as shown in 
Figure 6.12C & D. 
 A 1 µM ZA treatment led to a multi-layered epithelium, as shown in Figure 6.12E. 
As expected from the metabolic activity data, 10 µM ZA caused a reduction in epithelial 
thickness, shown in Figure 6.12F. When treated with 30 µM ZA for 7 days, the epithelium 
of the models were disrupted, as demonstrated in Figure 6.12G, where the epithelium was 











Figure 6.11. Metabolic activity of primary keratinocyte oral mucosa models when cultured 
at ALI for 7 days in control medium, then treated with 50, 75 and 100 µM pamidronic acid 
and 1, 10 and 30 µM zoledronic acid for 7 days, measured with a resazurin assay. Blank 
well reading subtracted from values before normalising to day 7 values for each model. 
Day 7 not shown as all values 100 %. N=3, n=3. Error bars = SD. Statistical significance 
against control at each time point indicated by *P≤0.05. 
 
  















































































Figure 6.12. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and primary human oral keratinocytes culutred at ALI for 7 days in control 
medium, then treated with (A) control medium, (B) 50 µM, (C) 75 µM and (D) 50 µM 
pamidronic acid, (E) 1 µM, (F) 10 µM and (G) 30 µM zoledronic acid, respectively, for 
7 days. Representative images used.  




6.4.4 Models wounded with biopsy punch showed capacity to regenerate; models 
wounded with cauteriser and soldering iron did not 
 
Models were cultured with immortalised human oral keratinocytes at ALI for 10 days. At 
this point, they were wounded with one of three methods – biopsy punch, cauteriser or 
soldering iron – or left unwounded as a control. Following this, they were cultured at ALI 
for a further 10 days. 
 Figure 6.13 shows images of the models immediately after wounding, with the 
soldering iron causing the most superficial damage, and biopsy punch the least. Metabolic 
activity was also measured, normalised against values from 1 day prior to wounding, as 
shown in Figure 6.14. The metabolic activity of the unwounded model continued to 
increase until day 3, at which point it levelled off at approximately 160 %, indicating the 
model may still have been stratifying at this point before stabilising by day 3. The level of 
superficial damage observed matched the reduction of metabolic activity by the wounding 
method. The model wounded by biopsy punch increased in metabolic activity but only by 
5 %. The cauteriser caused metabolic activity to reduce by approximately 5 %, and the 
soldering iron by around 20 %. Between day 0 and day 3, the metabolic activity of the 
wounded models increased by approximately 30 %, before levelling off. The metabolic 
activity of all models had decreased slightly from their maximal points by day 10. 
Models were fixed and stained with H&E, both immediately after wounding, and 
10 days after wounding. Figure 6.15A shows the unwounded sample had a multi-layered 
epithelium after 10 days of culture, with differentiated keratinocytes visible. After 10 
further days of culture, this was still intact in some places, with differentiated keratinocytes 
again visible, as seen in Figure 6.15B. However the epithelium was thinner, matching the 
slight drop in metabolic activity seen following this culture length. 
The biopsy punch created a small wound, shown in Figure 6.15C, damaging both 
the epithelium and the underlying connective tissue. The epithelium healed over 10 days, 
with a full epithelium visible in Figure 6.15D. However the connective tissue was still 
indented. The soldering iron caused severe damage to both the epithelium and connective 
tissue. Figure 6.15E shows burned sections of epithelium above damaged dermis. Figure 
6.15F indicates this did not heal at all over 10 days, with thermally damaged epithelial 
sections still visible. The cauteriser created a wound similar to both the biopsy punch and 
the soldering iron, with a small wound created in both the epithelium and connective tissue 
but with burned epithelium at the edges, shown in Figure 6.15G. Again, this did not heal 
over the 10 day period, with the damaged epithelium still appearing in Figure 6.15H. 
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Figure 6.14. Metabolic activity of immortalised keratinocyte DED models wounded after 
10 days culture by three different methods – damaged with a biopsy punch, burned with a 
cauteriser or burned with a soldering iron – or unwounded, measured with a resazurin 
assay. Blank well reading subtracted from values and values normalised to day prior to 
wounding (-1). N=1, n=1. 
 
  

























































Figure 6.15. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and immortalised human oral keratinocytes cultured at ALI for 10 days. 
Samples were then (A, B) unwounded, (C, D) damaged with a biopsy punch, (E, F) burned 
with a soldering iron or (G, H) burned with a cauteriser. Samples A, C, E and G were fixed 
immediately after wounding. Samples B, D, F and H were cultured for a further 10 days 
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Due to the reduction in metabolic activity after 20 days total culture, a model was 
wounded with a biopsy punch after 7 days and then cultured for a further 10 to assess 
healing. The biopsy punch was chosen as models previously wounded with this method 
demonstrated a capacity to heal. Figure 6.16A shows the full section of a model wounded 
by biopsy punch at 10 days and fixed immediately, and Figure 6.16B shows a model 
wounded after 7 days and cultured for a further 10 days before fixing. 
As Figure 6.16A is a cross section from the centre of the sample, the circular wound 
from the biopsy punch is visible as two wounds. The two wounds were not consistent, with 
one penetrating the dermis and the other only damaging the epithelium. In the post-healing 
sample in Figure 6.16B, it was possible to locate one of the wound edges due to the 
superficial damage to the dermis not healing, as before. However the other edge was not 
readily apparent, suggesting the damage was again only to the epithelium and thereby 
inconsistent across the wound. Earlier wounding to prevent the model from becoming too 
old and losing metabolic activity was successful, with the epithelium appearing thicker over 
the model than the sample wounded at 10 days in Figure 6.15B & D. Whilst the biopsy 
punch created a wound which then healed over time, the lack of reproducibility within the 
sample, and the difficulty in identifying the wound area in the healed samples prevent its 
use when tracking the BP effect on wound healing. 
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Figure 6.16. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and immortalised human oral keratinocytes, cultured for (A) 10 days, then 
wounded with a biopsy punch and fixed immediately or (B) cultured for 7 days, wounded 
with a biopsy punch then cultured for a further 10 days. Arrows indicate wound edges. 
Representative images used. 
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6.4.5 Seeding with bespoke 3D printed cell culture rings created a 3D wound 
healing assay 
 
To overcome the reproducibility issues found with the biopsy punch wounds, cells were 
instead selectively seeded onto DED using a bespoke cell culture ring made from a 3D 
printed resin. This created an exclusion zone, similar to the 2D migration work shown in 
the previous chapter, which allowed the formation of an epithelial wound equivalent of 
fixed size. 
 Figure 6.17 shows models seeded in this method, then cultured for 7 days in 
different BP-containing media, with cell regions visualised through a resazurin reduction 
assay, whereby cells are coloured pink. At day 0, the areas of keratinocyte seeding were 
obvious, with a clear exclusion zone in the middle. No difference was seen after 1 day.  
When cultured in control medium, by day 4 and 7, the cells migrated across the exclusion 
zone and at day 7 the whole model was entirely coloured pink. Two concentrations of PA 
were examined, and while migration into the exclusion zone occurred in both cases, the 
amount was reduced in comparison to the control and a dose dependent response was 
seen. When treated with 10 µM ZA, the cells began to migrate, with a larger area of pink 
seen at day 4. At day 7, little pink colour remained. 
Figure 6.18 shows resazurin assay results for the same models. All models showed 
a slight drop in signal between day 0 and day 1, before recovering and increasing between 
day 1 and 4. At day 7, the metabolic activity of the control and 50 µM PA treated models 
had increased to around 400 %. The metabolic activity of the models treated with ZA and 
100 µM PA stayed constant between day 4 and 7, demonstrating the effect on cell 
metabolic activity. 
A histological section of a model 1 day after removing the ring is shown in Figure 
6.19, which indicated the thin nature of the epithelial sections immediately after seeding. 
Histological sections of these models at day 7 can be seen in Figure 6.20. The control 
model is shown in Figure 6.20A, where, as before, the epithelium has stratified in the areas 
of original seeding and migrated across the exclusion zone. The epithelium had begun to 
stratify in the place of the original wound. When treated with 50 µM PA, a stratified 
epithelium was visible on one side of the model, and some thinner epithelium is evident in 
the middle of the model, shown in Figure 6.20B. Figure 6.20C shows the 100 µM PA 
treated model, which has remnants of a single celled epithelium in some places, but the 
original seeding areas were no longer apparent. In the ZA treatment model, some epithelial 
cells are visible on the surface in Figure 6.20D, however, as expected from the resazurin 
images and data, the drug had largely removed the epithelium   










































    
Figure 6.17. Selectively seeded oral mucosa models, cultured for 7 days in control 
medium, pamidronic acid and zoledronic acid. Imaged immediately following a resazurin 
assay, pink colour indicates presence of cells. Columns denote length of time, rows denote 
medium. DED = de-cellularised dermis. Scale bars = 5 mm. 
Cells 
DED 




Figure 6.18. Metabolic activity of selectively seeded immortalised keratinocyte DED 
models cultured for 7 days in pamidronic acid and zoledronic acid, measured by resazurin 
assay. N=1, n=1. Values normalised to day 0. Error bars = SD. Statistical significance 




Figure 6.19. H&E stained sections of oral mucosa model selectively seeded with human 
oral fibroblasts and immortalised human oral keratinocytes, then placed at ALI in control 

















Figure 6.20. H&E stained sections of oral mucosa models selectively seeded with human 
oral fibroblasts and immortalised human oral keratinocytes, then placed at ALI in (A) 
control medium, (B) 50 µM pamidronic acid, (C) 100 µM pamidronic acid and (D) 10 µM 
zoledronic acid for 7 days. Arrows show approximate edges of original seeding area, when 
apparent. Representative images used. 
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While the 3D printed rings potentially allowed for a repeatable, successful wound 
healing model, the epithelial sections were only a single cell thick. While BPs are known 
to affect the epithelium of a patient before the BRONJ-precipitating event, the epithelial 
sections either side of a wound will be healthy and multi-layered. Therefore, models were 
seeded at ALI, with the medium inside the ring removed to allow for the epithelium to 
stratify, while maintaining the exclusion zone, and thereby more closely represent the in 
vivo scenario. 
 Models were cultured at ALI for 4 and 7 days, before rings were removed and a 
resazurin assay was performed to visualise cell seeding, as shown in Figure 6.21. A model 
with the ring taken off before moving to ALI is included as a control. In all models, the 
exclusion zone appeared in place, with two sections of pink colour apparent. Figure 6.22 
shows models cultured at ALI for 7 days, then cultured in control medium for a further 
7 days. By day 4, the exclusion zone had closed and at day 7, the model was completely 
coloured pink. 
 Figure 6.23 shows histological sections of models when cultured at ALI for 4 or 
7 days with the culture ring in place. After 4 days, in Figure 6.23A, the epithelium was 
present in two sections, as expected, though largely still single layered. Figure 6.23B 
shows a model cultured at ALI for 7 days. The epithelium was able to stratify in place, with 
multi-layered epithelial sections appeared either side of a mostly cell free wound 
equivalent. 
Figure 6.23C, D and E show models cultured at ALI for 7 days, then fixed during 
the healing process. Figure 6.23C shows two single layered migration fronts had begun to 
form across the wound. By day 4, these continued further along the model, while stratifying 
in place. By day 7, the model was covered entirely by a multi-layered epithelium and the 
areas of original seeding were no longer apparent, indicating successful healing. 
 
  




Ring left on at ALI 
0 days 4 days 7 days 
   
Figure 6.21. Selectively seeded oral mucosa models, placed at ALI with the culture ring 
for 0, 4 or 7 days. Imaged immediately following a resazurin assay, pink colour indicates 
presence of cells. Scale bars = 5 mm. 
 
Ring left on at ALI for 7 days, then cultured for 
0 days 4 days 7 days 
   
Figure 6.22. Selectively seeded oral mucosa models, cultured at ALI for 7 days before the 
culture ring was removed, then cultured for 1, 4 or 7 days. Imaged immediately following 
a resazurin assay, pink colour indicates presence of cells. Scale bars = 5 mm. 
  

























Figure 6.23. H&E stained sections of oral mucosa models selectively seeded with human 
oral fibroblasts and immortalised human oral keratinocytes, then placed at ALI with a 3D 
printed cell culture ring preventing migration for (A) 4 days and fixed immediately, or for 
7 days and fixed (B) immediately, (C) after 1 day, (D) after 4 days or (E) after 7 days further 
culture. Arrows indicate approximate edge of seeding area. Representative images used. 




6.4.6 Seeding models at air-liquid interface is not reproducible 
 
After initial success in prototyping the wound model when cultured at ALI, more were 
seeded. A resazurin reduction assay was performed with these models immediately after 
removing the ring. As Figure 6.24 shows, the seeding process was not successful. While 
some of the models had two distinct regions of pink colouring, the seeding was not 
localised to those specific areas as previously. As the model on the bottom centre and 
bottom right seemed to be most successful and seemingly had an exclusion zone, these 
models were treated with either 50 µM PA or control medium for 7 days. 
 
 
Figure 6.24. Oral mucosa models selectively seeded at ALI with human oral fibroblasts 
and immortalised human oral keratinocytes. Images taken immediately following a 
resazurin assay. 
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6.4.7 Pamidronic acid prevents re-epithelisation of the oral mucosa wound model 
 
Figure 6.25 shows that while clear epithelial regions were seen immediately after removing 
the ring, by day 4 these regions were impossible to distinguish. At day 7, both models 
appeared similar, with pink colouration across the whole sample. 
 Histology, however, showed a clear difference between the samples. When treated 
with control medium, the models appeared as in Figure 6.23E, with a multi-layered 
epithelium present over the whole sample. Figure 6.26 shows that while the PA treated 
model did have a whole epithelium, as suggested from the pink colouring in Figure 6.25, 
it was not stratified in all areas, while the control sample had a stratified epithelium past 
the point of original seeding. Figure 6.26A demonstrates that two distinct stratified sections 
exist, confirming the successful seeding of the model. Figure 6.26B, however, shows that 
in the original exclusion zone, while cells have migrated, they have not stratified. The 
epithelium is only 1 or 2 cells thick across the exclusion zone. When treated with control 
medium, the epithelial region across the exclusion zone was thicker, as shown in Figure 
6.26C. 
 A further set of mucosa models were seeded at ALI, however, in this case, even 
fewer were successfully seeded, so another seeding method was performed. 
  





























Figure 6.25. Oral mucosa models selectively seeded at ALI with human oral fibroblasts 
and immortalised human oral keratinocytes, then cultured for 7 days before removing the 
cell culture ring, and culturing for 7 days in 50 µM pamidronic acid or control medium. 
Images taken immediately following a resazurin assay, pink colour indicates presence of 
cells. 
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Figure 6.26. H&E stained sections of oral mucosa models selectively seeded at ALI with 
human oral fibroblasts and immortalised human oral keratinocytes, then treated at ALI with 
(A, B) 50 µM pamidronic acid or (C) control medium for 7 days. Whole epithelial region 
shown in (A), dotted line indicates area shown in (B). Arrows show approximate edges of 
original seeding area, when apparent. Representative images used. 




6.4.8 Seeding models with an in situ ALI provides a more reproducible wound 
model 
 
As seeding at ALI proved difficult to reproduce, models were seeded in a well plate, as 
standard. Rather than removing the rings at day 4, however, the medium inside the rings 
was removed to create an in situ ALI. Models were cultured for 7 days in this state, before 
removing the ring and performing a resazurin assay. Figure 6.27 demonstrates that this 
method created much more well defined seeding areas, with two distinct regions of cells 
present on all models. 
 Figure 6.28 shows histological sections of a model seeded with an in situ ALI. Two 
distinct epithelial regions were present, with an exclusion zone across the middle of the 




Figure 6.27. Oral mucosa models selectively seeded with human oral fibroblasts and 
immortalised human oral keratinocytes, before creating an in situ ALI and culturing for a 
further 7 days. Images taken immediately following a resazurin assay, pink colour 
indicates presence of cells. 
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Figure 6.28. H&E stained sections of an oral mucosa model selectively seeded with human 
oral fibroblasts and immortalised human oral keratinocytes, before creating an in situ ALI 
and culturing for 7 days. Whole epithelial region shown in (A), dotted line indicates area 
shown in (B). Arrows show approximate edges of original seeding area, when apparent. 
Representative images used. 




6.4.9 Pamidronic acid and zoledronic acid prevented full healing of in situ wound 
model 
 
As seeding with an in situ ALI allowed for more consistency, models seeded through this 
method were treated with BPs. Figure 6.29 shows these models immediately following a 
resazurin assay after 0, 4 and 7 days of BP treatment. When cultured in control medium, 
migration of the epithelial regions occurred, and by 7 days the model was entirely pink. 
Treatment with PA prevented this in a dose dependent manner. When treated with 50 µM 
PA, some cells had migrated, but the model was not entirely coloured pink by day 7. A 
100 µM PA treatment also saw increasing pink colour, suggesting migration, at day 4, but 
by day 7 the pink colouration was no longer present. A 1 µM ZA treatment had no effect, 
with a full pink model present at 4 and 7 days. Treating with 10 µM ZA allowed for migration 
between 0 and 4 days, but by 7 days little pink was seen, suggesting toxicity. 
 Figure 6.30 shows the metabolic activity of models seeded with an in situ ALI and 
cultured in BPs for 7 days, normalised to day 0. High variation was seen in these models. 
Control medium allowed for an increase in metabolic activity over the 7 days, rising to 
approximately 250 %. A 50 µM PA treatment halted growth, with metabolic activity 
remaining approximately 100 % at all time points, though with an incredibly high amount 
of variation at day 7. Treating with 100 µM PA reduced metabolic activity, with a significant 
reduction in comparison to the control at 7 days. When treated with 1 µM ZA, no 
differences were seen in comparison to the control, with metabolic activity increasing over 
time. A 10 µM ZA treatment also reduced metabolic activity in comparison to the control 
at 7 days. 
 Figure 6.31 shows histological sections of models at day 7, demonstrating one 
section of original seeding and part of the wound equivalent. Figure 6.31A shows a model 
cultured in control medium, where a thin epithelium was present across the wound area. 
When treated with 50 µM PA, shown in Figure 6.31B, a consistent epithelium was again 
present across the wound. Figure 6.31C shows that, while some keratinocytes remained 
in the original area of seeding following a 100 µM PA treatment, no epithelium was present 
across the wound. Treating with 1 µM ZA allowed for re-epithelialisation, with a consistent 
epithelium seen in Figure 6.31D. No epithelium is seen following a 10 µM ZA treatment, 
shown in Figure 6.31E. 
  
 The development of an in vitro model of the soft tissue component of BRONJ  
157 
 













































   
Figure 6.29. Selectively seeded oral mucosa models, cultured with an in situ ALI for 7 days, 
before culturing for 7 days in control medium, pamidronic acid or zoledronic acid. Imaged 
immediately following a resazurin assay, pink colour indicates presence of cells. Columns 
denote length of time, rows denote medium. Scale bars = 5 mm. 





Figure 6.30. Metabolic activity of selectively seeded immortalised keratinocyte DED 
models using in situ ALI, cultured for 7 days in pamidronic acid and zoledronic acid, 
measured by resazurin assay. N=3, n=1. Values normalised to day 0. Error bars = SD. 
  













Figure 6.31. H&E stained sections of oral mucosa models selectively seeded with human 
oral fibroblasts and immortalised human oral keratinocytes, before creating an in situ ALI 
and culturing for 7 days, then placed at ALI in (A) control medium, (B) 50 µM pamidronic 
acid, (C) 100 µM pamidronic acid, (D) 1 µM zoledronic acid and (E) 10 µM zoledronic acid 
for 7 days. Arrows show approximate edges of original seeding area, when apparent. 
Representative images used.  




6.5 Discussion  
 
The epithelium of the oral mucosa in BRONJ patients will exist in several different forms. 
Firstly, there will be a healthy, stratified epithelium, found before any precipitating event 
occurs, and surrounding the wounded tissue after the event. As the wounded tissue begins 
to heal, tissue will exist as two separate sections which migrate to close the wound. When 
the wound is first closed, the epithelium will exist in a single layer. We have demonstrated 
that in all these cases, clinically relevant concentrations of PA and ZA negatively affect the 
epithelium. 
 To approximate cell viability in 3D, resazurin reduction assays were used. These 
provide a measure of metabolic activity, however with little cytotoxicity, unlike the MTT 
assay [292], [305]. This allows for more than one assay to be performed on a model over 
time, reducing the number of models required per experiment which is beneficial in 3D 
culture, due to the greater complexity and higher number of cells required. When models 
were cultured for 7 days before treating with PA and ZA, metabolic activity decreased 
between day 7 and day 14. This is likely due to the maturation of the models: when a 
model is stratifying, the metabolic activity will increase as cells proliferate, yet after they 
become mature, metabolic activity is likely to decrease. Metabolic activity of cells can also 
increase in response to cellular stresses, and the large variation seen when primary 
models were treated with low concentrations of PA and ZA is potentially due to this 
mechanism. The overall trend, however, is clear, with higher concentrations of PA and ZA 
causing a more pronounced effect and the lower concentrations behaving similarly to the 
control treatment. 
To examine how BPs affect the development of epithelia, we treated models with 
PA and ZA immediately after placing at ALI. When treated with 50 to 100 µM PA, metabolic 
activity did not increase and histology showed a dose dependent reduction of epithelial 
thickness. This is the first time this effect has been demonstrated. ZA proved more toxic 
to the models than PA, as expected from our 2D work. While 1 µM ZA performed similarly 
to PA, with no metabolic activity reduction but a thinner epithelium, both 10 and 30 µM ZA 
led to a reduction in metabolic activity and the removal of the epithelium. Previously, it has 
been demonstrated 1 µM ZA had no effect on the epithelial formation of oral mucosa 
models using OKF6 cells [173]. Our results support this, and demonstrate for the first time 
that higher concentrations of ZA lead to toxicity of newly formed epithelia in vitro.  As we 
demonstrated in chapter 5, clinically relevant concentrations of both PA and ZA prevent 
epithelial cell proliferation, and this has also been demonstrated in 3D [164], [187]. We 
surmise that the lack of stratification seen is due to this inhibition of proliferation. This 
indicates a pathway by which necrotic bone exposure could continue over time. 
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For a BRONJ diagnosis, exposure of necrotic bone must persist for 8 weeks [1]. 
During oral mucosa wound healing, keratinocytes migrate to close the wound, before cells 
in the basal layer begin proliferation. This proliferation causes the epithelium to stratify in 
place to form a new, multi-layered epithelium [99]. In the development of BRONJ, this 
process is clearly prevented, evidenced by the lack of soft tissue wound closure identified 
as the key clinical feature of the disease [2]. Our results suggest that PA will cause newly 
formed tissue to be thinner, and therefore more susceptible to injury, and ZA will be toxic 
to this newly formed tissue, thereby demonstrating a reason for the persistent soft tissue 
wound. 
 The epithelium surrounding a BRONJ wound will exist as a healthy, established 
epithelium, which will be exposed to BPs following the dental event, such as extraction of 
a tooth, that precedes the development of the disease. We have demonstrated that 
clinically relevant concentrations of both PA and ZA cause established epithelia to thin in 
a dose dependent manner. Kim et al. demonstrated PA concentrations of 10 µM reduced 
the epithelial thickness of established oral mucosa models [164]. We chose concentrations 
above this value due to the IC50 values determined in the previous chapter, however our 
results show a similar effect. Though no significant change in metabolic activity was seen, 
the epithelial thickness of both immortalised and primary keratinocyte models was reduced 
in a dose dependent manner. 
 ZA treatment not only reduced epithelial thickness, but led to cytotoxicity. A 1 µM 
ZA treatment caused similar effects to PA, with no metabolic effect seen but epithelial 
thickness reduced. When treated with 10 µM ZA, immortalised cell models saw no 
significant metabolic effect, though models seeded with primary cells did. As our IC50s in 
chapter 5 show, immortalised keratinocytes are more resistant to ZA toxicity than primary 
keratinocytes, therefore this effect was expected. A 30 µM ZA treatment proved toxic to 
both immortalised and primary models. Previously ZA concentrations from 4 to 10 µM have 
been demonstrated to reduce epithelial thickness of in vitro oral mucosa models [177], 
[187], [202]. Our data confirms this effect, while also using metabolic activity data to 
produce a quantitative measurement of cell viability of these models for the first time, and 
indicating that a ZA concentration well within the expected range received by the oral 
mucosa in BRONJ patient will lead to cytotoxicity. 
 Though it has been demonstrated that BPs reduce epithelial thickness, the 
mechanism by which this effect happens is not understood. It has been suggested that PA 
and ZA may increase the speed of the keratinocyte differentiation process, leading to 
keratinised outer layers, but fewer middle layers [164], [177], [187]. However, Bae et al. 
observed the opposite effect, with fluorescently labelled ZA localising to the outer layers 
of the epithelium and eventually leading to a reduction in the number of keratinised layers 
[202]. This effect was suggested to be due to the higher level of calcium present in the 




outer layers of the epithelium and supports work from Arai et al., who showed increasing 
calcium concentration had a synergistic effect on ZA toxicity [176]. No keratinised layers 
were present in our models, including our controls, however our immortalised keratinocyte 
models demonstrated fewer middle layers. In the models where no metabolic effect was 
noted, and therefore no toxicity was seen, the outer layer of the epithelium was consistently 
flatter than the basal layers. As keratinocytes differentiate through the layers of the 
epithelium, they flatten [91]. Hence, our immortalised keratinocyte work supports the 
theory that BPs are affecting differentiation, and further investigation into this mechanism 
would be useful, particularly investigating the effects on parakeratinised epithelial tissue 
models, however this was outside the scope of this project. 
Our primary keratinocyte models did not show the same effect, with differences in 
the morphology of the layers seen across the samples. Primary keratinocytes are 
inherently variable, with variation even within one patient, as epithelial thickness varies 
across the mouth and even across the gingiva [91], [92], and it is therefore difficult to make 
strong conclusions based on these histological slides. What is clear, however, is that PA 
and ZA reduce the thickness of the oral epithelium. ZA led to more toxicity at lower 
concentrations than PA, which explains why ZA patients are more likely to develop 
BRONJ.  
 This data offers both an explanation as to why BRONJ can spread across the jaw 
with ease, and a reason for BRONJ development in the first place. The epithelium provides 
a barrier against both mechanical forces and bacterial infection [99]. If the integrity of this 
barrier is compromised, then the mucosa is more susceptible to injury and infection. BPs 
are known to promote bacterial adhesion and biofilm formation [58], [148]. Therefore, as 
clinically relevant concentrations of BPs reduce the integrity of healthy epithelium, it follows 
that the worsening of the disease is likely. 
In terms of disease development, the oral mucosa surrounding the jaw bone is 
known to be thinner than other areas of the mouth [43], [48]. The oral mucosa is situated 
directly above the bone with no fat, fascia or muscle tissues between the mucosa and the 
bone which could potentially prevent exposure, with the gingiva even closer due to the 
lack of submucosal layer [91], [92], [164]. It has been suggested that oral mucosa exposure 
to BPs occurs regularly before any dental event or osteonecrosis, through examination of 
patient tissue [189] and measuring salivary BP concentrations of patients with no clinical 
BRONJ features [142]. It may be that ZA has an effect on epithelial thickness before the 
BRONJ preceding dental event, due to the low concentrations at which ZA toxicity occurs. 
This could also explain the ‘spontaneous’ cases of the disease. In the development of a 
treatment for BRONJ, it will be important to investigate whether this thinner epithelium 
could recover if local BP concentration was reduced. Due to the finite culture length of the 
oral mucosa models, however, this was not possible in this project. 
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 To further understand BRONJ development, and to examine potential treatment 
mechanisms, being able to model the soft tissue component of the disease is vital. 
Following oral surgery, the epithelium will exist in two sections, cleanly separated through 
a sharps wound [98]. These sections will then migrate to form a complete layer, before 
stratifying to re-establish a full epithelium. We have begun the development of this soft 
tissue model, and through its use have demonstrated that PA and ZA both prevent the 
re-epithelialisation of the oral mucosa. 
In optimising the wound healing model, immortalised keratinocytes were used. As 
with the previous chapter, this is due to the relative ease in the culture of these cells in 
comparison to their primary equivalents, and the inherent variability that arises from using 
primary cells. Immortalised cells, including the OKF6 cells used in this thesis, have 
previously been demonstrated to be successful when culturing epithelial models [94], 
[173], [202], [203]. Our work again shows this, with models performing well over 
approximately 18 days of culture. However, following this time point, model viability tended 
to decrease, with epithelia becoming thinner, and optimisation was required. 
In vitro epithelial models have a finite culture time, falling between 14 and 28 days 
in literature, depending on the cells used and passage number [207]. However, epithelial 
stratification takes time, and a full epithelium was needed for the model. As 10 days led to 
a fully stratified epithelium across a whole sample, initially this point was used as a 
wounding time, but as model viability began to decrease at day 18, and thinner epithelia 
were present following this time point, wounding time was changed to day 7. While the 
epithelia at this point were not completely stratified, they were consistent enough to use 
as a wounding time point. 
Different wounding methods were performed, with the aim of finding a wound that 
could be used to represent that found in a BP patient following oral surgery. Three criteria 
defined the success of the wound healing assay: reproducibility of the wound, ability to 
heal, and similarity to the clinical scenario. 
The soldering iron did not succeed in any of the criteria. Creating the wound was 
difficult to perform consistently due to the large amount of damage done to the model, and 
several models were lost entirely as they contracted around the heated tip. The level of 
damage was so severe the model seemed to not heal. The burn wound was also unlike 
those seen in an extraction patients. This method was included in the test as it has been 
successfully used in literature [203], [204]. 
The cauteriser created a much more consistent wound, however again, the wound 
did not heal over time, appearing the same before and after 10 days of culture time. 
Macroscopically the wound did not change over the time of the experiment, with the burn 
obvious at all times. These models are limited as they only contain fibroblasts, 
keratinocytes and connective tissue, therefore do not have the immune response required 




for large scale healing. It is likely that the damage to the connective tissue was too great 
for the model to overcome. 
Previously, both hot and cold burn wounds have been used on epithelial models to 
stimulate wound healing [94], [203], [204]. In these cases, the epithelium alone was 
damaged and separated from the connective tissue, allowing for migrating keratinocytes 
to heal below the damaged epithelium. In our work, while some of the epithelium separated 
in the both the soldering iron and cauteriser wounds, no migration front formed below. 
Breetveld et al. held a soldering iron to their epithelia for 10 seconds and created clean, 
repeatable epithelial wounds with seemingly no connective tissue damage [204]. In our 
study, 1 second of contact with the soldering iron caused severe damage. As such, a third 
method was trialled. 
The biopsy punch created a wound that healed consistently, and as a sharps 
wound it is similar to that found following a tooth extraction. However reproducibility was 
an issue. Variation was found in single wounds, with one side of the wound often deeper 
than the other. When the connective tissue was wounded, it was simple to find the original 
site of wounding as the epithelium migrated into the defect. This is similar to work from 
Geer et al. who found keratinocytes migrated into defects formed when DED models were 
wounded with a scalpel [198]. When the connective tissue was unaffected in our work, the 
wound healed completely and undetectably. While in some ways this was a positive, it 
made assessing the healing process difficult. 
None of the tested wound models performed well in all three of the criteria for 
success. As such, we devised a method for testing epithelial migration similar to the 2D 
assay used in the previous chapter. While this was less clinically relevant, it allowed for 
increased reproducibility and a more well-defined wound by which to study BP effects on 
re-epithelialisation. 
The use of selective keratinocyte seeding to study migration has been used before 
in skin models, with a technique developed by MacNeil et al. using two concentric stainless 
steel rings of different diameters, to create a ‘donut’ shape of epithelial cells [207]. Whilst 
this is also applicable for oral mucosa work, the method requires large amounts of cells 
and dermis, making it more difficult to perform. Collagen models have also been used for 
similar assays, where smaller devices have been used to prevent keratinocyte seeding in 
a particular area [208], [209]. These use fewer cells, however they have a much simpler 
and less representative model of the dermal compartment, with no rete ridges and poor 
mechanical properties [194], [306]. 
Here, we have begun the development of an oral mucosa wound model using a 
combination of these previous methods which removes the main disadvantages of them. 
Our model retains the use of DED and is thereby more representative of the in vivo setting 
than collagen models, while removing the two main obstructions to the MacNeil model by 
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requiring fewer cells and smaller pieces of dermis. Creating an ALI with the ring in place 
for 7 days allowed for a multi-layered epithelium to form on either side of the exclusion 
zone, approximating the natural scenario for an epithelial wound. A 3 mm wound was 
created repeatedly, and over 7 days of culture the wound closed, leaving a model with a 
complete, stratified epithelium. 
Our results suggest clinically relevant concentrations of BPs prevent 
re-epithelialisation. Treatment with 100 µM PA and 10 µM ZA consistently removed any 
epithelial cells from the wound models, independent of original epithelial thickness. A 
50 µM PA treatment allowed for epithelial migration, but prevented stratification, which was 
particularly evident in our successful ALI seeded model. As we have previously 
demonstrated, BPs prevent proliferation but do not affect migration, and prevent the 
stratification of newly formed epithelia. From both the resazurin visualisation and histology, 
the migration of keratinocytes across the model is consistently evident, even when treated 
with toxic concentrations of PA or ZA. However, the epithelia formed following this 
migration were rarely stratified. Epithelial stratification is known as a proliferation effect 
[99]. Our results thereby suggest that BPs prevent the healing of soft tissue by preventing 
a full thickness epithelium from forming following surgery. 
Previously, both PA and ZA have previously been demonstrated to effect 
re-epithelialisation in 3D, with proliferation identified as a cause, however only 10 µM 
concentrations were tested [164], [187]. We chose higher concentrations of PA due to our 
earlier 3D work and IC50s, and have demonstrated by the first time the clear effect these 
concentrations have on epithelial wound healing. We have also indicated that 1 µM ZA 
does not prevent re-epithelialisation. In reducing local BP concentration, this concentration 
would therefore be a suitable target to prevent BRONJ development. 
In their work, Saito et al. also identified a further potential pathway by which BPs 
can affect keratinocyte wound healing – downregulation of the αvβ6 integrin [187]. 
Keratinocytes do not normally express the integrin αvβ6, however during wound healing it 
is upregulated [188], whereby it promotes cell migration and activates TGFβ. This presents 
an interesting area for further study. However, due to our model using immortalised 
keratinocytes, which behave differently and may not follow this same signalling pathway, 
this was outside of the scope of the work in this thesis. Following the optimisation of the 
model, performing the assay with primary keratinocytes and investigating further the 
mechanisms by which BPs effect the oral mucosa through immunohistochemistry would 
provide valuable information on BRONJ.  
Optimising the model was difficult. The 3D printed ring successfully allowed for the 
selective seeding of cells onto DED. Resazurin assays allowed for a visual representation 
of seeding success, which was confirmed through histology. However, when placed 
immediately at ALI the epithelial sections were single layered, and therefore not a good 




representation of the in vivo BRONJ scenario. Seeding at ALI gave some success, 
allowing for the stratification of the epithelium with the ring in place, and in initial tests 
allowed for a good model of the soft tissue component of BRONJ. However, this was not 
reproducible. The donor skin which was processed into DED was from a variety of patients, 
and as such, was inconsistent. The thickness of the skin in particular changed from batch 
to batch. When the models were seeded at ALI, the DED needed to be thick to allow for a 
good seal to be created. Due to the seeding process requiring both a 3D printed ring and 
the heavier stainless steel ring atop it, the structure was top heavy. Therefore, when the 
well plates were moved, the rings were unsteady and could also move. With thin DED, this 
movement caused the DED to move and aggregate at the holes of the stainless steel grid, 
which broke the seal created by the rings and caused the seeded cells to move outside of 
the sections created by the ring. To achieve distinct epithelial sections but to allow a 
greater seal, another method was chosen. 
Models were seeded on the bottom of a well plate, but media removed from the 
insides of the ring to create an in situ ALI. This created two distinct, multi-layered epithelial 
sections. Though these sections were not as thick as when models were seeded at ALI, 
this allowed for greater reproducibility. As such, this mechanism allowed for a wound 
model that most closely satisfied our three criteria: reproducibility of the wound, healing 
potential, and similarity to the clinical scenario, and was used for further testing of the BP 
effect on epithelial wound healing, however still presented with issues. 
The final epithelia on the models seeded with an in situ ALI were thin, appearing 
similar to the models originally cultured in the rings with no ALI. The epithelia also 
appeared discontinuous in places. Though stratified, the keratinocyte areas seeded with 
the in situ ALI were only a few cells thick, as such, it follows that the overall epithelium of 
these models would be thin at day 7, as fewer keratinocytes were present to proliferate 
and migrate. To perform the resazurin assays on these models, they had to be transferred 
between well plates. When transferred, the models often folded and had to be flattened 
out with forceps. This happened more when the DED used was thinner. This process is 
likely to have disrupted the epithelium of the models, particularly if the epithelia were 
thinner to begin with. All this contributed to a model with high variation, indicated by the 
resazurin results in Figure 6.30. Although these models have provided some results 
indicative of how BPs contribute to the failure of soft tissue to heal following oral surgery, 
further optimisation is still required before this is truly a repeatable in vitro model of BRONJ. 
Re-epithelialisation is not just effected by BPs, and as such, these models have a 
wide scope for use in the tissue engineering field once fully optimised. Several diseases 
present with non-healing epithelia, not just in the oral mucosa, but in skin, and several 
drugs have been tested for their ability to promote re-epithelialisation. For example, a study 
by Vukelic et al. investigated the effects of glucocorticoid receptor on cutaneous wound 
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healing, whereby they explanted patient tissue and created 3 mm biopsy punch wounds 
and treated with different drugs [307]. Our wound healing model could potentially allow the 
consistent creation of a 3 mm epithelial wound by which to study these effects. The models 
could also be used to generate more data, following optimisation, through the 
measurement of cytokines and other secreted factors, in order to fully examine the wound 
healing process of the model. Whilst there is no blood supply in the models, and therefore 
will be a smaller inflammatory response, studies have previously demonstrated the 
detection of inflammatory cytokines possible with in vivo models, both through an enzyme-
linked immunosorbent assay of the medium [308] and through a polymerase chain reaction 
following the digestion and homogenisation of the models [309]. These assays would give 
a much more specific view of the wound healing response, and therefore add to the validity 




In summary, we have demonstrated that clinically relevant concentrations of PA prevent 
the stratification of newly formed epithelia, and reduce the thickness of healthy epithelia. 
ZA treatment had the same effect at low concentrations, with higher concentrations leading 
to toxicity. We have also begun the development of a 3D in vitro model of the soft tissue 
component of BRONJ, and indicated that PA and ZA prevent re-epithelialisation of the oral 
mucosa. 
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To assess whether hydroxyapatite (HA) in different forms can bind bisphosphonates 




We have demonstrated in the previous chapters that BP effects on soft tissue have a key 
role in the development of BRONJ. It is clear these effects must be inhibited in the 
prevention and treatment of the disease. Due to the severity and complexity of the later 
stages of BRONJ, and the difficulty that comes with treating them, preventing the disease 
development entirely would be the most beneficial solution [1], [40]. Most BRONJ cases 
follow a preceding event, and most of these events are oral surgeries [1], [123]. These 
therefore offer an obvious point at which to start preventative treatment. As BPs cause a 
wide variety of different effects, rather than managing each specific effect, reducing the 
BP level to which the oral mucosa is exposed may be a more elegant and efficient method 
of treating the condition, and recent literature has indicated potential methods by which to 
do this – either through using EDTA to chelate calcium or by replacing bound BPs with the 
less potent etidronic acid [40], [226], [227]. 
 It is well-documented that BPs have a high binding affinity for calcium, and calcium 
phosphate based materials have previously been used to bind BPs [34], [52], [60], [241], 
[251]–[253], [266]. Therefore, it may be possible to use this binding affinity to reduce local 
BP concentration, prevent BP effects, and allow for soft tissue wound closure. This would 
be particularly advantageous, as calcium phosphate bone filler materials are currently in 
use in the clinic in the treatment of several different BRONJ-preceding events [242]. 
However, demonstrating this effect would require the detection of BPs, which is a difficult 
process [273], [274]. 
 This chapter aims to assess the ability of HA to bind pamidronic acid (PA) and 
zoledronic acid (ZA). This was first investigated chemically through a variety of 
spectroscopic techniques, examining both the ability of HA to bind BPs, and retain BPs 
once bound. Following this, biological tests took place, examining whether HA could be 
used to counteract the PA and ZA toxicity demonstrated in chapters 5 and 6. 
  




7.3 Materials and methods 
 
7.3.1 Preparation of HA 
 
CAPTAL® ‘R’ sintering grade, high purity HA powder (Plasma Biotal Limited) was used for 
the work in this chapter. In order to reliably examine the ability of HA, it was first pressed 
into uniform discs. Amounts of 0.7 g were weighed and loaded into a 13 mm die (Specac) 
and pressed under uniaxial pressure in a manual hydraulic press (Specac) with 5 tonnes 
of pressure held for 30 seconds. 
 
7.3.2 Sintering of HA discs 
 
Discs were sintered to fuse the HA powder. Discs were placed on an alumina boat and 
into a chamber furnace (Lenton Thermal Designs) where they were sintered in air at 
1200 °C with a ramp rate of 5 °C/minute and a dwell time of 2 hours. The final weight of 
the discs was approximately 0.65 g. 
 
7.3.3 HA granules 
 
ReproBone® 1 to 4 mm HA granules were kindly provided from Ceramisys Limited. 
Granules were weighed into amounts of 0.65 g to match the final weight of the sintered 
HA discs. 
 
7.3.4 X-ray diffraction (XRD) 
 
To examine the crystalline phase of the discs, XRD was carried out on a diffractometer 
(Siemens D5000) with a 2θ angular range of 10 to 60 ° and a step size of 0.05 °. The 
spectra obtained were compared using the SIeve+ software (ICDD) against the Powder 
Diffraction Files (PDF) database of the Joint Committee on Powder Diffraction Standards 
(JCPDS), using reference cards 09-432 (HA) and 09-169 (β-tricalcium phosphate (TCP)). 
 
7.3.5 Brunauer–Emmett–Teller (BET) surface area 
 
In order to calculate the surface area of the discs and granules, nitrogen gas adsorption 
was performed. The surface area/volume ratio of the 13 mm diameter discs was 
calculated, before discs were pressed in a 5 mm die (Specac) and sintered, as in sections 
7.3.1 and 7.3.2, ensuring the same surface area/volume ratio. The final weight of the discs 
was approximately 0.03 g. 
 Nitrogen gas adsorption was performed as a service by Duncan Schofield from the 
Department of Chemical and Biological Engineering, University of Sheffield. Granules 
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were measured in duplicate, and 2 discs were analysed together. Firstly, samples were 
placed in 9 mm diameter test tubes, which were degassed at 30 °C in a degasser 
(Micrometrics VacPrep 061). Then, nitrogen adsorption isotherms were obtained using a 
surface are analyser (Micrometrics TriStar II) at -196 °C. 
 Isotherms were analysed and surface area calculated using 3Flex (Micrometrics). 
Full isotherms are displayed in Figure 10.5 (see Chapter 10). BET surface area was 
calculated in the relative pressure region of 0.05 to 0.2, due to the linearity of the 
measurements in this region. 
 
7.3.6 Ultraviolet-visible (UV-vis) spectroscopy 
 
UV-vis spectroscopy was used to measure BP concentration. All samples were placed in 
quartz micro-cuvettes with a 0.7 ml capacity (Thor Labs) and measured in a UV-vis 
spectrophotometer (Unicam UV300) between 200 and 230 nm, referenced against distilled 
water. 
 
7.3.7 Calibration curves 
 
BPs were prepared as described in section 4.2. BP stock solutions were diluted in distilled 
water to give PA and ZA solutions of concentrations ranging from 0 to 250 µM. Samples 
of each concentration were read in triplicate in a UV-vis spectrophotometer, as described 
above. 
 
7.3.8 Hydroxyapatite binding and release of zoledronic acid 
 
To examine the ZA binding properties of HA discs, they were placed individually into a 
sterile universal tube containing 200 µM ZA in distilled water and incubated at 37 °C for 
14 days. At select time points, a sample of the supernatant was removed and ran through 
a UV spectrophotometer, as above. When unsintered discs were used, the sample was 
centrifuged to remove any HA powder. As controls, 200 µM ZA containing no HA was 
incubated, and HA discs were incubated in distilled water. Three samples were incubated 
for each condition. To ensure ZA degradation did not take place when incubated, a 
refrigerated sample of 200 µM ZA in distilled water was also examined at each time point 
for comparison (not shown). 
 After the 14 day binding study, the HA discs were removed, dried in air, and placed 
into new universal tubes. Distilled water was added to each tube before incubation. Over 
10 days, samples of this water were examined in the UV-vis spectrophotometer, to assess 
whether any ZA was released. 
 




7.3.9 Fourier-transform infra red spectroscopy - attenuated total reflectance 
(FTIR-ATR) 
 
FTIR-ATR was used to examine the chemical structure of the HA before and after BP 
binding. Samples were crushed to powder with an agate mortar and pestle prior to testing. 
Spectra were obtained between 4000 and 800 cm-1 with a FTIR-ATR spectrometer 
(Thermo Fisher Scientific Nicolet 380). Powder from HA discs of four different preparations 
were tested: control sintered HA discs, HA incubated in water for 14 days, HA incubated 
in 200 µM ZA for 14 days, and HA incubated in 200 µM ZA for 14 days then incubated in 
water for 10 days. 
 
7.3.10 Raman spectroscopy 
 
The chemical structure of HA discs was also examined through Raman spectroscopy. HA 
discs were examined using a Raman spectrometer (Thermo Fisher Scientific Nicolet DXR) 
using a 532 nm laser with a 2 cm-1 resolution. Samples were analysed between a spectral 
range of 4000 and 400 cm-1 with a 10 mW power, with exposure times of approximately 
300 seconds. The spectra generated were processed using OMNICTM (Thermo Fisher 
Scientific). 
 Discs were tested after no treatment, 14 days incubation in 200 µM ZA, and 
14 days incubation in 200 µM ZA then 10 days incubation in water. To assess the ability 
of Raman spectroscopy to quantify ZA binding, samples were incubated in 100, 200 or 
300 µM ZA for 14 days before examination. 
 
7.3.11 Biological binding assays 
 
Discs and granules were sterilised through autoclaving, then added to sterile universal 
tubes, with one disc or 0.65 g of granules per tube. Empty tubes were used as controls. 
BP containing medium was added to each tube, ranging from 0 to 100 µM PA and 
0 to 50 µM ZA, with a 5 ml volume used. 
 Cell culture was performed as described in section 4.1. After 48 hours, cells were 
seeded in preparation for an MTT assay as described in section 5.3.1. The following day, 
after 72 hours of BP binding, the medium was removed from the cells and replaced with 
0.3 ml of HA conditioned media. MTT assays were performed 24, 48 and 72 hours after 
this step. 
 Granules were also weighed into smaller amounts, from 0.065 to 0.65 g, to create 
a calibration curve for granule weight and HA binding ability. Granules were placed into 
universal tubes and MTT assays performed as before. 
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 Oral mucosa models were seeded as in section 6.3.1, halved with a sterile scalpel 
and placed at ALI for 7 days, at which point a resazurin assay was performed as in 
section 6.3.3. Following the assay, models were returned to ALI and treated with either 
control medium or 30 µM ZA in sextuplicate. Of the six models treated with either medium, 
two were cultured as normal. Two of the models of each treatment were cultured with a 
sterile disc placed under the stainless steel grid, and two with 0.65 g of sterile HA granules 
placed under the grid. At day 10, a resazurin assay was performed and media was 
replaced. At day 14, another resazurin assay was performed, following which samples 




Statistics were performed using Prism as described in section 4.3. ‘N’ is used to denote 
experimental repeats, while ‘n’ is used to denote technical repeats throughout. Prism 7 
was used to plot linear regressions to create UV-vis calibration curves for PA and ZA. 
Curves were also plotted for the UV binding and release data. Linear regressions were 
plotted for each data set, except for when HA was incubated in 200 µM ZA for 14 days, 
where a one phase exponential decay was plotted. 
MTT results were normalised as before in section 5.3.9 and resazurin results were 
normalised as before in section 6.3.9. In this chapter, a two way ANOVA was again 
performed, however post-hoc analysis was performed using Tukey’s test. To assess the 
HA effect, significance was calculated between the control group and each HA group; 
comparing the individual BP concentration of the controls with their corresponding 
concentration in the HA group (e.g. Control 100 µM PA vs. Granules 100 µM PA). 
 To create a calibration curve for HA granule weight and 100 µM PA toxicity, 
metabolic activity values were normalised to the highest weight used (0.65 g) and an 
exponential growth curve was plotted. 
 
  






7.4.1 Hydroxyapatite retains phase purity when sintered at 1200 °C  
 
HA can transform to tricalcium phosphate (TCP) at temperatures above 1200 °C, therefore 
XRD was performed following sintering to confirm the crystalline phase of the discs. The 
spectra generated for the sintered discs is shown in Figure 7.1. Also included are Joint 
Committee on Powder Diffraction Standards (JCPDS) reference cards for HA and β-TCP. 
The spectra demonstrate that the sintered HA produced was indeed HA, with all peaks 
found in the sintered disc matching those from the reference card. No unique β-TCP peaks 
were found. Further peak matching analysis of the data in the software package confirmed 




Figure 7.1. X-ray diffraction patterns for hydroxyapatite discs pressed and sintered at 
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7.4.2 Hydroxyapatite granules have a larger surface area than sintered discs 
 
As surface area is thought to affect the BP binding ability of HA, nitrogen gas adsorption 
isotherms were generated for HA granules and discs and the surface area calculated using 
the BET equation. Figure 7.2 shows the surface area of HA granules and discs. The 
granules had a mean surface area of approximately 345 m2/g. The discs had a surface 




Figure 7.2. BET surface area measurements for hydroxyapatite granules and sintered 
discs. N=1, n=2. Error bars = mathematical error from BET equation. 
  




7.4.3 Zoledronic acid concentration was quantified using ultraviolet-visible 
spectroscopy 
 
To assess whether UV-vis spectroscopy could be used to measure BP concentration, 
samples of ZA and PA were measured in a UV-vis spectrophotometer at a 210 nm 
wavelength. There was a strong trend between ZA concentration and absorbance for 
samples from 0 to 250 µM, as shown in Figure 7.3. Samples containing no BP measured 
approximately 0, as expected. Linear regression was performed with the data to generate 
a calibration curve, with an r2 value of 0.99, indicating a strong linear relationship between 
concentration and absorbance. 
 PA, however, did not give a strong enough reading through this technique for the 
determination of unknown concentrations. While there was still a general upward trend 
and a good linear fit, the standard deviation of each concentration overlapped, indicating 
this method was unsuitable for the detection of PA concentration. 
 
 
Figure 7.3. Ultraviolet-visible spectroscopy calibration curves for aqueous zoledronic acid 
and pamidronic acid at 210 nm, from 0 to 250 µM. Distilled water used as a reference 
blank. N=1, n=3. Error bars = SD. Linear regressions for each data set shown. 
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7.4.4 Unsintered hydroxyapatite effected bisphosphonate signal 
 
Initially, unsintered, pressed HA discs were incubated in ZA. Samples of the supernatant 
were taken periodically, with UV-vis spectroscopy used to assess concentration over time. 
Samples were centrifuged before reading to remove any HA powder in the samples. Figure 
7.4 shows the UV-vis spectroscopy readings for samples taken after 1 day, from 200 to 
230 nm, across the region of the ZA peak. While the ZA had a similar value to both that of 
the calibration curve in Figure 7.3, when HA was present, samples were indistinguishable 
from one another. No ZA peak was visible. Both readings go above 2, which according to 
Beer-Lambert Law suggests almost 100% absorbance, and below 210 nm (not shown due 
to peak height) these values were at the maximum possible value of the 
spectrophotometer. Sintered discs were therefore used from this point onwards. 
 
 
Figure 7.4. Ultraviolet-visible spectroscopy readings for water containing a hydroxyapatite 
disc, 200 µM zoledronic acid containing a hydroxyapatite disc, and 200 µM zoledronic acid 
alone, incubated at 37 °C for 1 day. Samples centrifuged prior to reading. Distilled water 








7.4.5 Sintered hydroxyapatite discs exhibited a potential zoledronic acid binding 
behaviour 
 
To assess the ZA binding capability of sintered HA discs, they were incubated in 
200 µM ZA for 14 days. Figure 7.5 demonstrates that the concentration of the ZA solution 
reduced over time. Over the first 2 days, the concentration dropped to approximately 
140 µM before the reduction steadied, ending at approximately 120 µM. An exponential 
decay plot indicated binding had levelled off, though with a relatively average fit of the data 
indicated by the r2 value. 
 ZA alone maintained an approximate constant level across the experiment, with a 
linear regression fitting the data well. The final concentration of this solution was close to 
210 µM, however there was a larger amount of error with this value. 
 When a sintered HA disc was incubated in water alone for 14 days, the absorbance 
at 210 nm suggested an increase in ZA concentration. This concentration steadily 
increased over the period of the experiment, in a well-defined linear trend. By day 14, this 
solution had an absorbance value equivalent to 70 µM, despite no ZA being present in this 
system, however with a large standard deviation. 
 
 
Figure 7.5. Ultraviolet-visible spectroscopy readings for water containing a sintered 
hydroxyapatite disc, 200 µM zoledronic acid containing a hydroxyapatite disc, and 200 µM 
zoledronic acid alone, incubated at 37 °C for 14 days. Distilled water used as a reference 
blank. N=3, n=3. Error bars = SD. Linear regressions shown, except for zoledronic acid 
and hydroxyapatite disc, where one phase exponential decay plotted. 
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7.4.6 Sintered hydroxyapatite may have released previously bound zoledronic 
acid 
 
The sintered discs which had previously been incubated in either water or 200 µM ZA were 
dried in air, then incubated in water for 10 days, and UV-vis readings of the supernatants 
were taken over time, to assess whether any bound BP was being released. Figure 7.6 
suggests that previously bound ZA was released from the sintered disc. At 10 days, the 
solution read as approximately 115 µM ZA, though again with large standard deviation. 
This was higher than the calculated level of binding from the data in section 7.4.5. 
 However, when HA was incubated in water, the solution gave a reading suggesting 
the presence of ZA, which again increased linearly over the duration of the experiment. By 
day 10 the solution gave a reading that corresponded to approximately 70 µM ZA, though 
no ZA had been in the system. This again suggested interference of HA with the readings. 
Linear regressions were performed with each data set, which indicated a strong linear 
increase in ZA concentration. 
 
 
Figure 7.6. Ultraviolet-visible spectroscopy readings for water containing a sintered 
hydroxyapatite disc incubated at 37 °C for 10 days. Discs had previously been incubated 
for 14 days in either water or 200 µM zoledronic acid. Distilled water used as a reference 
blank. N=3, n=3. Error bars = SD. Linear regressions for each sample shown. 
  




7.4.7 Sintered hydroxyapatite interfered with the ultraviolet-visible spectroscopy 
signal at 210 nm 
 
Due to the interference in signal exhibited over the experiment, the solutions were 
examined over a wider spectrum. Figure 7.7 shows the spectra from sintered discs 
incubated in 200 µM ZA or water for 14 days, before soaking in water for 6 days. The ZA 
incubated sample showed a small peak close to 210 nm, as expected. 
When a sintered HA disc was incubated in water, there was absorbance at 210 nm. 
As these spectra are referenced against distilled water, a constant value of 0 is the 
expected reading of the sample. The shape of the absorbance spectra is similar to that of 
Figure 7.4, though of lower absorbance, which suggested that HA interference caused this 
reading. It therefore appeared that measuring the concentration of the solutions was not 




Figure 7.7. Ultraviolet-visible spectroscopy readings for water containing a sintered 
hydroxyapatite disc incubated at 37 °C for 6 days. Discs had previously been incubated 
for 14 days in either water or 200 µM zoledronic acid. Distilled water used as a reference 
blank. N=1, n=3. Error bars = SD.  
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7.4.8 FTIR-ATR cannot be used to detect zoledronic acid bound to sintered 
hydroxyapatite discs 
 
FTIR-ATR spectroscopy can be used to identify compounds based on the excitation of 
bonds within the compound at certain light wavelengths. As we expected ZA to be bound 
to the sintered HA discs following the binding and release experiment, discs were analysed 
with this technique. Sintered HA discs were crushed to powder so as to be able to be 
loaded onto the FTIR-ATR fully and maintain a complete contact with the IR beam. Figure 
7.8 shows the spectra generated for an untreated sintered control disc, a sintered disc 
incubated in water for 14 days, a sintered disc incubated in 200 µM ZA for 14 days, and a 
sintered disc incubated in 200 µM ZA for 14 days and then water for a further 10 days. 
 All samples generated similar spectra, with no obvious regions of difference, 
except for one area of the control sample. Each sample had a PO4
3-
 band at approximately 
1000 cm-1, characteristic of calcium phosphates. In the control sample, there was a peak 
at approximately 2360 cm-1. This peak is characteristic of CO2, and therefore indicates an 
incomplete contact of the sample with the beam. ZA peaks were expected at around 
1500 cm-1 due to the aromatic ring and, due to the phosphorous in ZA, stretches to the 
PO4
3-




Figure 7.8. FTIR-ATR spectra for sintered hydroxyapatite discs after three different 
treatments: 14 days incubation in water, 14 days incubation in 200 µM zoledronic acid, 
and 14 days incubation in 200 µM zoledronic acid followed by 10 days incubation in water. 
An untreated disc was also measured. N=1, n= 1. 
  




7.4.9 Raman spectroscopy indicated some surface binding of zoledronic acid to 
sintered hydroxyapatite discs, though not quantitatively 
 
Raman spectroscopy is a similar technique to FTIR, however is performed through the 
focussing of a laser onto a sample, so could be performed on our sintered discs without 
the need for crushing to powder. 
 Figure 7.9 shows Raman spectra of an untreated sintered HA disc, a sintered HA 
disc incubated in 200 µM ZA for 14 days, and a sintered HA disc incubated in 200 µM ZA 
for 14 days and then water for a further 10 days. In the region shown in the spectra, no 
obvious peaks appeared in the control sample. All samples showed the beginning of the 
characteristic strong PO4
3-
 band at around 962 cm-1, (not fully shown due to relative height 
of the peak). In the samples incubated in ZA, small peaks were visible at 906, 878, 850, 
824 and 740 cm-1. The peaks at 878 and 850 cm-1 indicated carbon bonding, with the 
850 cm-1 peak indicative of the aromatic ring found in ZA. These peaks were smaller in the 
sample from the release study, suggesting that previously bound ZA has been released 
when incubated in water for 10 days. 
 
 
Figure 7.9. Raman spectra for sintered hydroxyapatite discs: untreated as a control, 
incubated in 200 µM zoledronic acid for 14 days, or incubated in 200 µM zoledronic acid 
for 14 days and then incubated into water for a further 10 days. N=1, n=1. 
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To determine the reliability of this technique in identifying the amount of bound ZA, 
sintered discs were incubated in three different concentrations for 14 days before 
analysing. Figure 7.10 shows the Raman spectra for these discs. While the peaks were 
slightly shifted compared to Figure 7.9, the shift was consistent for all samples indicating 
this is due to the equipment precision rather than a chemical change in the material. The 
peaks all appeared as before, however the ratio of the peaks does not follow the 
concentration of the drug (and thereby the assumed level of binding). While Raman 
spectroscopy was therefore suitable for the detection of bound ZA, it was not capable of 




Figure 7.10. Raman spectra for sintered hydroxyapatite discs incubated in 100, 200 or 
300 µM zoledronic acid for 14 days. N=1, n=1. 
  




7.4.10 Hydroxyapatite granules prevented bisphosphonate metabolic activity 
effects in 2D 
 
As our UV and Raman studies suggested that HA had the ability to bind BPs, we tested 
this biologically. For this, we also included some commercially available HA granules, as 
these are currently used clinically. A sintered HA disc or an equal weight of granules were 
incubated for 72 hours in PA and ZA concentrations above the IC50 values defined in 
chapter 5. PA and ZA incubated with no HA were used as controls. 
Figure 7.11 shows metabolic activity for human oral fibroblasts after treating with 
PA or ZA that had been previously incubated with HA. At 24 hours, no significant 
differences were seen between any BP concentration of either HA group, compared to the 
corresponding concentration of the control group. 
 After 48 hours treatment, both 50 and 100 µM PA and 50 µM ZA reduced cell 
metabolic activity of the control cells. Incubating with a HA disc led to no significant 
differences to the controls, with the same overall trends seen. Incubating with HA granules 
prevented the PA reduction in metabolic activity by a significant amount for both 
concentrations. All conditions had similar levels of metabolic activity to the control, 
untreated cells. 
 At 72 hours treatment, PA and ZA were again toxic to cells at both concentrations 
in the control group. HA discs had no effect, with no significant differences to the control 
group at any concentration. HA granules prevented the BP toxicity. The untreated cells 
showed no significant differences to the untreated control cells, indicating the HA granules 
were not affecting metabolic activity. HA granules showed significantly higher metabolic 
activity for all four BP treatments, in comparison to the control groups. 
  






Figure 7.11. Human oral fibroblast metabolic activity over 72 hours in the presence of 
pamidronic acid and zoledronic acid, incubated prior for 72 hours with hydroxyapatite in 
sintered disc or granule form. Media incubated with no hydroxyapatite used as a control. 
Values normalised to control cells at 24 hours. N=3, n=3. Error bars = SD. Significance 
against control at each time point indicated by *P≤0.05. 




Immortalised human oral keratinocytes were also used to biologically study the 
ability of HA to bind PA and ZA. Figure 7.12 shows the metabolic activity over 72 hours. 
After 24 hours, no significant differences were seen between the control group and either 
HA group. 
 At 48 hours, a dose dependent response was seen for both PA and ZA in the 
control samples. The same trend was seen when PA and ZA were incubated with a HA 
disc for 72 hours prior to the experiment. This trend was not apparent when granules were 
used to bind BPs. All values appear similar, though with higher variation. When treated 
with 20 µM ZA, HA granules led to a significantly higher level of metabolic activity, 
indicating the HA granules were reducing the level of BP toxicity. 
 After 72 hours, in the control group a dose dependent toxicity response was seen 
for both PA and ZA, with both drugs reducing metabolic activity. This was the same in the 
disc group. HA granules inhibited this reduction, though variation was again high, and no 
significant differences were seen between any HA granules treated groups and their 
corresponding control groups.  






Figure 7.12. Immortalised human oral keratinocyte metabolic activity over 72 hours in the 
presence of pamidronic acid and zoledronic acid, incubated prior for 72 hours with 
hydroxyapatite in sintered disc or granule form. Media incubated with no hydroxyapatite 
used as a control. Values normalised to control cells at 24 hours. N=3, n=3. Error bars = 
SD. Significance against control at each time point indicated by *P≤0.05. 




7.4.11 Hydroxyapatite granules prevented zoledronic acid toxicity to oral mucosa 
models 
 
To assess HA inhibition of BP toxicity in a more representative model, oral mucosa models 
were raised to ALI and cultured for 7 days. At this time point, a resazurin assay was 
performed to measure metabolic activity. A HA disc or an equal weight of HA granules 
were placed below the stainless steel grid, and models were treated with control medium 
or 30 µM ZA for 7 days. This concentration was chosen as it caused the greatest reduction 
in metabolic activity in chapter 6. Models with no HA below the grid were used as controls. 
 Figure 7.13 demonstrates the effect of HA granules on ZA toxicity, normalised to 
the day 7 values. With no HA, model metabolic activity was approximately 100 % at day 10 
when treated with control medium, while 30 µM ZA approximately halved this. When 
cultured in the presence of a HA disc, the same trend was seen, with no significant 
differences to the control group. When cultured with HA granules, the metabolic activity of 
both the untreated and treated cells was approximately the same. However, no significant 
differences were seen compared to the control group. 
 At day 14, metabolic activity of the control models remained at approximately 
100 %. Treatment with 30 µM ZA reduced metabolic activity to less than 5 %. This was 
again the case when cultured in the presence of a HA disc. HA granules prevented the 
toxicity of 30 µM ZA, with metabolic activity of around 100 % for models cultured in ZA, a 
significant increase compared to the control group. No significant difference was seen 
between the untreated models of the control group and granules group, indicating the HA 
itself caused no effect on metabolic activity when placed in direct contact with the models. 
  





Figure 7.13. Metabolic activity of immortalised keratinocyte oral mucosa models when 
treated with control medium or 30 µM zoledronic acid, in the presence of a sintered 
hydroxyapatite disc or granules, after first culturing at ALI in control medium for 7 days. 
Models cultured with no HA present as controls. Metabolic activity measured with a 
resazurin assay. Blank well reading subtracted from values before normalising to day 7 
values for each model. Day 7 not shown as all values 100 %. N=3, n=2. Error bars = SD. 
Statistical significance against control at each time point indicated by *P≤0.05. 
  




Histological sections from day 14 are shown in Figure 7.14. When treated with 
control medium from day 7 to day 14, as before, a multi-layered epithelium was visible 
across the whole model and can be seen in Figure 7.14A. This was also the case when 
HA was added to the well, both in disc or granule form, with a stratified epithelium present 
in both Figure 7.14B and Figure 7.14C. 
 When treated with 30 µM ZA, as before, no epithelium was present on the model, 
as shown in Figure 7.14D. This was also the case when a disc was present, in Figure 
7.14E. However, when treated with 30 µM ZA in the presence of HA granules, a full 
stratified epithelium was present across the sample, as shown in Figure 7.14F, though 
with slight disruptions to the outer layer. 
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Figure 7.14. H&E stained sections of oral mucosa models seeded with human oral 
fibroblasts and primary human oral keratinocytes cultured at ALI for 7 days in control 
medium, then treated with (A) control medium, (B) control medium and a sintered HA disc, 
(C) control medium and HA granules, (D) 30 µM zoledronic acid, (E) 30 µM zoledronic acid 
and a sintered HA disc, (F) 30 µM zoledronic acid and HA granules, respectively, for 
7 days, with a full media changing occuring at day 3 and day 10. Representative images 
used. 
  



















































7.4.12 BP binding was affected by HA surface area 
 
As discs consistently showed no effect in the biological assays, we further examined how 
HA surface area affected the BP binding ability of HA. Lower weights of granules were 
incubated in 100 µM PA for 72 hours, before fibroblast cells were treated with this medium. 
Figure 7.15 shows a calibration curve for granule weight, in comparison to a sintered disc, 
and metabolic activity, normalised to the metabolic activity of 100 % weight of granules 
(0.65 g). Increasing weight of granules caused an exponential increase in metabolic 
activity, with 20 % weight of granules leading to a metabolic activity of less than 10 %, and 
50 % weight of granules leading to a metabolic activity of approximately 20 %.  
 When 100 µM PA was previously incubated for 72 hours with a disc, metabolic 
activity was approximately 5 % compared to an equal weight of granules. This metabolic 
activity value was converted using the calibration curve, and suggested a binding ability of 
approximately 17 %, less than the 45 % expected from the BET data. 
 
 
Figure 7.15. Human oral fibroblast metabolic activity after 72 hours in the presence of 
100 µM pamidronic acid previously incubated for 72 hours with hydroxyapatite granules. 
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7.5 Discussion  
 
This chapter has examined the ability of two forms of HA to bind BPs, both commercially 
available HA granules, and HA powder pressed into discs and sintered. When sintered for 
2 hours at 1200 °C, HA did not decompose and remained phase pure. All peaks visible in 
the XRD spectrum were indexed to HA, with analysis suggesting the discs were made of 
pure HA. The sintering conditions used were those used by Muralithran and Ramesh, who 
also found the same result [310]. When sintered above 1200 °C, OH groups in the HA are 
eliminated due to the HA becoming unstable, through this process TCP is formed [311]. In 
terms of BP binding properties, it has been demonstrated that the surface Ca:P ratio of 
calcium phosphates helps define binding properties, with higher calcium increasing 
binding [52]. Maintaining phase purity is therefore important, as TCP has a lower Ca:P 
ratio (1.5) than HA (1.67) [312]. 
In order to examine the BP binding properties of HA, the ability to detect either BP 
concentration or a quantifiable chemical change to the HA is required. Here we have 
shown UV-vis spectroscopy alone can be used to detect ZA at concentrations relevant to 
BRONJ patients. This is the first time ZA concentration has been determined through this 
method. While UV-vis spectroscopy alone has been used to detect other BPs [265], [266], 
previous detection of ZA with UV-vis has followed complex HPLC separation methods 
[273], [275], [283], [284], [287]. 
Determination of PA was not possible by UV-vis spectroscopy alone as the 
absorbance was not high enough at the concentrations of interest. Previously, several 
methods have been performed to detect PA, including a ninhydrin assay, ion-pair HPLC, 
HPLC with light scattering detection, and a fluorescent assay using carbon dots [273], 
[274], [277], [281]. These methods should theoretically allow for detection of PA within the 
concentrations used in this project, however all came with issues that took them outside 
of the scope of this project. Ninhydrin assays were attempted though required too high a 
volume of PA to be feasible over long periods. Both HPLC methods were too complex and 
costly to perform. Though the carbon dot method used is cheap, can also detect zoledronic 
acid, and was tested with interference from calcium ions, this is a novel method and would 
require optimisation. For these reasons, the chemical binding experiments were done with 
ZA alone. 
UV detection could not be used to assess the BP binding ability of unsintered HA, 
due to HA interference. While HA does not have an absorbance peak between 200 and 
230 nm, it is known to absorb light of those wavelengths [313], [314]. Using unsintered 
discs, this caused interference within 24 hours of placing the HA into the solution, even 
following centrifugation. As such, discs were sintered to convert the powder into a solid 
mass. 




ZA concentration was reduced in the presence of a sintered HA disc over 14 days. 
The concentration fell rapidly over 24 hours before slowly levelling off. The quick removal 
of BPs would be highly beneficial for BRONJ patients, potentially preventing the soft tissue 
from being exposed to BPs entirely. The initial high rate was expected, as binding of ZA 
has previously been demonstrated at as short a time as 5 minutes [257], and within 
24 hours with other BPs [46], [49], [52], [266]. 
We also saw some ZA released from the HA discs, however due to the interference 
in the signal it is difficult to conclude much based on this data. In our study, the absorbance 
peak corresponded to a concentration higher than the amount thought to be bound, 
indicating the assumed HA signal was contributing to a false reading. Palazzo et al. studied 
the release of alendronic acid bound to nanohydroxyapatite (nHA), and showed only 
around 20 % of the BP was released [52]. ZA has a similar calcium binding affinity to 
alendronic acid, as they are two of the highest affinity BPs [42]. High binding affinity BPs 
are known to have lower desorption rates [45]. Our Raman spectroscopy results also 
suggest ZA remained bound to the sintered discs following the release study. This 
indicates the UV-vis release study, which implied that almost all of the previously bound 
BP was released, may have given a false result due to the HA interference. It may also be 
that BP binding is dependent on local concentration and placing into fresh water changed 
the equilibrium and caused release. However, due to the issues with this assay, it was 
impossible to investigate this effect further. 
Sintered discs prevented HA interference to begin with, but over time the 
absorbance in the region of interest increased, though not to the level of the original 
powder interference. Our results suggest that there is HA dissolution occurring over the 
total 24 days of the experiment. This supports what is known about HA dissolution. HA is 
known to slowly dissolve in distilled water due to an ionic imbalance [315]. The dissolution 
of HA has been shown to occur as quickly as 15 minutes after being placed in solution 
when kept at 37 °C [312]. Interestingly, the visibility of a peak and lower variance in Figure 
7.7 suggests less HA interference was present in samples containing both ZA and HA. It 
is known that inorganic pyrophosphate, an analogue of BPs, can delay the dissolution of 
HA, and this prevention of dissolution contributes to the overall reduction in resorption in 
bone [31], [316]. Our result suggests that ZA reduces the dissolution of HA over 24 days. 
Though interesting, the dissolution of HA and therefore the unsuitability of our control in 
this experiment makes it difficult to draw many strong conclusions about the chemical 
binding of ZA by HA. As such, methods of detecting changes in the disc before and after 
ZA incubation were examined. 
FTIR-ATR was used to examine the discs after various incubations in ZA and 
water. This technique requires full contact with the crystal for a good reading with no noise 
from the atmosphere. When the machine was tightened to ensure contact with the discs, 
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the brittle nature of the discs caused them to fracture. For this reason, discs were crushed 
to powder before performing FTIR. No detectable differences were seen by this method, 
except for a peak in one sample, characteristic of CO2 and indicating issues with sample 
contact [317]. Based on previous FTIR studies, ZA peaks corresponding to the aromatic 
ring were expected at approximately 1500  cm-1 [318], along with stretches to the PO4
3-
 
band at 1000 cm-1 [49]–[51]. These were not visible in our work, which is likely due to the 
crushing of the discs. High affinity BPs are known to bind to the surface, with low 
dissolution through the HA [45]. It therefore follows that ZA binding would be at the surface, 
and through this method little differences should be expected. Therefore a method which 
did not require the discs to be crushed was performed. 
We have demonstrated that it is possible to detect binding of ZA to HA discs using 
Raman spectroscopy, however not quantifiably. When HA was incubated in ZA, peaks 
were present at approximately 906, 878, 850, 824 and 740 cm-1. Similar peaks were 
present when Juillard et al. incubated both HA and bone in ZA for 48 hours [286]. While 
these peak heights were weaker in our release study sample, when incubated with 
different concentrations of ZA, the peaks did not correlate with concentration. However, 
due to the issues in measuring BP concentration in liquid, it was impossible to say whether 
these different concentrations had different binding mechanics. While this offers some use, 
in order to fully investigate binding mechanics, a more quantifiable method is required. 
Yet, as previously discussed, these methods are either costly, complex, or newly 
developed and not optimised, so were outside the scope of this project. 
Given the wide range of literature demonstrating the ability of HA and other calcium 
phosphates to bind BPs [34], [52], [60], [241], [251]–[253], [266], and the suggestion of ZA 
binding from the UV and Raman studies in our work, we were confident in our hypothesis 
that HA could be used to reduce local BP concentration. As such, we tested this 
biologically using assays previously defined in chapters 5 and 6. 
We have demonstrated for the first time that HA can be used to reduce toxicity to 
cells of the oral mucosa, both in 2D with two cell types, and in a 3D model representative 
of the clinical scenario. This has huge scope to help in the treatment of BRONJ, particularly 
given there is currently no definitive treatment for the disease [1]. Recent in vivo studies 
have suggested that reduction of the BP concentration to which the oral mucosa is 
exposed can prevent the development of BRONJ [40], [226], [227], and our work offers a 
method by which to do that. As HA is currently used in several oral applications relating to 
BRONJ preceding events [242], our method could be translated to the clinic, following 
further optimisation. 
Several questions must be addressed before granules could be used clinically. For 
example, when granules are used in oral surgeries, a membrane is normally used to 
prevent mobilisation [246], [260], which may have an effect both on the exposure of the 




granules to BPs and the re-epithelialisation of the oral mucosa. In addition, while the 
granules may be initially successful in reducing the concentration of BPs, as the jaw 
regenerates and the granules are resorbed, the bound BPs may be released again. 
Although the release of BPs through resorption is a normal process in BP patients, the 
level of BPs released from the granules could potentially be greater than that from bone 
and this would need to be monitored. It is also unclear as to whether this method could be 
used in the treatment of already established BRONJ, as there was no bone component 
including in testing, and reducing BP concentration is unlikely to affect necrotic bone. The 
well-defined rodent BRONJ model presents an ideal method for investigating this further, 
following the completion of in vitro studies. 
HA granules clearly prevented both PA and ZA toxicity to oral fibroblasts and 
keratinocytes, with concentrations well above the previously defined IC50s leading to 
metabolic activities similar to those of the non-BP treated cells following incubation in the 
presence of granules for 72 hours prior to treatment. When immortalised keratinocytes 
were cultured in medium that had been incubated with HA granules, there was larger 
variation in the data, particularly in those also treated with PA and ZA. This variation will 
have contributed to the overall lack of mathematical significance in this data set. It has 
previously been demonstrated that culturing with HA can inhibit keratinocyte proliferation 
[319]. It has also been reported that calcium and ZA can have a synergistic effect on 
keratinocyte viability, with higher cellular calcium increasing the potency of BPs [176]. As 
such, keratinocytes could have been negatively affected by the HA, which may have 
contributed to the overall variance in the data. The general trend suggests that HA 
granules inhibit PA and ZA toxicity to keratinocytes in 2D, however, and therefore this was 
tested further in an assay more representative of the clinical scenario. 
HA granules also reduced toxicity in our 3D mucosa model. This model is much 
closer to the clinical scenario and supports our hypothesis that HA can be used as a 
BRONJ preventative treatment. In our study, the models were treated twice, at days 7 and 
10. In a long-term BP patient, the local concentration in the mouth is known to spike 
following receiving a BP dose [142]. Our result indicates that the HA granules would be 
able to absorb at least one of these dosing spikes. In BRONJ patients, these doses range 
from monthly to yearly, dependent on BP potency [118]. If BP concentration could be 
reduced for a month, this would be within the time frame of the full re-epithelialisation of 
an extraction socket [97]. This mechanism is particularly advantageous due to several 
calcium phosphate based materials, including the granules used in this study, already 
being approved and available for clinical use and could be used following the oral surgeries 
that make up BRONJ-preceding events [242]. 
When 3D mucosa models were cultured in ZA with HA granules, while an 
epithelium of full thickness appeared across the model, the top layer appeared disrupted, 
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similar to an effect seen by Bae et al. in their osteomucosal model [202]. The outer layers 
of the oral mucosa are known to contain more calcium [211]. As previously discussed, ZA 
and calcium have been shown to have a synergistic relationship [176]. It may be that due 
to the previously discussed HA dissolution, cellular calcium levels were increasing, 
causing HA to have a stronger effect on the outer layers of the model. The overall trend, 
however, was clear, with no effect on metabolic activity and the presence of an epithelium 
suggesting HA granules can be used to reduce BP toxicity. 
The differences in BP binding of the HA discs and granules was in part due to surface 
area. We have demonstrated that surface area effects BP binding, though the relationship 
was not linear. Our work indicated that the discs had a surface area of 45 % of the 
granules, however our metabolic activity data suggested a BP binding ability of only 
approximately 17 % of an equal weight of granules. Previously, the surface area of HA 
granules has been demonstrated to affect ZA binding, though again this was not a linear 
relationship [257]. Further investigations into this are clearly necessary, however, due to 
the difficulties found in measuring BP binding chemically, this was not possible as part of 
this thesis. 
It is known that high potency BPs mostly bind to the surface of bone, and do not 
diffuse much into the bone, therefore a surface area effect was expected [45]. PA has 
previously been demonstrated to cause a surface level binding onto HA through X-ray 
photoelectron spectroscopy (XPS) analysis [46]. Our results support this and suggest this 
is also true for ZA. This offers an important consideration for the future of BRONJ 
treatment. If HA is to be used in the localised reduction of BPs to prevent BRONJ, having 
a form with a high surface area is likely to be hugely beneficial. The granules used in this 
study were fairly large, with smaller sizes commercially available, as well as nHA powders 





In summary, we have demonstrated that UV-vis spectroscopy can be used to determine 
ZA concentration, though not PA. It is not possible, however, to determine ZA binding to 
HA through this method due to HA interference. We have demonstrated that FTIR-ATR 
cannot be used to determine HA binding to HA discs, due to sample loading issues. Raman 
spectroscopy could detect ZA binding, though not quantifiably. Finally, we have 
demonstrated for the first time that HA granules can be used to reduce BP toxicity to the 
oral mucosa, in vitro, in both 2D and 3D, and retain epithelial stratification, which 
represents an important step in the development of a preventative treatment for BRONJ.





The failure of the soft tissue to heal following oral surgery is hypothesised to be key to the 
initiation and development of BRONJ [2]. In this thesis, we have demonstrated clear 
mechanisms by which both PA and ZA, two BPs most commonly associated with BRONJ 
[153], [163], affect cells of the oral mucosa. We have demonstrated for the first time that 
PA prevents keratinocyte proliferation, and that ZA reduces keratinocyte adhesion. 
Clinically relevant concentrations of PA and ZA led to a reduction in both viability and 
proliferation of fibroblasts and keratinocytes, and in a 3D oral mucosa model caused 
negative effects in three stages of epithelial development. Our work therefore supports the 
hypothesis regarding the soft tissue role in BRONJ. Clearly, the BP effects on the oral 
mucosa are numerous, which indicates why, as of yet, no standardised treatment for 
BRONJ exists. 
 In chapters 5 and 6, we looked at the toxicity of PA and ZA, in 2D and 3D, 
respectively. We performed a methodical examination of BP toxicity to oral fibroblasts and 
keratinocytes, and calculated IC50 values for PA and ZA for these cell types. These values 
provide a key piece of information on the drugs that was heretofore missing. Due to the 
soft tissue toxicity associated with BRONJ, it suggests that the oral mucosa is exposed to 
concentrations at or above those defined in this thesis. There were differences between 
cytotoxic BP concentration in 2D and 3D. Though similar ZA concentrations caused toxicity 
to both 2D monolayers and 3D models, models were treated for 7 days while monolayers 
for 72 hours. PA concentrations higher than the IC50s for all three cell types tested did not 
lead to toxicity of oral mucosa models. 3D cell culture requires greater cell numbers, and 
their orientation within the scaffold changes the way tested treatments interact with cells, 
and therefore differences are expected. 3D cell culture models are known to be more 
resistant to toxicity than 2D equivalents [320]. The higher concentrations used in 3D were 
still within the expected dose for BRONJ patient oral mucosa, however [55]–[57], [142], 
and therefore the prevention of epithelial formation and wound healing, and the reduction 
in established epithelial thickness seen in chapter 6 indicate why the soft tissue of BRONJ 
patients does not heal. 
 We also looked at 2D toxicity in chapter 7. We chose values above the previously 
defined IC50s, and found slightly different results than those in chapter 5. ZA was less toxic 
to fibroblasts, and PA to immortalised keratinocytes than we expected based on our earlier 
work. This highlights the limits of 2D cell culture, where variation can occur over long term 
projects due to cell passage number and differences in foetal calf serum [321]. Overall, 
the trends are still clear. PA and ZA cause toxicity to keratinocytes and fibroblasts at 
clinically relevant concentrations and HA granules can be used to reverse this effect. 
The model developed as part of this thesis will, when fully optimised, allow for 
further investigations into BRONJ treatment methods currently showing potential in the 




treatment of the disease, such as GGOH [86], [144], [164], [168], [171] and cell based 
therapies [237]–[240]. The model would provide a key step between 2D work and the clinic, 
allowing for the reduction of animal testing in line with the 3Rs [219]. 
Prevention of BRONJ development is potentially the most effective solution for the 
disease [1], [40], [159]. We hypothesise that reducing the BP concentration to which the 
oral mucosa is exposed is the most suitable method by which to do this, as given the 
multitude of effects caused by BPs, preventing their effects individually would be difficult. 
The local reduction of BP concentration to prevent BRONJ is the focus of recent literature 
[40], [227]. We have shown another method by which this can be done, using clinically 
available materials. We have demonstrated for the first time that HA can be used to reduce 
BP toxicity to the oral mucosa in both 2D and 3D. The 3D work, in particular, indicates a 
method to prevent soft tissue toxicity following oral surgery and thereby prevent BRONJ 
development, while still allowing for the systemic BP effects required for patient quality of 
life. Further investigations into these materials are clearly warranted, as the potential use 
of clinically licensed materials to ameliorate a problem with no definitive treatment is highly 
engaging, and this work could feasibly move towards a clinical trial. 
 In conclusion, we have demonstrated that both PA and ZA have a wide variety of 
effects on human oral fibroblasts and keratinocytes in vitro, at concentrations well within 
the expected range for BRONJ patients. This presents a clear picture of how BPs cause 
the soft tissue toxicity associated with the disease. 
 We have also begun the development of an in vitro approximation of the soft tissue 
component of BRONJ, in a model that, with more optimisation, could be used further to 
study both potential BRONJ treatments, and other conditions that present with non-healing 
epithelia. 
 We have demonstrated that hydroxyapatite can be used to inhibit BP toxicity to the 
oral mucosa in 2D and 3D. This is the first time this effect has been demonstrated. This 
presents a novel strategy for the prevention of BRONJ, and has the advantage that many 
HA bone filler materials are already licensed for use following many of the dental surgeries 
that have triggered the development of the disease. However, due to difficulties in the 
detection of BP binding to HA, we could not confirm this binding chemically. Further work 
is required to investigate the binding relationship between HA and BPs, and whether other 
forms of the material could be used to reduce the toxicity further.
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9. Future work 
 
This thesis has demonstrated a wide variety of effects of BPs on the oral mucosa and 
indicated several mechanisms by which soft tissue effects contribute to the development 
of BRONJ. Clear effects were seen on human oral fibroblasts, keratinocytes, and a 3D 
oral mucosa model, and methods by which to examine BP effects on the oral mucosa are 
now well defined. Now these methods are optimised, repeating the 2D work from chapter 5 
with primary human oral keratinocytes from a group of different patients would provide 
valid, more clinically relevant data on BP effects on apoptosis, proliferation, migration and 
adhesion. 
 Two interesting pathways for further research were suggested from our 2D data. 
Firstly, investigating keratinocyte senescence would allow for clarity on the mechanism 
leading to BP toxicity currently debated in literature [57], [86], [140], [164]. Secondly, the 
data from our adhesion assay suggested that ZA was causing an effect on integrin binding. 
Further investigation into the effects of BPs on epithelial adhesion presents an interesting 
pathway for future work. Well defined assays exist for the detection of integrin binding [82], 
and a direct assay for this would allow for the confirmation of our hypothesis. This would 
be a key finding, as BPs had not been shown to affect keratinocyte adhesion before our 
work. Again, repeating this work with primary cells would also add more clinical relevance. 
Investigations could also be performed with our 3D models. Desmoglein is known to be 
affected in BP patients [189], and there may be other potential adhesion pathways. Using 
immunohistochemistry, it may be possible to gain further information regarding this. 
 Immunohistochemistry could also provide more information on 3D BP effects in 
general. While we have demonstrated apoptosis and proliferation effects in 2D, our 3D 
work was more focussed on developing the in vitro representations of BRONJ patient 
tissue. Now these are defined, confirmation of these effects also appearing in 3D would 
be useful. This could also help answer the question of how BPs affect the differentiation 
of keratinocytes, as there is currently no literature consensus [164], [187], [202]. 
 Clearly, our model of the soft tissue of BRONJ requires more development to 
create consistently thick epithelial sections. Alterations for the seeding process are needed 
to allow this. Theoretically, producing the rings out of a heavier material would prevent the 
use of the stainless steel ring as a weight, thereby reducing the fragility of the seeding 
process. Rather than using a stainless steel grid with large holes that caused the collection 
of DED and broke the seal, a mesh-like platform would allow the transfer of medium 
required at ALI but provide a smoother surface. These changes could potentially allow for 
a highly reproducible seeding method but would require a lengthy design and optimisation 
process. An alternate solution would be to further reduce the representativeness of the 
model. Deshayes et al. have designed a similar epithelial wound healing model using a 




commercially sourced, collagen based dermal compartment and a stainless steel ring to 
successfully examine drug effects on re-epithelisation [208]. The use of a collagen based 
dermis allowed for a collagen stain to visualise re-epithelialisation, in the inverse of our 
work. Though a collagen dermal equivalent is less representative, the thickness and 
consistency is more repeatable than DED, and may be a useful alternative in the 
production of a full soft tissue BRONJ model. 
 Our work focussed on the soft tissue toxicity related to BRONJ, however other 
mechanisms contribute to its pathophysiology, and adding further complexity to the models 
could provide key data on BRONJ development. The inclusion of a bone component would 
provide a full model of the condition, further reducing the need for animal models of the 
disease. While osteomucosal models exist [201], [202], they are fraught with issues – 
requiring lengthy seeding or rat calvariae. The optimisation of an experimental treatment 
regimen with the ability to mimic that found in BRONJ – whereby BPs are bound to bone 
and left dormant until the creation of a wound – would add further challenges. As infection 
is known to play a key role in BRONJ development, the introduction of bacterial culture to 
the BRONJ model could add further details as to how the soft tissue is affected. Models of 
infected dental tooth tissue have been developed, and could potentially be translated 
[322]. Adding complexity to this model would provide increased difficulty, however, a fully 
developed in vitro BRONJ model would be a huge leap in the field. 
 The quantifiable detection of PA and ZA binding to HA is difficult. Though we 
investigated several techniques, there are others that were outside of the scope of this 
project. Using fluorescent carbon dots as a sensor has the potential to be a simple, cost 
effective process and has been tested with the interference of a wide variety of different 
ions [274], however would require optimisation as it is not a widely used technique. Ion 
pair HPLC and LC-MS have been used before to detect ZA concentration in systems 
involving HA and bone, respectively [283], [290]. However these techniques require high 
specification equipment. BPs modified to be fluorescent have been used to detect BP 
binding onto calcium phosphates and to determine BP localisation [40], [202]. These BPs 
are less potent than their non-fluorescent analogues though, and as such make 
determining the full picture of BP effects difficult. Further investigation into these 
techniques is evidently required to determine a reproducible way to examine BP binding 
kinetics both on the bench and in vitro. Following this, it would be possible to define the 
binding properties of calcium-phosphate materials chemically and add clarity to the trends 
seen biologically in this thesis. 
Surface area had an effect on the binding properties of HA. Several different HA 
based materials exist, all with different surface areas. In the optimisation of a BRONJ 
treatment method, further investigation into the BP binding affinity of these materials could 
potentially reveal a material with a greater capacity to inhibit BP toxicity. These tests would 
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encompass biological assays used previously, tests using the optimised wound model – 
preferably with a bone component - and a chemical method to confirm binding. Ideally, a 
treatment regimen to match the clinical scenario would also be used, however, given the 
difficulties in estimating the concentration of BPs the oral mucosa is exposed to, this may 
not be possible. These tests would allow for the determination of the ideal amounts of HA 
to be used, give further indication of how the granules perform over time, and could also 
investigate how a clinically used membrane would affect bone and soft tissue 
regeneration. A HA form performing successfully in all these tests would thereby justify its 
use in an in vivo animal model, and going further, a clinical trial in humans. 
 Our work showed HA has potential as a BRONJ treatment method, however the 
work was entirely in vitro. In vivo testing is an important step from the bench to the clinic. 
As there are several common in vivo models of BRONJ, these present a logical step for 
further examination of the ability of HA to prevent BRONJ development. Though the rodent 
models are limited in terms of their representation of human bone, their high reproducibility 
and lower animal welfare concerns, compared to minipigs, offer the most suitable route of 
testing. These models would allow for the determination of the most suitable application 
of the granules in this indication and answer questions not able to be answered in vitro. 
As the exact BP concentration to which the oral mucosa is exposed is as yet unknown, as 
well as the length and release pattern for this exposure, an in vivo model would be required 
to fully assess the suitability of the HA granules in the prevention of BRONJ. These models 
would also allow for the investigation of longer term effects, such as the clarification of how 
the resorption of granules which had previously bound HA would affect the soft tissue 
above them. Following successful animal studies and the determination of the method of 
administration, a clinical trial in humans using HA as an adjunctive treatment following oral 
surgery in patients receiving BPs would be feasible. 
  





10.1 Appendix 1 - Cell seeding densities 
 
Human oral fibroblasts and immortalised human oral keratinocytes were seeded at 
different densities before culturing for 72 hours in control medium, with cell confluence 
recorded every 24 hours. 
 Fibroblast confluence is shown in Figure 10.1. For the apoptosis and necrosis, and 
proliferation assays, cell confluence was required at 72 hours, and therefore seeding 
density of 5.55 x 103 cells per cm2 was chosen. While confluence was also required at 72 
hours for the MTT assay, due to the low signal from these cells, a seeding density of 1.0 
x 104 cells per cm2 was chosen. For the migration assay, confluence was required at 24 
hours and therefore a seeding density of 5.4 x 104 cells per cm2 was chosen. 
 
 
Figure 10.1. Human oral fibroblast confluence over 72 hours at different seeding densities. 
  
  




Keratinocyte confluence is shown in Figure 10.2. For the MTT, apoptosis and 
necrosis, and proliferation assays, cell confluence was required at 72 hours, so a seeding 
density of 1.67 x 104 cells per cm2 was chosen. One density (1.5 x 104 cells per cm2) was 
chosen for both for the adhesion assays and immunohistochemistry, as this was one body 
of work performed by an MEng student, and this was slightly lower as cells were cultured 
for up to 120 hours in the immunohistochemistry so required more space for growth. As 
cell confluence was required at 24 hours for the migration assay, a density of 1.33 x 105 
cells per cm2 was chosen. 
 
 
Figure 10.2. Immortalised human oral keratinocyte confluence over 72 hours at different 
seeding densities. 
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10.2 Appendix 2 – Migration assay after cell tracing 
 
 
Figure 10.3. Human oral fibroblast migration over 72 hours in the presence of pamidronic 
acid. N=3, n=3. Error bars = SD. 
  




10.3 Appendix 3 – Removal of outliers 
 
One outlying value was removed from the MTT data. This value was indicated to be a 
significant outlier using Grubbs’ test for outliers. The equation for this is given in Equation 
10.1. 
 
𝐺 =  
|?̅? −  𝑦|
𝑛
 
Equation 10.1. Grubbs’ test for outliers. 
Grubbs and Beck previously determined critical values for G based on n [323]. For 
a sample size of 36, P≤0.001 when G≤3.616. Figure 10.3 shows the raw data from the 
assay where an outlier was removed, and the data transformed via Equation 10.1. One 
value was determined as above the critical limit, and therefore removed. 
 
 
Figure 10.4. MTT data for human oral fibroblasts treated with pamidronic acid for 72 hours. 
Grubbs’ test for outliers was performed to indicate outliers. Significant outlier indicated by 
highlighting in red, P<0.001. 
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Figure 10.5. Brunauer-Emmett-Teller surface area plots for hydroxyapatite granules, 
granules and discs, generated by Micrometrics 3Flex. 
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